Azetidine derivative, preparation method therefor and medical use thereof

By developing azetidine derivatives as M4 forward allosteric regulators, the problems of insufficient selectivity and poor penetration ability of existing M4 receptor agonist subtypes are solved, and higher selectivity and safety are achieved , possess potential for the treatment of schizophrenia and other neurological diseases.

WO2024230794A1PCT designated stage expired Publication Date: 2024-11-14CHINA PHARM UNIV +1

Patent Information

Application Number
PCT/CN2024/092163
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-03-07
Filing Date
2024-05-10
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

The existing M4 receptor agonists have many side effects due to insufficient subtype selectivity, which limits their clinical application and is difficult to effectively penetrate the blood-brain barrier, affecting the therapeutic effect.

Method used

A new class of azetisinone derivatives were developed as M4 forward allosteric regulators, which increased the selectivity and penetration of compounds by improving pharmacokinetic properties and increasing inhibition of cytochrome P450 isoenzymes. The ability of the blood-brain barrier.

Benefits of technology

It improves the selectivity and safety of compounds, reduces side effects, enhances the ability to regulate activity on M4 receptors, improves the bioavailability and half-life of drugs, and has the potential for the treatment of schizophrenia and other neurological diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024092163_14112024_PF_FP_ABST
    Figure CN2024092163_14112024_PF_FP_ABST
Patent Text Reader

Abstract

A compound represented by general formula I as shown below or a pharmaceutically acceptable salt, stereoisomer, tautomer, and deuterated compound thereof, a composition containing the compound, a preparation method therefor, an intermediate thereof, and a use thereof in the field of medicines.
Need to check novelty before this filing date? Find Prior Art

Description

Azetidine derivatives, preparation methods and medical uses thereof

[0001] This application claims priority to Chinese application No. 202310527406.4 filed on May 11, 2023, entitled “Azetidine derivatives, their preparation methods and their medical uses”, priority to Chinese application No. 202311178072.0 filed on September 13, 2023, entitled “Azetidine derivatives, their preparation methods and their medical uses”, and priority to Chinese application No. 202410258884.4 filed on March 7, 2024, entitled “Azetidine derivatives, their preparation methods and their medical uses”, the contents of which are incorporated herein by reference in their entirety. Technical Field

[0002] The present invention belongs to the field of medicine, and specifically relates to azetidine derivatives, their stereoisomers, deuterated products or pharmaceutically acceptable salts, preparation methods and compositions containing the compounds, intermediates thereof and applications in the field of medicine. Background Art

[0003] Patients with schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, depression, and various other neurological / neurodegenerative disorders often suffer from behavioral and cognitive impairments that can lead to debilitating disruptions in their daily lives. Over the years, numerous pharmacological treatments have been discovered that have provided some improvement in behavioral and cognitive function.

[0004] In order to discover new and improved pharmacological treatments, researchers began to consider muscarinic acetylcholine receptors (mAChRs) as a possible mechanism. Muscarinic acetylcholine receptors are G protein-coupled receptors (GPCRs) composed of five subtypes called M1, M2, M3, M4, and M5. Five mAChR subtypes (M1-M5) have been identified and are part of the G protein-coupled receptor (GPCR) superfamily. These subtypes are widely distributed throughout the peripheral and central nervous systems, with M1 and M4 subtypes primarily expressed in the CNS. The M4 receptor is coupled to G1 and is primarily expressed in the cerebral cortex, striatum, hypothalamus, and hippocampus (Lebois, et al., Neurop Harmacology 2018, 136, 362-373).

[0005] It is well known that cholinergic neurotransmission plays a crucial role in cognitive function. Cholinergic receptor antagonists have been shown to cause severe memory impairment, while acetylcholinesterase inhibitors such as donepezil have been shown to promote cognition in Alzheimer's disease. In schizophrenia, hyperdopaminergic states in the striatum and nucleus accumbens are associated with psychosis. Most antipsychotics improve symptoms by antagonizing dopamine D2 receptors, and this is the target of current antipsychotic drugs.

[0006] A clinical study of 345 Alzheimer's patients demonstrated that activation of muscarinic receptors by the M1 / M4 agonist xanomeline improved cognitive and psychiatric symptoms, such as hallucinations, delusions, and vocalizations (Bodick et al., Arch Neurol 1997, 54, 465-73). Furthermore, drugs acting at M receptors are also under clinical investigation for the treatment of schizophrenia. Karuna's KarXT (with xanomeline as the active ingredient) has already achieved positive results in Phase III clinical trials in the United States. Therefore, M1 / M4 agonists can improve cognitive and psychiatric symptoms.

[0007] Due to the high degree of spatial conservation of agonist recognition sites across different M receptor subtypes, these drugs lack subtype selectivity and are therefore prone to toxic side effects, limiting their clinical use. For example, xanomeline, the active ingredient in KarXT, is an M receptor agonist. Its low subtype selectivity has led to gastrointestinal discomfort and cardiovascular adverse reactions, causing some patients to discontinue treatment. In recent years, a growing number of allosteric modulator studies have revealed that key amino acids involved in receptor allosteric regulation are less conserved, providing a structural foundation for the development of more selective allosteric modulators. Allosteric modulators have been shown to enhance ligand subtype selectivity and improve drug efficacy. M4 receptor positive allosteric modulators can improve M receptor subtype selectivity, reduce off-target side effects, and increase patient compliance. Furthermore, M4 receptor positive allosteric modulators alter the conformation of the M4 receptor protein, enhancing the binding activity of endogenous acetylcholine (Ach) to the M4 receptor, producing effects similar to those of M4 receptor agonists.

[0008] Recently developed M4-specific positive allosteric modulators (PAMs) enhance the effects of the endogenous agonist acetylcholine, revealing a role for these receptors in controlling dopamine release in the striatum and at key synapses in the hippocampus known to be important for cognition.

[0009] In a recent study, it was demonstrated that M4 PAM reduced striatal dopamine release after amphetamine treatment in wild-type mice, but not in M4 knockout wild-type mice (Byun et al., NeuropsychopHarmacology 2014, 39, 1578). Another study showed that M4 PAM induced inhibition of glutamate excitatory synaptic transmission at Schaeffer collateral-CA1 synapses in the hippocampus (Thorn, et al., Hippocampus 2017, 27, 794-810).

[0010] Furthermore, in vivo studies in rodents showed that the M4 PAM VU0467154 improved associative learning impairment in a touch screen pair-wise visual discrimination task induced by the non-competitive NMDA receptor antagonist MK-801. These effects were absent in M4 knockout mice, demonstrating that this phenotype is specific to the M4 receptor (Bubser, et al., ACS Chemical Neuroscience 2014, 5, 920-942).

[0011] By activating striatal and hippocampal M4 receptors using specific PAMs, we can reduce the hyperdopaminergic state of the striatum and the overstimulation of the hippocampus, providing treatment for the psychosis and cognitive impairment of schizophrenia.

[0012] Therefore, regulating M4 receptor activity is a promising therapeutic strategy for treating or preventing M4-mediated diseases or disorders, such as Alzheimer's disease, schizophrenia, psychosis, Parkinson's disease, pain, addiction and Huntington's disease.

[0013] SUMMARY OF THE INVENTION

[0014] There is a great need to develop new compounds and formulations for treating or preventing M4-mediated diseases or disorders. Therefore, the present invention aims to provide compounds useful for treating, preventing, or alleviating such diseases, which have good druggability, particularly enhanced brain penetration and improved pharmacokinetic properties.

[0015] The following is a summary of some aspects of the present invention and is not intended to limit the present invention. In the event of a discrepancy between the disclosure of this specification and a reference, the disclosure of this specification shall prevail.

[0016] The present invention aims to provide an azetidine derivative or its stereoisomer, deuterated product or pharmaceutically acceptable salt and its pharmaceutical composition, its preparation method, and its intermediates. The compound and pharmaceutical composition can be used to prevent or treat diseases related to the M4 receptor.

[0017] In one aspect, the present invention provides a compound of formula I, its stereoisomers, deuterated derivatives, or pharmaceutically acceptable salts thereof.

[0018] wherein R1, R2, and R3 are each independently selected from H, deuterium, halogen, hydroxyl, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl, and C2-C6 alkynyl;

[0019] Each R4, when present, is independently selected from deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, and hydroxy;

[0020] E is selected from -(CH2)q-, -O- and -NH-;

[0021] L is selected from C optionally substituted by one or more substituents 6-14 Aryl, 5-10 membered heteroaryl optionally substituted by one or more substituents, and 5-8 membered nitrogen-containing heterocyclic group optionally substituted by one or more substituents; the one or more substituents are independently selected from deuterium, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 deuterated alkyl, C1-C6 deuterated alkoxy, nitro, C1-C6 alkylthio, hydroxyl and cyano;

[0022] A is selected from 5-14 membered heteroaryl, C 6-14 Aryl, 5-8 membered heterocyclic group and C 6-10 Aryl and 5-8 membered heterocyclic group;

[0023] Each Ra group, when present, is independently selected from deuterium, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkylthio, halogen, cyano, hydroxy, nitro, amino, oxo, optionally substituted C3-C6 cycloalkyl, -N(R5)(R6), -N(R5)C(=O)R6, -C(=O)-N(R5)(R6), -C(= O)-OR7, -C(=O)-R7 and -S(=O)2-R7, the optional substituents being independently selected from deuterium, halogen, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, -N(R5)(R6), -N(R5)(C(=O)R6), -C(=O)-N(R5)(R6), -C(=O)-OR7, -C(=O)-R7 and -S(=O)2-R7;

[0024] R5 and R6 are each independently selected from H, deuterium, C1-C6 alkyl optionally substituted with one or more Rb, C3-C8 cycloalkyl optionally substituted with one or more Rb, C1-C6 alkoxy optionally substituted with one or more Rb, and C1-C6 alkylthio optionally substituted with one or more Rb, the Rb being independently selected from hydrogen, deuterium, C1-C6 alkoxy, halogen, -N(CH3)2, -NHCH3, and hydroxyl;

[0025] or R5 and R6 are linked to the nitrogen atom to which they are attached to form a 3-8 membered nitrogen-containing heterocyclic group optionally substituted by one or more substituents; the one or more substituents are independently selected from deuterium, hydrogen, halogen, hydroxyl, nitro, amino, C1-C6 alkylthio, C1-C6 deuterated alkylthio, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 deuterated alkyl, C1-C6 deuterated alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy;

[0026] R7 is independently selected from C1-C6 alkyl;

[0027] m is 0, 1, 2, 3 or 4;

[0028] p is 0, 1, 2, or 3;

[0029] q is 0, 1, 2, or 3;

[0030] n is any integer from 0 to 5.

[0031] On the other hand, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound represented by Formula I as described above, its stereoisomers, deuterated substances or pharmaceutically acceptable salts thereof, optionally further comprising a pharmaceutically acceptable excipient, carrier, adjuvant, solvent or a combination thereof.

[0032] On the other hand, the present invention provides a compound of Formula I, its stereoisomers, deuterated substances or pharmaceutically acceptable salts, or pharmaceutical compositions thereof for use in preparing a medicament, preferably for use in preparing a medicament for treating an M4-mediated or M4-related disease or disorder in a patient. The M4-mediated or M4-related disease or disorder is selected from one or more of Alzheimer's disease, schizophrenia, pain, addiction, sleep disorders, cognitive disorders, Parkinson's disease, Parkinson's disease-levodopa-induced dyskinesia, Huntington's disease, movement disorders, dry mouth, pulmonary hypertension, chronic obstructive pulmonary disease, asthma, urinary incontinence, glaucoma, trisomy 21 syndrome, cerebral amyloid angiopathy, dementia, Dutch hereditary amyloidosis cerebral hemorrhage, Creutzfeld-Jakob disease, prion disorder, amyotrophic lateral sclerosis, progressive supranuclear palsy, head trauma, stroke, pancreatitis, inclusion body myositis, other peripheral amyloidosis, diabetes, autism and atherosclerosis, preferably one or more of Alzheimer's disease, schizophrenia, pain, addiction and sleep disorders, preferably schizophrenia.

[0033] In another aspect, the present invention provides a compound represented by Formula V, Va, Vb, Vc, Vd, Ve, Vf, Vg, Vh, Vi, Vj, Vk, Vl, Vm, Vn, Vo, Vp, Vq, Vr, Vs or Formula VI, VIa, VIb, VIc, VId, VIe, VIf, VIg, VIh, or VIi, a stereoisomer, a deuterated compound, or a salt thereof:

[0034] wherein A, Ra, and n are as defined in formula I, and R8 is a C1-C6 alkyl group.

[0035] In another aspect, the present invention provides a method for preparing a compound of formula I, comprising the following steps:

[0036] (i) a compound represented by Formula IA or a salt thereof undergoes a substitution reaction with a compound represented by Formula IB or Formula I-B' to produce a compound represented by Formula I;

[0037] (ii) a compound represented by Formula IC or a salt thereof undergoes a substitution reaction with a compound represented by Formula ID to produce a compound represented by Formula I;

[0038] (iii) the compound represented by Formula IE undergoes a substitution reaction with the compound represented by Formula IF to produce the compound represented by Formula I;

[0039] or,

[0040] (iv) the compound represented by formula IG undergoes a substitution reaction with the compound represented by formula IH to produce the compound represented by formula i-1;

[0041] wherein R8 is a C1-C6 alkyl group;

[0042] Y1 is halogen, preferably fluorine, chlorine or bromine, preferably fluorine;

[0043] Y2 is halogen, preferably fluorine, chlorine or bromine, preferably bromine;

[0044] Y3 is halogen, preferably fluorine, chlorine or bromine, preferably chlorine;

[0045] R1, R2, R3, R4, L, A, Ra, m, n, p and E are as defined in Formula I. DETAILED DESCRIPTION

[0046] Unless otherwise indicated or there is an obvious conflict in the context, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. In the event of a conflict, the definitions provided herein shall prevail. When a trade name appears in this article, it is intended to refer to the corresponding commercial product or its active ingredient. All patents, published patent applications and publications cited herein are incorporated herein by reference.

[0047] General Terms and Definitions

[0048] The term "optional" or "optionally" means that the subsequently described event or circumstance can but need not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.

[0049] The term "optionally substituted" can be used interchangeably with the term "substituted or unsubstituted", i.e., the structure or group is unsubstituted or substituted with one or more substituents described herein, wherein the substitution occurs at any reasonable position on the given structure or group as allowed by valence. If the substitution occurs on a structure or group that does not allow substitution, the substituent is not present.

[0050] Unless otherwise indicated, as used herein, the point of attachment of a substituent may be from any suitable position of the substituent. When a bond to a substituent is shown to pass through a bond connecting two atoms in a ring, then such a substituent may be bonded to any ring atom in the substitutable ring.

[0051] In general, the term "substituted" means that one or more hydrogen atoms in a given structure or group are replaced with a specified substituent. Unless otherwise indicated, a substituent may be substituted at every possible position in the group. When more than one position in a given structure can be substituted with one or more of the specified substituents, the substituents may be the same or different at every possible position in the structure.

[0052] In addition, it should be noted that, unless otherwise expressly stated, the description methods used in the present invention such as "respectively and independently" or "each independently" should be understood in a broad sense, which may mean that in different groups, the specific options expressed by the same symbols do not affect each other, or that in the same group, the specific options expressed by the same symbols do not affect each other.

[0053] When the lower limit and upper limit of a numerical range are disclosed, any numerical value and any included range falling within the range are specifically disclosed. In particular, each range of values ​​disclosed herein should be understood to represent each numerical value and range encompassed within a wider range. When any variable (e.g., Ra), and variables with markers (e.g., R1, R2, R3, R4, R5, R6, R7, etc.) appear more than once in the composition or structure of a compound, their definition in each case is independent at each occurrence. For example, if a group is substituted with 0, 1, 2, or 3 Ra substituents, the group can optionally be substituted with up to three Ra substituents, and the options for each Ra substituent in each case are independent of one another, i.e., each Ra substituent can be the same or different.

[0054] Throughout this specification, substituents of the compounds disclosed herein are disclosed in terms of group classes or ranges. It is specifically noted that the present invention includes each independent subcombination of the individual members of these group classes and ranges. For example, the expression mn as used herein refers to the range from m to n, as well as the subranges consisting of the individual values ​​therein, and the individual values.

[0055] The term "aryl" refers to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (i.e., rings that share adjacent pairs of carbon atoms) group having a conjugated electron system. The term "aryl" can be used interchangeably with the term "aromatic ring" or "aromatic ring." Examples of aryl groups include 6- to 14-membered aryl (i.e., C 6-14 Aryl), 6-10 membered aryl (i.e. C 6-10 The aryl group is optionally substituted with one or more substituents described herein.

[0056] The term "heteroaryl" refers to a heteroaromatic system having a conjugated electron system and containing 1 to 5 heteroatoms (e.g., 1, 2, 3, 4, or 5), 5 to 14 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14) ring atoms, wherein the heteroatoms are selected from one or more of oxygen, sulfur, and nitrogen. The term "heteroaryl" can be used interchangeably with the term "heteroaromatic ring" or "heteroaromatic compound." Examples of heteroaryl groups include 5-14 membered nitrogen-containing heteroaryl groups, 5-10 membered heteroaryl groups, 5-6 membered nitrogen-containing heteroaryl groups, 5-10 membered monocyclic or polycyclic heteroaryl groups, 5-6 membered heteroaryl groups, specifically including pyrimidinyl, pyridinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl, pyrazolyl, pyrrolyl, 1,2,3-triazolyl, thiadiazolyl, thienyl, furanyl, pyridazinyl, triazinyl, oxadiazolyl, isoxazolyl, pyranyl, 1,3,4-triazolyl, furopyrimidinyl, thienopyrimidinyl, pyrrolopyridinyl, pyranopyrimidinyl, benzothiazolyl, benzoxazolyl, thienopyrimidinyl, indolyl, quinolyl, isoquinolyl, imidazopyridinyl, benzothiadiazolyl, etc. The heteroaryl groups are optionally substituted with one or more substituents described herein.

[0057] The terms "heterocycle" and "heterocyclyl" are used interchangeably to refer to a monovalent or multivalent monocyclic, bicyclic, or tricyclic ring system containing 3-20 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms, 3-14 ring atoms, 3-8 ring atoms, or 5-8 ring atoms, wherein one or more ring atoms (e.g., 1, 2, 3, or 4 ring atoms) are independently replaced by heteroatoms, wherein the heteroatoms have the meanings described herein, and the rings may be fully saturated or contain one or more degrees of unsaturation. Unless otherwise specified, a -CH2- group in a heterocyclyl group may be optionally replaced by -C(=O)-. The sulfur atom of the ring may be optionally oxidized to form an S-oxide. The nitrogen atom of the ring may be optionally oxidized to form an N-oxide. Examples of heterocyclic groups include 5-8 membered heterocyclic groups, 3-8 membered nitrogen-containing heterocyclic groups, 5-8 membered nitrogen-containing heterocyclic groups, 5-8 membered oxygen-containing heterocyclic groups, and the like, specifically including: oxiranyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, 1,3-dioxolane, dithiolanyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiopyranyl, dihydrothiopyranyl, piperidinyl, morpholinyl, piperazinyl, dihydropyridinyl, 2-pyridonyl, 2-oxopyrrolidinyl, oxo-1,3-thiazolidinyl, oxazolidinyl, 2-oxoxazolidinyl, and the like. The heterocyclyl group may be optionally substituted with one or more substituents described herein. The heterocyclyl group may be fused to an aryl, heteroaryl or cycloalkyl ring, such as C 6-10 Aryl and 5-8 membered heterocyclic group, such as C 6-10 The aryl group is a 5-8 membered heterocyclic group containing 1-3 heteroatoms selected from nitrogen, oxygen and sulfur, such as a 5-6 membered nitrogen-containing heterocyclic group or a 5-6 membered oxygen-containing heterocyclic group, such as an indolinyl group, an isoindolinyl group, a dihydrobenzofuranyl group, a dihydroisobenzofuranyl group, a benzodioxolyl group, etc.

[0058] The term "alkyl" refers to a straight or branched chain saturated aliphatic hydrocarbon group consisting of carbon atoms and hydrogen atoms, which is connected to the rest of the molecule by a single bond. "Alkyl" can have 1 to 6 carbon atoms, i.e. "C1-C6 alkyl", for example C 1-4 Alkyl, C 1-3 Alkyl, C 1-2 Alkyl, C3 alkyl, C4 alkyl. It can also have 1-3 carbon atoms, i.e. "C1-C3 alkyl", such as C 1-3 Alkyl, C 1-2Alkyl, C3 alkyl. The term "C1-C5 alkyl" specifically refers to methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl disclosed independently. Examples of alkyl groups include, but are not limited to, methyl (Me, -CH3), ethyl (Et, -CH2CH3), propyl (including n-propyl (n-Pr, -CH2CH2CH3), isopropyl (i-Pr, -CH(CH3)2)), butyl (including n-butyl (n-Bu, -CH2CH2CH2CH3), isobutyl (i-Bu, -CH2CH(CH3)2), sec-butyl (s-Bu, -CH(CH3)CH2CH3), tert-butyl alkyl (t-Bu, -C(CH3)3)), pentyl (including n-pentyl (-CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH(CH3)2), 3-methyl-1-butyl (-CH2CH2CH(CH3)2 ), 2-methyl-1-butyl (-CH2CH(CH3)CH2CH3)), hexyl (including n-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH(CH3)C H(CH3)CH2CH3), 4-methyl-2-pentyl (-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl (-C(CH3)2CH(CH3)2), 3,3-dimethyl-2-butyl (-CH(CH3)C(CH3)3)), etc.

[0059] For example, the expression "C1-C6" or "C 1-6 " covers the range of 1-6 carbon atoms and should be understood to also cover any subranges and each point value therein, such as C1-C5, C3-C4, C2-C6, C3-C6, C4-C5, C4-C6, C2-C4, etc., as well as C1, C2, C3, C4, C5, C6, etc. For another example, the expression "C1-C5" or "C 1-5" covers the range of 1-5 carbon atoms and should be understood to also cover any subranges and each point value therein, such as C2-C5, C3-C4, C1-C2, C1-C3, C1-C4, C1-C5, etc., as well as C1, C2, C3, C4, C5, etc. For another example, the expression "C2-C5" or "C 2-5 " covers the range of 2-5 carbon atoms, and should be understood to also cover any subranges and each point value therein, such as C2-C5, C3-C4, C2-C3, C2-C4, C3-C5, C4-C5, etc., as well as C2, C3, C4, C5, etc. For another example, the expression "ternary to octamembered" should be understood to cover any subranges and each point value therein, such as ternary to pentad, ternary to hexamembered, ternary to heptad, ternary to octamembered, quaternary to pentad, quaternary to hexamembered, etc., as well as three, four, five, six, etc. Other similar expressions herein should also be understood in a similar manner.

[0060] The term "one or more" or the similar expression "at least one" may mean, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more.

[0061] The term "selected from..." means one or more elements from the group listed thereafter, selected independently, and may include combinations of two or more elements.

[0062] The term "comprising" is an open expression, that is, including the contents specified in the present invention, but not excluding other contents.

[0063] When it is stated that each carbon atom in a group may be optionally replaced by a heteroatom, the normal valencies of all atoms in the group in the present circumstances are not exceeded and a stable compound is formed.

[0064] The term "heteroatom" refers to oxygen (O), sulfur (S) or nitrogen (N), including nitrogen (N) and sulfur (S) in any oxidation state; primary, secondary, tertiary amines and quaternary ammonium salts; or a form in which the hydrogen on the nitrogen atom in a heterocyclic ring is substituted, for example: N, NH, NR.

[0065] The term "hydrogen (H)" refers to a single hydrogen atom, which may be linked to other groups, such as oxygen atoms, to form a hydroxyl group.

[0066] The term "halogen" or "halo" is understood to mean fluorine (F), chlorine (Cl), bromine (Br) or iodine (I), preferably a fluorine, chlorine or bromine atom, more preferably a fluorine atom.

[0067] The term "alkoxy" refers to an alkyl group attached to the remainder of the molecule through an oxygen atom, wherein alkyl has the meaning as described herein. In one embodiment, the alkoxy group contains 1-6 carbon atoms. In one embodiment, the alkoxy group contains 1-5 carbon atoms; in another embodiment, the alkoxy group contains 1-3 carbon atoms. The alkoxy group may be optionally substituted with one or more substituents as described herein. Examples of alkoxy groups include, but are not limited to, methoxy (MeO, -OCH3), ethoxy (EtO, -OCH2CH3), 1-propoxy (n-PrO, n-propoxy, -OCH2CH2CH3), 2-propoxy (i-PrO, i-propoxy, -OCH(CH3)2), 1-butoxy (n-BuO, n-butoxy, -OCH2CH2CH2CH3), 2-methyl-1-propoxy (i-BuO, i-butoxy, -OCH2CH(CH3)2), 2-butoxy (s-BuO, s-butoxy, -OCH(CH3)CH2CH3), 2-methyl-2-propoxy (t-BuO, t-butoxy, -OC(CH3)3), and the like.

[0068] The term "alkylthio" refers to an alkyl group attached to the remainder of the molecule through a sulfur atom, wherein alkyl has the meaning herein. In one embodiment, the alkylthio group contains 1-6 carbon atoms. In one embodiment, the alkylthio group contains 1-5 carbon atoms; in another embodiment, the alkylthio group contains 1-3 carbon atoms. The alkylthio group may be optionally substituted with one or more substituents as described herein.

[0069] The term "cycloalkyl" refers to a cyclic hydrocarbon group or cyclic alkenyl group composed of carbon atoms and hydrogen atoms, preferably containing 1 or 2 rings. The cycloalkyl group may have 3-8 carbon atoms, i.e., "C3-C8 cycloalkyl", or 3-6 carbon atoms, i.e., "C3-C6 cycloalkyl", or 4-8 carbon atoms, i.e., "C4-C8 cycloalkyl", such as C6 cycloalkyl, C5 cycloalkyl, C4 cycloalkyl, C3 cycloalkyl. Examples of cycloalkyl groups include C3-C8 cycloalkyl, C4-C8 cycloalkyl, C4-C6 cycloalkyl, C3-C6 cycloalkyl, specifically including: cyclopropyl, cyclopropenyl, cyclobutenyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl, etc. The term also encompasses cases where a C atom may be substituted with oxo (=O).

[0070] The term "alkenyl" refers to a general term for hydrocarbons containing a carbon-carbon double bond in the molecule, which is an unsaturated aliphatic hydrocarbon. For example: vinyl (-CH2=CH-). The "alkene" can have 2-6 carbon atoms, i.e. "C2-C6" alkenyl, for example C 2-6 Alkenyl, C2-4 Alkenyl, C 2-5 Alkenyl, C3 alkenyl, C4 alkenyl, C6 alkenyl, C 2-6 Alkenyl, C 3-6 Alkenyl, etc. It can also have 2-5 carbon atoms, i.e. "C2-C5 alkenyl", such as C 2-5 Alkenyl, C 2-3 Alkenyl, C3 alkenyl, C5 alkenyl, etc. Examples of alkenyl groups include, but are not limited to, ethenyl (e.g., CH2=CH-), propenyl (e.g., CH2=CH-CH2-), butenyl (e.g., CH2=CH-CH2-CH2-, CH3-CH=CH-CH2-), pentenyl (e.g., CH2=CH-CH2-CH2-, CH3-CH2-CH=CH-CH2-, -CH(CH3)-CH=CH-CH3), hexenyl, heptenyl, octenyl, etc.

[0071] The term "alkynyl" is a general term for hydrocarbons containing a carbon-carbon triple bond in the molecule, which is an unsaturated aliphatic hydrocarbon. For example: ethynyl (-C≡CH). The "alkyne" can have 2-6 carbon atoms, i.e. "C2-C6" alkynyl, for example C 2-6 Alkynyl, C 2-4 Alkynyl, C 2-5 Alkynyl, C3 alkynyl, C4 alkynyl, C6 alkynyl, C 2-6 Alkynyl, C 3-6 Alkynyl, etc. It can also have 2-5 carbon atoms, i.e. "C2-C5 alkynyl", such as C 2-5 Alkynyl, C 2-3 Alkynyl, C3 alkynyl, C5 alkynyl, etc. Examples of alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, etc.

[0072] The terms "haloalkyl" and "halogen-substituted alkyl" are used interchangeably and refer to an alkyl group substituted with one or more halogens. Examples include, but are not limited to, halomethyl, haloethyl, halopropyl, halobutyl, and halopentyl. The halo group may be monohalogen-substituted, dihalogen-substituted, or trihalogen-substituted. When the methyl group is trihalogen-substituted, difluoromethyl or trifluoromethyl may be further preferred.

[0073] The terms "haloalkoxy" and "halogen-substituted alkoxy" are used interchangeably and refer to an alkoxy group substituted with one or more halogens. Examples include, but are not limited to, halomethoxy, haloethoxy, halopropoxy, halobutoxy, and halopentoxy, wherein the halo groups may be monohalogen-substituted, dihalogen-substituted, or trihalogen-substituted.

[0074] In the compounds mentioned in the present invention, hydrogen atoms may be partially or completely replaced by deuterium. Specifically, the term "deuterated compound" means that hydrogen atoms of the compounds of the present invention may be partially or completely replaced by deuterium.

[0075] The term "pharmaceutically acceptable salt" refers to an organic salt or an inorganic salt of a compound of the present invention.

[0076] The term "pharmaceutically acceptable carrier" refers to substances that are non-irritating to organisms and do not impair the biological activity and properties of the active compound. "Pharmaceutically acceptable carriers" include, but are not limited to, glidants, sweeteners, diluents, preservatives, dyes / colorants, flavorings, surfactants, wetting agents, dispersants, disintegrants, stabilizers, solvents, or emulsifiers.

[0077] The following detailed description of the invention is intended to illustrate non-limiting embodiments so that other technical personnel in the art can more fully understand the technical solutions, principles and practical applications of the present invention, so that other technical personnel in the art can modify and implement the present invention in many forms to best adapt it to the requirements of specific uses.

[0078] Compounds of formula I

[0079] In one aspect, the present disclosure provides a compound of Formula I, a stereoisomer, a deuterated substance, or a pharmaceutically acceptable salt thereof,

[0080] wherein R1, R2, and R3 are each independently selected from H, deuterium, halogen, hydroxyl, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl, and C2-C6 alkynyl;

[0081] Each R4, when present, is independently selected from deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, and hydroxy;

[0082] E is selected from -(CH2)q-, -O- and -NH-;

[0083] L is selected from C optionally substituted by one or more substituents 6-14 Aryl, 5-10 membered heteroaryl optionally substituted by one or more substituents, and 5-8 membered nitrogen-containing heterocyclic group optionally substituted by one or more substituents; the one or more substituents are independently selected from deuterium, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 deuterated alkyl, C1-C6 deuterated alkoxy, nitro, C1-C6 alkylthio, hydroxyl and cyano;

[0084] A is selected from 5-14 membered heteroaryl, C 6-14 Aryl, 5-8 membered heterocyclic group and C6-10 Aryl and 5-8 membered heterocyclic group;

[0085] Each Ra group, when present, is independently selected from deuterium, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkylthio, halogen, cyano, hydroxy, nitro, amino, oxo, optionally substituted C3-C6 cycloalkyl, -N(R5)(R6), -N(R5)C(=O)R6, -C(=O)-N(R5)(R6), -C(= O)-OR7, -C(=O)-R7 and -S(=O)2-R7, the optional substituents being independently selected from deuterium, halogen, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, -N(R5)(R6), -N(R5)(C(=O)R6), -C(=O)-N(R5)(R6), -C(=O)-OR7, -C(=O)-R7 and -S(=O)2-R7;

[0086] R5 and R6 are each independently selected from H, deuterium, C1-C6 alkyl optionally substituted with one or more Rb, C3-C8 cycloalkyl optionally substituted with one or more Rb, C1-C6 alkoxy optionally substituted with one or more Rb, and C1-C6 alkylthio optionally substituted with one or more Rb, the Rb being independently selected from hydrogen, deuterium, C1-C6 alkoxy, halogen, -N(CH3)2, -NHCH3, and hydroxyl;

[0087] or R5 and R6 are linked to the nitrogen atom to which they are attached to form a 3-8 membered nitrogen-containing heterocyclic group optionally substituted by one or more substituents; the one or more substituents are independently selected from deuterium, hydrogen, halogen, hydroxyl, nitro, amino, C1-C6 alkylthio, C1-C6 deuterated alkylthio, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 deuterated alkyl, C1-C6 deuterated alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy;

[0088] R7 is independently selected from C1-C6 alkyl;

[0089] m is 0, 1, 2, 3 or 4;

[0090] p is 0, 1, 2, or 3;

[0091] q is 0, 1, 2, or 3;

[0092] n is any integer from 0 to 5.

[0093] In one embodiment, R1, R2, and R3 in the compound of Formula I herein are each independently selected from H, deuterium, halogen, hydroxy, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl, and C2-C6 alkynyl;

[0094] Each R4, when present, is independently selected from deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, and hydroxy;

[0095] E is selected from -(CH2)q-, -O- and -NH-;

[0096] L is selected from C optionally substituted by one or more substituents 6-14 Aryl, 5-10 membered heteroaryl optionally substituted by one or more substituents, and 5-8 membered nitrogen-containing heterocyclic group optionally substituted by one or more substituents; the one or more substituents are independently selected from deuterium, halogen, C1-C6 alkyl, C1-C6 alkoxy and cyano;

[0097] A is selected from 5-14 membered heteroaryl, C 6-14 Aryl, 5-8 membered heterocyclic group and C 6-10 Aryl and 5-8 membered heterocyclic group;

[0098] Each Ra group, when present, is independently selected from deuterium, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkylthio, halogen, cyano, hydroxy, nitro, amino, oxo, optionally substituted C3-C6 cycloalkyl, -N(R5)(R6), -N(R5)(C(=O)R6), -C(=O)-N(R5)(R6), -C(=O)-OR7, -C(=O)-R7 and -S(=O)2-R7, and the optional substituents are independently selected from deuterium, halogen and hydroxy;

[0099] R5 and R6 are each independently selected from H, deuterium and C1-C6 alkyl, or R5 and R6 are linked to the nitrogen atom to form a 3-8 membered nitrogen-containing heterocyclic group;

[0100] R7 is independently selected from C1-C6 alkyl;

[0101] m is 0, 1, 2, 3 or 4;

[0102] p is 0, 1, 2, or 3;

[0103] q is 0, 1, 2, or 3;

[0104] n is any integer from 0 to 5.

[0105] Another aspect of the present disclosure provides a compound of Formula IA, a stereoisomer, a deuterated form thereof, or a pharmaceutically acceptable salt thereof,

[0106] wherein R1, R2, and R3 are independently selected from H, deuterium, halogen, hydroxyl, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl, and C2-C6 alkynyl;

[0107] R4, when present, is selected from deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, and hydroxy, and when m is 2 or more, R4 may be different;

[0108] L is selected from 6-14 membered aryl groups optionally substituted by one or more substituents, 5-10 membered heteroaryl groups optionally substituted by one or more substituents, and 5-8 membered nitrogen-containing heterocyclic groups optionally substituted by one or more substituents; further preferably selected from phenyl groups optionally substituted by one or more substituents and 5-6 membered heteroaryl groups optionally substituted by one or more substituents; the one or more substituents are independently selected from deuterium, halogen, C1-C6 alkyl, C1-C6 alkoxy, and cyano;

[0109] A is selected from 5-14 membered heteroaryl, 6-14 membered aryl, 5-8 membered heterocyclic group, preferably selected from 5-14 membered heteroaryl, 6-10 membered aryl and 5-8 membered nitrogen-containing heterocyclic group containing heteroatoms such as nitrogen, oxygen and sulfur, further preferably selected from 5-7 membered monocyclic heteroaryl containing 1 / 2 / 3 heteroatoms such as nitrogen, oxygen and sulfur, 8-10 membered bicyclic heteroaryl containing 1 / 2 / 3 heteroatoms such as nitrogen, oxygen and sulfur, phenyl and 6 membered nitrogen-containing heterocyclic group; further preferably selected from pyridyl, phenyl, piperazinyl and quinolinyl;

[0110] each Ra group, when present, is independently selected from deuterium, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, halogen, cyano, optionally substituted C3-C6 cycloalkyl, -C(=O)-N(R5)(R6) and -C(=O)-OR7, said optional substituents being independently selected from deuterium, halogen and hydroxy, and if n is 2 or 3 or 4 or 5, then Ra may be different;

[0111] R5 and R6 are each independently selected from H, deuterium and C1-C6 alkyl, and R7 is independently selected from C1-C6 alkyl;

[0112] m is 0, 1, 2, 3 or 4;

[0113] p is 0, 1, 2, or 3;

[0114] q is 0, 1, 2, or 3;

[0115] n is any integer from 0 to 5, preferably any integer from 0 to 4, and more preferably any integer from 0 to 2.

[0116] In one embodiment, the compound of the present disclosure is a compound of formula II,

[0117] Preferred are compounds of formula III,

[0118] wherein X1, X2, and X3 are each independently N or CH, and X1, X2, and X3 are not N at the same time.

[0119] In one embodiment, R1, R2, and R3 in the compounds of the general formula herein are each independently selected from H, deuterium, halogen, hydroxyl, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl, and C2-C6 alkynyl, preferably selected from hydrogen, halogen, C1-C6 alkyl, and C1-C6 alkoxy, preferably hydrogen, halogen, or C1-C6 alkyl. In one embodiment, R1 is halogen or C1-C6 alkyl, preferably chlorine or C1-C3 alkyl. In one embodiment, R2 is hydrogen. In one embodiment, R3 is C1-C6 alkyl, preferably C1-C3 alkyl.

[0120] In one embodiment, R4 in the compounds of the general formula herein is each independently deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl or hydroxy, preferably C1-C6 alkyl, preferably C1-C3 alkyl.

[0121] In one embodiment, E in the compounds of the general formula herein is selected from -(CH2)q-, -O- and -NH-, preferably selected from -(CH2)q- or -O-.

[0122] In one embodiment, E in the compounds of the formulae herein is selected from -(CH2)q-.

[0123] In one embodiment, L in the compounds of the general formula herein is selected from C, 6- 14 Aryl, 5-10 membered heteroaryl containing 1-3 heteroatoms selected from nitrogen, oxygen and sulfur, which are optionally substituted by one or more substituents, and 5-8 membered nitrogen-containing heterocyclic group which are optionally substituted by one or more substituents; preferably selected from C 6-14 Aryl, 5-10 membered heteroaryl containing 1-3 heteroatoms selected from nitrogen, oxygen and sulfur, which are optionally substituted by one or more substituents; preferably C 6-10Aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms selected from nitrogen, oxygen and sulfur, which is optionally substituted by one or more substituents; preferably selected from phenyl optionally substituted by one or more substituents, pyridyl optionally substituted by one or more substituents, pyrazinyl optionally substituted by one or more substituents, pyrimidinyl optionally substituted by one or more substituents, pyridazinyl optionally substituted by one or more substituents, thiazolyl optionally substituted by one or more substituents and thienyl optionally substituted by one or more substituents; preferably selected from phenyl optionally substituted by one or more substituents, pyridyl optionally substituted by one or more substituents, pyridazinyl optionally substituted by one or more substituents, pyrazinyl optionally substituted by one or more substituents, thiazolyl optionally substituted by one or more substituents and thienyl optionally substituted by one or more substituents; preferably selected from The one or more substituents are independently selected from deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 deuterated alkyl, C1-C6 deuterated alkoxy, C1-C6 alkylthio, hydroxyl and cyano, and the one or more substituents are independently preferably selected from deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 deuterated alkyl and C1-C6 deuterated alkoxy, and the one or more substituents are independently preferably selected from halogen, C1-C6 alkyl and C1-C6 haloalkyl.

[0124] In one embodiment, L in the compounds of the general formula herein is selected from phenyl optionally substituted with one or more substituents, said one or more substituents being independently preferably selected from halogen, C1-C6 alkyl and C1-C6 haloalkyl.

[0125] In one embodiment, L in the compounds of the general formula herein is selected from pyridyl optionally substituted with one or more substituents, said one or more substituents being independently preferably selected from halogen, C1-C6 alkyl and C1-C6 haloalkyl.

[0126] In one embodiment, A in the compounds of the general formula herein is selected from 5-14 membered heteroaryl containing 1-5 heteroatoms selected from nitrogen, oxygen, sulfur, C 6-14 Aryl, 5-8 membered heterocyclic group containing 1-3 heteroatoms selected from nitrogen, oxygen, sulfur and C 6-10 The 5-8 membered heterocyclic group containing 1-3 heteroatoms selected from nitrogen, oxygen and sulfur is preferably selected from the 5-10 membered heteroaryl group containing 1-3 heteroatoms selected from nitrogen, oxygen and sulfur, C 6-10Aryl, 5-6 membered nitrogen-containing heterocyclic group, 5-6 membered oxygen-containing heterocyclic group, benzo 5-6 membered oxygen-containing heterocyclic group, benzo 5-6 membered sulfur-containing heterocyclic group and benzo 5-6 membered nitrogen-containing heterocyclic group, preferably selected from phenyl, piperazinyl, piperidinyl, pyridinyl, pyrazolyl, quinolyl, isoquinolyl, morpholinyl, thienyl, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydroisobenzofuranyl, benzodioxolyl, imidazopyridinyl, oxazolyl, benzothiadiazolyl, benzothiazolyl, imidazolyl, oxazolidinyl and pyrrolyl, preferably selected from phenyl, piperazinyl, piperidinyl, pyridinyl, pyrazolyl, quinolyl Preferably, the phenyl group is selected from the group consisting of phenyl, piperazinyl, piperidinyl, pyridinyl, pyrazolyl, quinolinyl, isoquinolinyl, morpholinyl, thienyl, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydroisobenzofuranyl, benzodioxolyl, imidazopyridinyl, benzothiadiazolyl, benzothiazolyl, imidazolyl, oxazolidinyl and pyrrolyl, and is further preferably selected from the group consisting of phenyl, piperazinyl, piperidinyl, pyridinyl, pyrazolyl, quinolinyl, isoquinolinyl, morpholinyl, thienyl, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydroisobenzofuranyl, benzodioxolyl, imidazopyridinyl, benzothiadiazolyl, benzothiazolyl, imidazolyl and pyrrolyl.

[0127] In one embodiment, when A is a polycyclic heteroaryl group, L may be attached to any ring of the polycyclic heteroaryl group, and Ra may be substituted on any ring of the polycyclic heteroaryl group.

[0128] In one embodiment, A in the compounds of the general formula herein is selected from a 5-10 membered heteroaryl group containing 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur, preferably selected from pyridyl, pyrazolyl, quinolyl, isoquinolyl, thienyl, imidazopyridinyl, oxazolyl, imidazolyl, and pyrrolyl.

[0129] In one embodiment, A in the compounds of the general formula herein is selected from C 6-10 The aryl group is preferably selected from phenyl groups.

[0130] In one embodiment, A in the compounds of the general formula herein is selected from 5-6 membered nitrogen-containing heterocyclic groups, preferably piperazinyl and piperidinyl.

[0131] In one embodiment, A in the compound of the general formula herein is selected from a 5-6 membered oxygen-containing heterocyclic group, preferably selected from morpholine and oxazolidinyl, and more preferably morpholine.

[0132] In one embodiment, A in the compounds of the general formula herein is selected from benzo 5-6 membered oxygen-containing heterocyclic groups, preferably dihydrobenzofuranyl, dihydroisobenzofuranyl, and benzodioxolyl.

[0133] In one embodiment, A in the compounds of the general formula herein is selected from benzo 5-6 membered sulfur-containing heterocyclic groups, preferably selected from benzothiadiazolyl and benzothiazolyl.

[0134] In one embodiment, A in the compounds of the general formula herein is selected from benzo 5-6 membered nitrogen-containing heterocyclic groups, preferably selected from indolinyl, isoindolinyl, oxazolidinyl, and further preferably selected from indolinyl and isoindolinyl.

[0135] In one embodiment, the compounds of the general formula herein for Rc is selected from deuterium, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, preferably selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl; z is selected from an integer of 0-4, preferably 0 or 1.

[0136] In one embodiment, Wherein, Rc is selected from deuterium, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, preferably selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl; z is selected from an integer of 0-4, preferably 0 or 1.

[0137] In one embodiment, for Wherein, Rc is selected from deuterium, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, preferably selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl; z is selected from an integer of 0-4, preferably 0 or 1.

[0138] In one embodiment, for Wherein, Rc is selected from deuterium, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, preferably selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl; z is selected from an integer of 0-4, preferably 0 or 1.

[0139] In one embodiment, for Wherein, Rc is selected from deuterium, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, preferably selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl; z is selected from an integer of 0-4, preferably 0 or 1.

[0140] In one embodiment, for Wherein, Rc is selected from deuterium, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, preferably selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl; z is selected from an integer of 0-4, preferably 0 or 1.

[0141] In one embodiment, for Wherein, Rc is selected from deuterium, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, preferably selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl; z is selected from an integer of 0-4, preferably 0 or 1.

[0142] In one embodiment, for Wherein, Rc is selected from deuterium, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, preferably selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl; z is selected from an integer of 0-4, preferably 0 or 1.

[0143] In one embodiment, for Wherein, Rc is selected from deuterium, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, preferably selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl; z is selected from an integer of 0-4, preferably 0 or 1.

[0144] In one embodiment, the Ra groups in the compounds of the general formula herein, when present, are independently selected from deuterium, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, halogen, cyano, nitro, oxo, amino, optionally substituted C3-C6 cycloalkyl, -N(R5)(R6), -C(=O)-N(R5)(R6), -C(=O)-OR7, -C(=O)-R7, -N(R5)C(=O)R6 and -S(=O)2-R7, and each Ra group is preferably independently selected from deuterium, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, halogen, cyano, nitro, oxo, optionally substituted C3-C6 cycloalkyl, - N(R5)(R6), -C(=O)-N(R5)(R6), -C(=O)-OR7, -N(R5)C(=O)R6 and -S(=O)2-R7, each Ra group is independently preferably selected from deuterium, -CHF2, -CF3, -OCHF2, cyano, cyclopropyl, -C(=O)-NH2, -C(=O)-N(CH3)2, fluorine, chlorine, -C(=O)-OCH2CH3, -C(=O)-OCH3, methyl, ethyl, isopropyl, -OCH3, -OCH2CH3, -OCH2F, -OCF3, -N(CH3)2, oxo, nitro, -S(=O)2-CH3, -CH2N(CH3)2, azetidinyl, Azocyclopentyl, -NHCH(CH3)2, -N(CH3)CH(CH3)2, -NH2, -NH(CH2)3OCH3, -NHCH2CH3, -N(CH2CH3)2, -NHCH3, -NCH3CD3, -N(CH3)(C2H5) and -NHC(=O)CH3;

[0145] The optional substituents are independently selected from deuterium, halogen, hydroxyl, C1-C6 alkyl, -N(R5)(R6), -C(=O)-OR7, -C(=O)-R7 and -S(=O)2-R7, the optional substituents are independently preferably selected from deuterium, halogen and -N(R5)(R6), the optional substituents are independently preferably selected from deuterium, fluorine, chlorine and -N(CH3) 2。

[0146] In one embodiment, R5 and R6 are each independently selected from H, deuterium, C1-C3 alkyl optionally substituted by one or more Rb, C3-C6 cycloalkyl optionally substituted by one or more Rb and C1-C3 alkoxy optionally substituted by one or more Rb, preferably selected from H, C1-C3 alkyl optionally substituted by one or more Rb, cyclopropyl, cyclobutyl and C1-C3 alkoxy optionally substituted by one or more Rb; said Rb being independently selected from deuterium, halogen and C1-C3 alkoxy.

[0147] In one embodiment, R5 and R6 are linked to the nitrogen atom to which they are attached to form a 5-6 membered nitrogen-containing heterocyclic group optionally substituted by one or more substituents; the one or more substituents are independently selected from deuterium, hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 deuterated alkyl, C1-C6 deuterated alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy, the one or more substituents are independently preferably selected from deuterium, hydrogen, halogen and C1-C3 alkyl, the one or more substituents are independently preferably selected from fluorine, chlorine and C1-C3 alkyl.

[0148] In one embodiment, the compound of the present disclosure is a compound of formula IB,

[0149] wherein R1, R2, R3, R4, m, z, p, q, Rc, Ra and n are as defined above.

[0150] In one embodiment, the compound of the present disclosure is a compound of formula IB-1,

[0151] wherein R1, R2, R3, z, Ra, Rc and n are as defined above. In one embodiment, L in the compound of the general formula herein is selected from C 6-14Aryl, 5-10 membered heteroaryl optionally substituted by one or more substituents and 5-8 membered nitrogen-containing heterocyclic group optionally substituted by one or more substituents; preferably selected from C 6-14 aryl, 5-10 membered heteroaryl containing 1-3 heteroatoms selected from nitrogen, oxygen and sulfur, which are optionally substituted by one or more substituents, and 5-8 membered nitrogen-containing heterocyclic group, which are optionally substituted by one or more substituents; preferably C 6-14 Aryl and 5-10 membered heteroaryl containing 1-3 heteroatoms selected from nitrogen, oxygen and sulfur, which are optionally substituted by one or more substituents; preferably C 6-10 Aryl and 5-6 membered heteroaryl containing 1-3 heteroatoms selected from nitrogen, oxygen and sulfur, which are optionally substituted by one or more substituents; preferably selected from phenyl optionally substituted by one or more substituents, pyridyl optionally substituted by one or more substituents, pyrazinyl optionally substituted by one or more substituents, pyrimidinyl optionally substituted by one or more substituents, pyridazinyl optionally substituted by one or more substituents, thiazolyl optionally substituted by one or more substituents and thienyl optionally substituted by one or more substituents; preferably selected from phenyl optionally substituted by one or more substituents, pyridyl optionally substituted by one or more substituents, pyridazinyl optionally substituted by one or more substituents, thiazolyl optionally substituted by one or more substituents and thienyl optionally substituted by one or more substituents; preferably selected from The one or more substituents are independently selected from deuterium, halogen, C1-C6 alkyl, C1-C6 alkoxy and cyano.

[0152] In one embodiment, A in the compounds of the general formula herein is selected from 5-14 membered heteroaryl, C 6-14 Aryl, 5-8 membered heterocyclic group and C 6-10 The aryl and 5-8 membered heterocyclic group are preferably selected from 5-14 membered heteroaryl containing 1-5 heteroatoms selected from nitrogen, oxygen and sulfur, 6-14 membered aryl, 5-8 membered heterocyclic group containing 1-3 heteroatoms selected from nitrogen, oxygen and sulfur, and C 6-10 The 5-8 membered heterocyclic group containing 1-3 heteroatoms selected from nitrogen, oxygen and sulfur is preferably selected from the group consisting of a 5-10 membered heteroaryl group, a C 6-10The aryl group, the 5-6 membered nitrogen-containing heterocyclic group, the 5-8 membered oxygen-containing heterocyclic group, the benzo 5-6 membered oxygen-containing heterocyclic group and the benzo 5-6 membered nitrogen-containing heterocyclic group are preferably selected from phenyl, piperazinyl, piperidinyl, pyridinyl, pyrazolyl, quinolyl, isoquinolyl, morpholinyl, thienyl, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydroisobenzofuranyl, benzodioxolyl and imidazopyridinyl.

[0153] In one embodiment, when A is a polycyclic heteroaryl group, L may be attached to any ring in the polycyclic heteroaryl group, and Ra may be substituted on any ring in the polycyclic heteroaryl group. 6-10 When the aryl group is a 5-8 membered heterocyclic group, L can be 6-10 Any one of aryl or 5-8 membered heterocyclic group is connected, Ra can be 6-10 For example, when A is an imidazopyridyl group, L can be connected to either the imidazole ring or the pyridine ring.

[0154] In one embodiment, for wherein the L group is optionally substituted by one or more substituents, said one or more substituents being independently selected from the group consisting of deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 deuterated alkyl, C1-C6 deuterated alkoxy, C1-C6 alkylthio, hydroxyl and cyano, said one or more substituents being independently preferably selected from the group consisting of deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 deuterated alkyl and C1-C6 deuterated alkoxy, said one or more substituents being independently preferably selected from the group consisting of halogen, C1-C6 alkyl and C1-C6 haloalkyl.

[0155] In one embodiment, for wherein the L group is optionally substituted by one or more substituents, said one or more substituents being independently selected from the group consisting of deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 deuterated alkyl, C1-C6 deuterated alkoxy, C1-C6 alkylthio, hydroxyl and cyano, said one or more substituents being independently preferably selected from the group consisting of deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 deuterated alkyl and C1-C6 deuterated alkoxy, said one or more substituents being independently preferably selected from the group consisting of halogen, C1-C6 alkyl and C1-C6 haloalkyl.

[0156] In one embodiment, the Ra group in the compound of the general formula herein, when present, is independently selected from deuterium, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkylthio, halogen, cyano, hydroxy, nitro, amino, oxo, optionally substituted C3-C6 cycloalkyl, -N(R5)(R6), -N(R5)(C(=O)R6), -C(=O)-N(R5)(R6), -C(=O)-OR7, -C(=O)-R7 or -S(= O)2-R7, preferably selected from deuterium, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, halogen, cyano, nitro, oxo, optionally substituted C3-C6 cycloalkyl, -N(R5)(R6), -C(=O)-N(R5)(R6), -C(=O)-OR7 or -S(=O)2-R7, the substituents are independently selected from deuterium, halogen or hydroxy; preferably selected from deuterium, -CHF2, -CF3, -OCHF2, cyano, cyclopropyl, -C(=O)-NH2, - C(=O)-N(CH3)2, fluoro, chloro, -C(=O)-OCH2CH3, -C(=O)-OCH3, methyl, ethyl, isopropyl, -OCH3, -OCH2CH3, -OCH2F, -OCF3, -N(CH3)2, oxo, nitro and -S(=O)2-CH3.

[0157] In one embodiment, R5 and R6 are each independently selected from hydrogen, deuterium and C1-C6 alkyl, preferably selected from hydrogen, deuterium and C1-C3 alkyl.

[0158] In one embodiment, R5 and R6 are linked to the nitrogen atom to which they are attached to form a 3-8 membered nitrogen-containing heterocyclic group, preferably a 5-6 membered nitrogen-containing heterocyclic group.

[0159] In one embodiment, R7 are each independently selected from C1-C6 alkyl, preferably selected from C 1-3 alkyl.

[0160] In one embodiment, m is 0, 1, 2, 3 or 4, preferably 0, 1 or 2, preferably 0.

[0161] In one embodiment, p is 0, 1 or 2 or 3, preferably 0, 1 or 2, preferably 1 or 2.

[0162] In one embodiment, q is 0, 1, 2 or 3, preferably 0, 1 or 2, preferably 0 or 1.

[0163] In one embodiment, n is any integer from 0 to 5, preferably any integer from 0 to 4, preferably 0, 1, 2 or 3.

[0164] In one embodiment, A in the compounds of the general formula herein is selected from 5-14 membered heteroaryl, C 6-14 Aryl and 5-8 heterocyclic groups, preferably selected from 5-14 membered heteroaryl groups containing heteroatoms such as nitrogen, oxygen, sulfur, C 6-10 Aryl and 5-8 membered nitrogen-containing heterocyclic groups, further preferably selected from 5-7 membered monocyclic heteroaryl groups containing 1 / 2 / 3 heteroatoms such as nitrogen, oxygen, and sulfur, 8-10 membered bicyclic heteroaryl groups containing 1 / 2 / 3 heteroatoms such as nitrogen, oxygen, and sulfur, phenyl and 6 membered nitrogen-containing heterocyclic groups; further preferably selected from pyridyl, phenyl, piperazinyl and quinolinyl.

[0165] In one embodiment, L in the compounds of the general formula herein is selected from phenyl optionally substituted with one or more substituents, pyridinyl optionally substituted with one or more substituents, pyrazinyl optionally substituted with one or more substituents, pyrimidinyl optionally substituted with one or more substituents, pyridazinyl optionally substituted with one or more substituents, and thiazolyl optionally substituted with one or more substituents, wherein the one or more substituents are independently selected from H, deuterium, halogen, C1-C6 alkyl, C1-C6 alkoxy and cyano.

[0166] In one embodiment, A in the compounds of the formula herein is selected from phenyl, piperazinyl, pyridinyl, and quinolinyl.

[0167] In one embodiment, the L in the compound of the general formula herein is optionally substituted with one or more substituents. Phenyl and The one or more substituents are independently selected from deuterium, halogen, C1-C6 alkyl, C1-C6 alkoxy and cyano.

[0168] In one embodiment, the L in the compound of the general formula herein is optionally substituted with one or more substituents. Phenyl or The one or more substituents are independently selected from H, deuterium, halogen, C1-C6 alkyl, C1-C6 alkoxy and cyano.

[0169] In one embodiment, the Ra group in the compounds of the general formula herein, when present, is independently selected from deuterium, optionally substituted C1-C3 alkyl, optionally substituted C1-C3 alkoxy, halogen, cyano, optionally substituted C3-C6 cycloalkyl, -C(=O)-N(R5)(R6), -C(=O)-OR7, and the optional substituents are independently selected from deuterium, halogen, hydroxyl; R5 and R6 are each independently selected from hydrogen and C1-C3 alkyl, and R7 is independently selected from C1-C3 alkyl.

[0170] In one embodiment, each Ra group, when present, is independently selected from deuterium, optionally substituted C1-C5 alkyl, optionally substituted C1-C5 alkoxy, halogen, cyano, optionally substituted C3-C6 cycloalkyl, -C(=O)-N(R5)(R6), -C(=O)-OR7, and the optional substituents are independently selected from deuterium, halogen, hydroxyl; and if n is 2, Ra may be different; R5 and R6 are each independently selected from hydrogen, deuterium and C1-C5 alkyl, R7 is independently selected from C1-C5 alkyl, further preferably R5 and R6 are each independently selected from hydrogen, deuterium and methyl, ethyl, propyl, butyl, pentyl, and R7 is independently selected from methyl, ethyl, propyl, butyl and pentyl.

[0171] In one embodiment, the Ra group, when present, is independently selected from deuterium, -CHF2, -CF3, -OCHF2, cyano, cyclopropyl, -C(=O)-NH2, -C(=O)-N(CH3)2, fluorine, chlorine, -C(=O)-OCH2CH3, -C(=O)-OCH3, methyl, ethyl, propyl, -OCH3, -OCH2CH3 and -OCH2F.

[0172] In one embodiment, the compound of formula I is further a compound of formula VII:

[0173] wherein R1, R2, R3, R4, m, A, Ra and n are as defined above.

[0174] In one embodiment, the compound of formula I is further a compound of formula VIII:

[0175] wherein R1, R2, R3, R4, m, A, Ra and n are as defined above.

[0176] In one embodiment, the compound of formula I is further a compound of formula IX:

[0177] wherein R1, R2, R3, R4, m, A, Ra and n are as defined above.

[0178] In one embodiment, the compound of the present invention is selected from the following compounds, stereoisomers, deuterated forms thereof, or pharmaceutically acceptable salts thereof:

[0179] In one embodiment, a method for preparing a compound of formula I, a compound of formula V, Va, Vb, Vc, Vd, Ve, Vf, Vg, Vh, Vi, Vj, Vk, Vl, Vm, Vn, Vo, Vp, Vq, Vr, Vs or a compound of formula VI, Via, Vib, Vic, Vid, Vie, Vif, Vig, Vih, Vii, a stereoisomer thereof, a deuterated compound, or a salt thereof:

[0180] wherein A, Ra and n are as defined above, and R8 is selected from C1-C6 alkyl.

[0181] In one embodiment, a method for preparing formula V comprises the following steps:

[0182] The compound represented by VA undergoes a substitution reaction with the compound represented by VB or a salt thereof to generate a compound represented by formula V;

[0183] wherein A, Ra and n are as defined above; Y4 is halogen, preferably fluorine, chlorine or bromine, preferably fluorine; and R8 is selected from C1-C6 alkyl.

[0184] Similarly, the preparation method of formula Va, Vb, Vc, Vd, Ve, Vf, Vg, Vh, and Vi herein comprises reacting the corresponding raw materials with the compound represented by VB or a salt thereof to form the compounds.

[0185] In one embodiment, a method for preparing Formula I, Formula II, and Formula III comprises the following steps:

[0186] wherein A, Ra and n are as defined above.

[0187] In one embodiment, a method for preparing a compound of formula I comprises the following steps:

[0188] (i) a compound represented by Formula IA or a salt thereof undergoes a substitution reaction with a compound represented by Formula IB or Formula I-B' to produce a compound represented by Formula I;

[0189] (ii) a compound represented by Formula IC or a salt thereof undergoes a substitution reaction with a compound represented by Formula ID to produce a compound represented by Formula I;

[0190] (iii) the compound represented by Formula IE undergoes a substitution reaction with the compound represented by Formula IF to produce the compound represented by Formula I;

[0191] or,

[0192] (iv) the compound represented by formula IG undergoes a substitution reaction with the compound represented by formula IH to produce the compound represented by formula i-1;

[0193] wherein R8 is selected from C1-C6 alkyl;

[0194] Y1 is halogen, preferably fluorine, chlorine or bromine, preferably fluorine;

[0195] Y2 is halogen, preferably fluorine, chlorine or bromine, preferably bromine;

[0196] Y3 is halogen, preferably fluorine, chlorine or bromine, preferably chlorine;

[0197] R1, R2, R3, R4, L, A, Ra, m, n, p and E are as defined above.

[0198] Beneficial technical effects of the present invention:

[0199] Compared with the prior art, the technical solution of the present invention has the following advantages:

[0200] The present invention relates to a class of novel structural compounds, which are M4 positive allosteric modulators for the treatment of diseases associated with M4 positive allostery. In some embodiments, the compounds of the present invention have high allosteric activity on the M4 receptor. In some embodiments, the compounds of the present invention also have improved physicochemical properties (e.g., solubility, physical and / or chemical stability), improved pharmacokinetic properties (e.g., cytochrome P 450In some embodiments, the compounds of the present invention have better drug properties such as lower inhibition of isozymes, improved bioavailability, suitable half-life and duration of action), improved safety (lower toxicity and / or fewer side effects), good patient compliance, and / or less tolerance. In some embodiments, the compounds of the present invention have stronger ability to penetrate the blood-brain barrier and higher ability to enter the brain. In some embodiments, the compounds of the present invention have improved safety, that is, lower acute toxicity and peripheral adverse reactions. In some embodiments, the compounds of the present invention have an improved safety window (for example, a larger safe dosage range, or a lower possibility of side effects at the same dose). Specifically, the results of the in vitro isotope binding test and the in vitro IP-1 test of the present disclosure show that the compounds of the present invention are effective M4 positive allosteric modulators, produce M4 agonist-like efficacy and have higher selectivity, avoiding the off-target effects of M4 receptor agonists. The test results on the effect of MK-801-induced high activity behavior in mice show that the compounds of the present invention can effectively inhibit MK-801-induced high activity behavior in mice and have the potential to treat schizophrenia. Pharmacokinetic studies in rats have shown that the compounds of the present application have the potential to reduce the number of medications taken, increase patient compliance, and improve brain penetration rate, reduce peripheral drug exposure at effective doses, and reduce the occurrence of peripheral adverse reactions.

[0201] Example

[0202] The following embodiments of the present invention are described in detail. The embodiments described below are exemplary and are only used to explain the present invention, and should not be construed as limiting the present invention. Unless otherwise specified, the ratios, percentages, etc. referred to herein are all by weight.

[0203] Some examples of synthetic formula:

[0204] Step 1: To a two-necked flask equipped with a stirrer, add 2-bromo-4-fluoropyridine (1 eq), the corresponding boronic acid pinacol (ester) (1.0-1.2 eq), tetrakistriphenylphosphine palladium (0.1 eq), and cesium carbonate (3 eq). Under nitrogen, add a mixture of dioxane and water (5:1). Purge the mixture three times with nitrogen and allow the reaction to proceed at 110°C. After completion of the reaction as monitored by TLC, cool to room temperature, quench with water, and extract with ethyl acetate. The combined organic phases are dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography to yield Intermediate S1.

[0205] Step 2: To a single-necked flask equipped with a stirrer, add intermediate S1 (1 eq), methyl 2-(azetidin-3-yl)acetate 2,2,2-trifluoroacetate (1.0-1.2 eq), and cesium carbonate (3 eq). DMSO was added at room temperature and the reaction was carried out at 120°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography to yield intermediate S2.

[0206] Step 3-1: To a single-necked flask equipped with a stirrer, add intermediate S2 (1 eq), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (1 eq), and 1,5,7-triazidobicyclo(4.4.0)dec-5-ene (4 eq). Add anhydrous tetrahydrofuran at room temperature and react at 70°C. After completion of the reaction as monitored by TLC, cool to room temperature, concentrate, and sequentially add purified water, saturated sodium chloride solution, and saturated ammonium chloride solution. Extract with dichloromethane, combine the organic phases, dry over anhydrous sodium sulfate, filter, concentrate the organic phase, and chromatograph on a silica gel column to obtain the desired product.

[0207] Step 3-2: In a single-necked flask equipped with a stirrer, add intermediate S2 (1 eq) and anhydrous lithium hydroxide (or anhydrous potassium hydroxide) (5-10 eq). Add a mixture of tetrahydrofuran and water (or anhydrous ethanol and water) (5:1) at room temperature and react at 70°C. After TLC monitoring, cool to room temperature, concentrate, and adjust to pH 4 with 1M aqueous HCl. Extract with ethyl acetate, combine the organic phases, dry over anhydrous sodium sulfate, filter, and concentrate to obtain intermediate S3 (1.0-1.2 eq). HATU (1.0-1.2 eq), DIPEA (3 eq), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (1 eq), and dichloromethane are then added in sequence and react at room temperature. After TLC monitoring, quench the reaction with water, extract with dichloromethane, combine the organic phases, dry over anhydrous sodium sulfate, filter, concentrate, and chromatograph on a silica gel column to obtain the desired product.

[0208] Example 1 Preparation of 1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-(1-(2'-methyl-6'-(trifluoromethyl)-[2,4'-bipyridyl]-4-yl)azetidin-3-yl)ethan-1-one

[0209] Step 1: Synthesis of I-1-1

[0210] To a two-necked flask equipped with a stirrer was added 2-bromo-4-fluoropyridine (118 μL, 1.14 mmol), 2-methyl-6-(trifluoromethyl)pyridine-4-boronic acid pinacol ester (390 mg, 1.36 mmol), tetrakistriphenylphosphine palladium (127 mg, 0.11 mmol), and cesium carbonate (1.11 g, 3.42 mmol). Under nitrogen, 6 mL of a 5:1 mixture of dioxane and water was added. The mixture was purged with nitrogen three times and allowed to react at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 50:1) to afford 235 mg of a white solid. 1 H NMR (300MHz, DMSO-d6) δ8.80(dd,J=8.8,5.5Hz,1H),8.38–8.32(m,2H),8.29(dd,J=10.7,2.4Hz,1H),7.50(ddd,J=8.4,5.6,2.4Hz,1H),2.66(s,3H).

[0211] Step 2: Synthesis of I-1-2

[0212] To a single-necked flask equipped with a stirrer, add 4-fluoro-2'-methyl-6'-(trifluoromethyl)-2,4'-bipyridine (235 mg, 0.92 mmol), methyl 2-(azetidin-3-yl)acetate 2,2,2-trifluoroacetate (268 mg, 1.10 mmol), and cesium carbonate (899 mg, 2.76 mmol). DMSO was added at room temperature and the reaction was allowed to proceed at 120°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 1:1) to afford 271 mg of a light yellow oil. 1 H NMR (300MHz, DMSO-d6) δ8.31(d,J=1.4Hz,1H),8.26(d,J=5.7Hz,2H),7.17(d,J=2.1Hz,1H),6.43(dd,J=5.6,2.1Hz,1H),4 .16(t,J=8.1Hz,2H),3.71(dd,J=8.3,5.7Hz,2H),3.62(s,3H),3.07(p,J=6.8Hz,1H),2.78(d,J=7.7Hz,2H),2.63(s,3H).

[0213] Step 3: Synthesis of I-1-3 and I-1

[0214] In a single-necked flask equipped with a stirrer, methyl 2-(1-(2'-methyl-6'-(trifluoromethyl)-[2,4'-bipyridyl]-4-yl)azetidin-3-yl)acetate (270 mg, 0.74 mmol) and anhydrous lithium hydroxide (89 mg, 3.70 mmol) were added. 5 mL of a mixture of tetrahydrofuran and water (5:1) was added at room temperature and the reaction was carried out at 70°C. After the reaction was completed as monitored by TLC, it was cooled to room temperature, concentrated, and 1 M aqueous HCl solution was added to adjust to pH 4. The mixture was extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated to give 2-(1-(2'-methyl-6'-(trifluoromethyl)-[2,4'-bipyridyl]-4-yl)azetidin-3-yl)acetic acid (I-1-3, 160 mg, 0.46 mmol), followed by the addition of HATU (175 mg, 0.46 mmol), DIPEA (215 μL, 1.23 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (91 mg, 0.41 mmol), and 5 mL of dichloromethane, and the reaction was allowed to proceed at room temperature. After the reaction was completed as monitored by TLC, water was added to quench the reaction, and the mixture was extracted with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was separated by silica gel column chromatography (ethyl acetate:methanol=50:1) to obtain 147 mg of the product, which was the title compound. 1 H NMR(300MHz,DMSO-d6)δ8.37–8.17(m,3H),7.18(s,1H),7.01 (s,1H),6.45(d,J=6.0Hz,1H),4.81(d,J=13.6Hz,2H),4.57(d,J=12.1Hz,2H),4.21(t,J=8.2Hz,2H),3.74(t,J= 7.0Hz,2H),3.14(q,J=13.0,9.7Hz,1H),2.88(d,J=7.7Hz,2H),2.63(s,3H),2.42(s,3H),2.23(d,J=4.9Hz,3H).

[0215] Example 2 Preparation of 2-(1-(2'-chloro-[2,4'-bipyridyl]-4-yl)azetidin-3-yl)-1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)ethan-1-one

[0216] Step 1: Synthesis of I-2-1

[0217] To a two-necked flask equipped with a stirrer, 2-bromo-4-fluoropyridine (118 μL, 1.14 mmol), 2-chloropyridine-4-boronic acid pinacol ester (326 mg, 1.36 mmol), tetrakistriphenylphosphine palladium (127 mg, 0.11 mmol), and cesium carbonate (1.11 g, 3.42 mmol) were added. Under nitrogen, 6 mL of a 5:1 mixture of dioxane and water was added. The mixture was purged with nitrogen three times and allowed to react at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 10:1) to afford 130 mg of a white powder. 1 H NMR(300MHz,DMSO-d6)δ8.79(dd,J=8.9,5.6Hz,1H),8.57(dd,J=5.2,0.7Hz,1H), 8.27–8.18(m,2H),8.14(dd,J=5.2,1.6Hz,1H),7.49(ddd,J=8.7,5.6,2.4Hz,1H).

[0218] Step 2: Synthesis of I-2-2

[0219] To a single-necked flask equipped with a stirrer, add 2'-chloro-4-fluoro-2,4'-bipyridine (130 mg, 0.62 mmol), methyl 2-(azetidin-3-yl)acetate 2,2,2-trifluoroacetate (180 mg, 0.74 mmol), and cesium carbonate (609 mg, 1.87 mmol). DMSO was added at room temperature and the reaction was allowed to proceed at 120°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (pure ethyl acetate) to afford 180 mg of a yellow oil. 1 H NMR (300MHz, DMSO-d6) δ8.48(d,J=5.2Hz,1H),8.25(d,J=5.6Hz,1H),8.15(s,1H),8.07(dd,J=5.2,1.5Hz,1H),7.10(d,J=2.2Hz,1 H), 6.41 (dd, J = 5.6, 2.1Hz, 1H), 4.14 (t, J = 8.2Hz, 2H), 3.69 (t, J = 6.9Hz, 2H), 3.06 (dt, J = 14.7, 7.5Hz, 1H), 2.78 (d, J = 7.7Hz, 2H).

[0220] Step 3: Synthesis of I-2-3 and I-2

[0221] In a single-necked flask equipped with a stirrer, methyl 2-(1-(2'-chloro-[2,4'-bipyridyl]-4-yl)azetidin-3-yl)acetate (210 mg, 0.66 mmol) and anhydrous lithium hydroxide (79 mg, 3.30 mmol) were added. 5 mL of a mixture of tetrahydrofuran and water (5:1) was added at room temperature and the reaction was carried out at 70°C. After the reaction was completed as monitored by TLC, it was cooled to room temperature, concentrated, and 1 M aqueous HCl solution was added to adjust to pH 4. The mixture was extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated to give 2-(1-(2'-chloro-[2,4'-bipyridyl]-4-yl)azetidin-3-yl)acetic acid (I-2-3, 150 mg, 0.49 mmol). HATU (188 mg, 0.49 mmol), DIPEA (235 μL, 1.35 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (100 mg, 0.45 mmol), and 5 mL of dichloromethane were added sequentially and reacted at room temperature. After the reaction was completed as monitored by TLC, water was added to quench the reaction, and the mixture was extracted with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was separated by silica gel column chromatography (ethyl acetate: methanol = 50:1) to obtain 67 mg of the product. 1 H NMR (300MHz, DMSO-d6) δ8.48(d,J=5.2Hz,1H),8.25(d,J=5.6Hz,1H),8.15(d,J=1.4Hz,1H),8. 08(dd,J=5.2,1.5Hz,1H),7.12(d,J=2.2Hz,1H),7.01(d,J=1.7Hz,1H),6.44(dd,J=5.6,2.1Hz, 1H),4.81(d,J=13.7Hz,2H),4.57(d,J=12.6Hz,2H),4.20(t,J=8.2Hz,2H),3.73(dd,J=8.3,5.6 Hz,2H),3.21–3.08(m,1H),2.87(d,J=7.7Hz,2H),2.43(d,J=1.5Hz,3H),2.23(d,J=4.9Hz,3H).

[0222] Example 3 Preparation of 2-(1-([2,4'-bipyridyl]-4-yl)azetidin-3-yl)-1-(2,4-dimethyl-5,7-dihydro-6-pyrrolo[3,4-b]pyridin-6-yl)ethan-1-one

[0223] Step 1: Synthesis of I-3-1

[0224] To a two-necked flask equipped with a stirrer, 2-bromo-4-fluoropyridine (118 μL, 1.14 mmol), 4-pyridineboronic acid pinacol ester (279 mg, 1.36 mmol), tetrakistriphenylphosphine palladium (127 mg, 0.11 mmol), and cesium carbonate (1.11 g, 3.42 mmol) were added. Under nitrogen, 6 mL of a 5:1 mixture of dioxane and water was added. The mixture was purged with nitrogen three times and allowed to react at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 1:1) to afford 155 mg of a white powder. 1 HNMR(300MHz,DMSO-d6)δ8.78(dd,J=9.0,5.6Hz,1H),8.74(d,J=1.7Hz,1H),8.73(d,J=1.7Hz,1H), 8.17–8.11(m,1H),8.10(d,J=1.7Hz,1H),8.09(d,J=1.7Hz,1H),7.44(ddd,J=8.8,5.6,2.4Hz,1H).

[0225] Step 2: Synthesis of I-3-2

[0226] To a single-necked flask equipped with a stirrer, add 4-fluoro-2,4'-bipyridine (200 mg, 1.15 mmol), methyl 2-(azetidin-3-yl)acetate 2,2,2-trifluoroacetate (392 mg, 1.61 mmol), and cesium carbonate (1.12 g, 3.45 mmol). DMSO was added at room temperature and the reaction was allowed to proceed at 120°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were separated by silica gel column chromatography (pure ethyl acetate) to afford 200 mg of a yellow oil. 1 H NMR (300MHz, DMSO-d6) δ8.69–8.60(m,2H),8.25(d,J=5.6Hz,1H),8.05–7.98(m,2H),7.01(d,J=2.1Hz,1H),6.40(dd,J =5.6,2.2Hz,1H),4.14(t,J=8.1Hz,2H),3.69(dd,J=8.2,5.6Hz,2H),3.36(s,3H),3.05(ddt,J=14.4,7.3,5.1Hz,1H), 2.78(d,J=7.7Hz,2H).

[0227] Step 3: Synthesis of I-3-3 and I-3

[0228] In a single-necked flask equipped with a stirrer, methyl 2-(1-([2,4'-bipyridyl]-4-yl)azetidin-3-yl)acetate (210 mg, 0.66 mmol) and anhydrous lithium hydroxide (79.2 mg, 3.3 mmol) were added. 5 mL of a mixture of tetrahydrofuran and water (5:1) was added at room temperature and the reaction was carried out at 70°C. After the reaction was complete as monitored by TLC, the mixture was cooled to room temperature, concentrated, and adjusted to pH 4 with the addition of 1M aqueous HCl. The mixture was then concentrated directly to afford 2-(1-([2,4'-bipyridyl]-4-yl)azetidin-3-yl)acetic acid (I-3-3, quantitative). HATU (198 mg, 0.52 mmol), DIPEA (247 μL, 1.42 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (104 mg, 0.47 mmol), and 5 mL of dichloromethane were subsequently added and allowed to react at room temperature. After the reaction was complete as monitored by TLC, the mixture was quenched with water and extracted with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. 43 mg of the product was isolated by reverse-phase column chromatography (methanol:H2O = 72:18). 1 H NMR (300MHz, DMSO-d6) δ8.79–8.47(m,2H),8.25(d,J=5.6Hz,1H),8.14–7.92(m,2H ),7.01(dd,J=4.8,1.9Hz,2H),6.42(dd,J=5.7,2.2Hz,1H),4.81(d,J=13.1Hz,2H), 4.57(d,J=12.2Hz,2H),4.19(t,J=8.1Hz,2H),3.72(dd,J=8.2,5.6Hz,2H),3.15(d ,J=8.0Hz,1H),2.87(d,J=7.7Hz,2H),2.42(d,J=1.5Hz,3H),2.23(d,J=4.9Hz,3H).

[0229] Example 4 Preparation of 1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-(1-(2'-(trifluoromethyl)-[2,4'-bipyridyl]-5-yl)azetidin-3-yl)ethan-1-one

[0230] Step 1: Synthesis of I-4-1

[0231] To a two-necked flask equipped with a stirrer, 2-bromo-5-fluoropyridine (59 μL, 0.57 mmol), 2-trifluoromethylpyridine-4-boronic acid pinacol ester (171 mg, 0.63 mmol), tetrakistriphenylphosphine palladium (69 mg, 0.06 mmol), and cesium carbonate (557 mg, 1.71 mmol) were added. Under nitrogen, 6 mL of a 5:1 mixture of dioxane and water was added. The mixture was purged with nitrogen three times and allowed to react at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 20:1) to afford 113 mg of a white solid. 1 H NMR (300MHz, DMSO-d6) δ8.90(dd,J=9.3,3.9Hz,2H),8.62(td,J=8.2,2.7Hz,1H),8.36(d,J=1.7Hz,1H),8.22–8.11(m,1H),7.45(dd,J=8.6,2.9Hz,1H).

[0232] Step 2: Synthesis of I-4-2

[0233] To a single-necked flask equipped with a stirrer, add 5-fluoro-2'-(trifluoromethyl)-2,4'-bipyridine (250 mg, 1.03 mmol), methyl 2-(azetidin-3-yl)acetate 2,2,2-trifluoroacetate (301 mg, 1.24 mmol), and cesium carbonate (1.21 g, 3.71 mmol). DMSO was added at room temperature and the reaction was allowed to proceed at 120°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 5:1) to afford 350 mg of a white solid. 1 H NMR(300MHz, DMSO-d6)δ8.70(dd,J=7.7,3.9Hz,2H),8.17–8.06(m,2H),8.03–7.90(m,1H),6.48(d,J=8.8Hz,1H),4 .17(t,J=8.4Hz,2H),3.73(dd,J=8.6,5.6Hz,2H),3.62(d,J=2.0Hz,3H),3.13–2.96(m,1H),2.75(d,J=5.1Hz,2H).

[0234] Step 3: Synthesis of I-4-3 and I-4

[0235] In a single-necked flask equipped with a stirrer, methyl 2-(1-(2'-(trifluoromethyl)-[2,4'-bipyridyl]-5-yl)azetidin-3-yl)acetate (200 mg, 0.57 mmol) and anhydrous lithium hydroxide (68 mg, 2.85 mmol) were added. 5 mL of a mixture of tetrahydrofuran and water (5:1) was added at room temperature and the reaction was carried out at 70°C. After the reaction was completed as monitored by TLC, it was cooled to room temperature, concentrated, and 1 M aqueous HCl solution was added to adjust to pH 4. The mixture was extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated to give 2-(1-(2'-(trifluoromethyl)-[2,4'-bipyridyl]-5-yl)azetidin-3-yl)acetic acid (I-4-3, 120 mg, 0.36 mmol), followed by the addition of HATU (137 mg, 0.36 mmol), DIPEA (172 μL, 0.99 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (72 mg, 0.33 mmol), and 5 mL of dichloromethane, and the reaction was allowed to proceed at room temperature. After the reaction was completed as monitored by TLC, water was added to quench the reaction, and the mixture was extracted with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was separated by silica gel column chromatography (ethyl acetate:triethylamine=100:1) to obtain 47 mg of the product. 1 H NMR (300MHz, DMSO-d6) δ8.95–8.58(m,2H),8.28–8.07(m,2H),8.01(dd,J=5.2 ,1.7Hz,1H),7.02(d,J=2.2Hz,1H),6.51(d,J=8.8Hz,1H),4.82(d,J=14.1Hz,2 H),4.59(d,J=12.3Hz,2H),4.23(t,J=8.3Hz,2H),3.77(dd,J=8.6,5.6Hz,2H) ,3.16–3.04(m,1H),2.88(d,J=7.6Hz,2H),2.44(s,3H),2.24(d,J=4.0Hz,3H).

[0236] Example 5 Preparation of 1-(2-chloro-4-methyl-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-(1-(2'-(trifluoromethyl)-[2,4'-bipyridyl]-4-yl)azetidin-3-yl)ethan-1-one

[0237] Step 1: Synthesis of I-5-1

[0238] To a two-necked flask equipped with a stirrer, 2-bromo-4-fluoropyridine (59 μL, 0.57 mmol), 2-trifluoromethylpyridine-4-boronic acid pinacol ester (156 mg, 0.57 mmol), tetrakistriphenylphosphine palladium (69 mg, 0.06 mmol), and cesium carbonate (557 mg, 1.71 mmol) were added. Under nitrogen, 6 mL of a 5:1 mixture of dioxane and water was added. The mixture was purged with nitrogen three times and allowed to react at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 20:1) to afford 130 mg of yellow crystals. 1 H NMR(300MHz,Chloroform-d)δ8.89(dt,J=5.1,0.7Hz,1H),8.78(dd,J=8.4,5.6Hz,1H),8.35(dd,J=1.7,0.8Hz,1H),8.11(dd,J=5.1,1.7Hz,1H),7.62(dd,J=9.6, 2.3Hz, 1H), 7.19 (ddd, J=8.0, 5.6, 2.3Hz, 1H).

[0239] Step 2: Synthesis of I-5-2

[0240] To a single-necked flask equipped with a stirrer, add 4-fluoro-2'-(trifluoromethyl)-2,4'-bipyridine (200 mg, 0.83 mmol), methyl 2-(azetidin-3-yl)acetate 2,2,2-trifluoroacetate (202 mg, 0.83 mmol), and cesium carbonate (811 mg, 2.49 mmol). DMSO was added at room temperature and the reaction was allowed to proceed at 120°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was separated by silica gel column chromatography (ethyl acetate) to afford 246 mg of a white solid. 1 H NMR(400MHz,Chloroform-d)δ8.80(d,J=5.1Hz,1H),8.36(d,J=5.7Hz,1H),8.25(t,J=1.2Hz,1H),8.05(dd,J=5.2,1.7Hz,1H),6.72(d,J=2.2Hz,1H),6 .33(dd,J=5.7,2.2Hz,1H),4.26(t,J=8.0Hz,2H),3.77(dd,J=8.0,5.4Hz,2 H), 3.73 (s, 3H), 3.23 (tdd, J = 10.5, 7.9, 4.0Hz, 1H), 2.78 (d, J = 7.8Hz, 2H).

[0241] Step 3: Synthesis of I-5-3 and I-5

[0242] In a single-necked flask equipped with a stirrer, methyl 2-(1-(2'-(trifluoromethyl)-[2,4'-bipyridyl]-4-yl)azetidin-3-yl)acetate (120 mg, 0.34 mmol) and anhydrous lithium hydroxide (41 mg, 1.70 mmol) were added. 5 mL of a mixture of tetrahydrofuran and water (5:1) was added at room temperature and the reaction was carried out at 70°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, concentrated, and adjusted to pH 4 with 1M aqueous HCl. The mixture was extracted with ethyl acetate, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to afford 2-(1-(2'-(trifluoromethyl)-[2,4'-bipyridyl]-4-yl)azetidin-3-yl)acetic acid (I-5-3, 62 mg, 0.18 mmol). HATU (68 mg, 0.18 mmol), DIPEA (94 μL, 0.54 mmol), 2-chloro-5,6,7,8-tetrahydro-4-methyl-1,6-naphthyridine hydrochloride (40 mg, 0.18 mmol), and 5 mL of dichloromethane were subsequently added and allowed to react at room temperature. After completion of the reaction as monitored by TLC, the mixture was quenched with water and extracted with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The product (60 mg) was isolated by silica gel column chromatography (ethyl acetate:methanol = 50:1). 1 H NMR(300MHz,Chloroform-d)δ8.72(d,J=5.1Hz,1H),8.27(d,J=5.6Hz,1H),8.15( s,1H),7.97(d,J=5.2Hz,1H),6.99(s,1H),6.63(d,J=2.3Hz,1H),6.25(dd,J=5.8 ,2.3Hz,1H),4.51(d,J=42.1Hz,2H),4.24(t,J=8.1Hz,2H),3.70(dt,J=8.3,3.8H z,4H),3.32–3.12(m,1H),3.02–2.89(m,2H),2.83(d,J=7.5Hz,2H),2.18(s,3H).

[0243] Example 6 Preparation of 1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-(1-(2'-(trifluoromethyl)-[2,4'-bipyridyl]-4-yl)azetidin-3-yl)ethan-1-one

[0244] Step 1: Synthesis of I-6-1

[0245] To a two-necked flask equipped with a stirrer, 2-bromo-4-fluoropyridine (59 μL, 0.57 mmol), 2-trifluoromethylpyridine-4-boronic acid pinacol ester (156 mg, 0.57 mmol), tetrakistriphenylphosphine palladium (69 mg, 0.06 mmol), and cesium carbonate (557 mg, 1.71 mmol) were added. Under nitrogen, 6 mL of a 5:1 mixture of dioxane and water was added. The mixture was purged with nitrogen three times and allowed to react at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 20:1) to afford 130 mg of yellow crystals. 1 H NMR(300MHz,Chloroform-d)δ8.89(dt,J=5.1,0.7Hz,1H),8.78(dd,J=8.4,5.6Hz,1H),8.35(dd,J=1.7, 0.8Hz, 1H), 8.11 (dd, J=5.1, 1.7Hz, 1H), 7.62 (dd, J=9.6, 2.3Hz, 1H), 7.19 (ddd, J=8.0, 5.6, 2.3Hz, 1H).

[0246] Step 2: Synthesis of I-6-2

[0247] To a single-necked flask equipped with a stirrer, add 4-fluoro-2'-(trifluoromethyl)-2,4'-bipyridine (200 mg, 0.83 mmol), methyl 2-(azetidin-3-yl)acetate 2,2,2-trifluoroacetate (202 mg, 0.83 mmol), and cesium carbonate (811 mg, 2.49 mmol). DMSO was added at room temperature and the reaction was allowed to proceed at 120°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was separated by silica gel column chromatography (ethyl acetate) to afford 246 mg of a white solid. 1 H NMR(400MHz,Chloroform-d)δ8.80(d,J=5.1Hz,1H),8.36(d,J=5.7Hz,1H),8.25(t,J=1.2Hz,1H),8.05(dd,J=5.2,1.7Hz,1H),6.72(d,J=2.2Hz,1H),6 .33(dd,J=5.7,2.2Hz,1H),4.26(t,J=8.0Hz,2H),3.77(dd,J=8.0,5.4Hz,2 H), 3.73 (s, 3H), 3.23 (tdd, J = 10.5, 7.9, 4.0Hz, 1H), 2.78 (d, J = 7.8Hz, 2H).

[0248] Step 3: Synthesis of I-6-3 and I-6

[0249] In a single-necked flask equipped with a stirrer, methyl 2-(1-(2'-(trifluoromethyl)-[2,4'-bipyridyl]-4-yl)azetidin-3-yl)acetate (120 mg, 0.34 mmol) and anhydrous lithium hydroxide (41 mg, 1.70 mmol) were added. 5 mL of a mixture of tetrahydrofuran and water (5:1) was added at room temperature and the reaction was carried out at 70°C. After the reaction was completed as monitored by TLC, it was cooled to room temperature, concentrated, and 1 M aqueous HCl solution was added to adjust to pH 4. The mixture was extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated to give 2-(1-(2'-(trifluoromethyl)-[2,4'-bipyridyl]-4-yl)azetidin-3-yl)acetic acid (I-6-3, 67 mg, 0.20 mmol). HATU (76 mg, 0.20 mmol), DIPEA (105 μL, 0.60 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (44 mg, 0.20 mmol), and 5 mL of dichloromethane were added sequentially and reacted at room temperature. After the reaction was completed as monitored by TLC, water was added to quench the reaction, and the mixture was extracted with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was separated by silica gel column chromatography (ethyl acetate: methanol = 50:1) to obtain 90 mg of the product. 1 H NMR(300MHz,Chloroform-d)δ8.83(d,J=5.1Hz,1H),8.36(d,J=5.8Hz,1H),8.24(t,J=1.2Hz, 1H),8.08(dt,J=4.2,1.9Hz,1H),6.94(d,J=4.7Hz,1H),6.73(d,J=2.0Hz,1H),6.36(dt,J=5. 9,1.9Hz,1H),4.86–4.69(m,4H),4.36(td,J=8.2,1.5Hz,2H),3.84(dt,J=8.2,5.4Hz,2H),3. 37(tt,J=8.0,5.3Hz,1H),2.87(t,J=7.3Hz,2H),2.55(d,J=3.3Hz,3H),2.29(d,J=3.9Hz,3H).

[0250] Example 7 Preparation of 2-(1-(2'-(difluoromethoxy)-[2,4'-bipyridyl]-4-yl)azetidin-3-yl)-1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)ethan-1-one

[0251] Step 1: Synthesis of I-7-1

[0252] Reference Example 1, step 1 of the synthesis method, except that the 2-methyl-6-(trifluoromethyl)pyridine-4-boronic acid pinacol ester in step 1 is replaced by 2-(difluoromethoxy)-4-(4,4,5,5-)tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (250 mg, 0.92 mmol), the same method was used to prepare compound I-7-1, and silica gel column chromatography (petroleum ether: ethyl acetate = 50: 1) was used to separate the oily substance 180 mg.

[0253] Step 2: Synthesis of I-7-2

[0254] The synthetic method of reference example 1 step 2 was used, except that 4-fluoro-2'-methyl-6'-(trifluoromethyl)-2,4'-bipyridine in step 2 was replaced with 2'-(difluoromethoxy)-4-fluoro-2,4'-bipyridine (220 mg, 0.92 mmol). Compound I-7-2 was prepared by the same method and separated by silica gel column chromatography (dichloromethane: methanol = 50:1) to obtain 170 mg of a light yellow oil.

[0255] Step 3: Synthesis of I-7-3 and I-7

[0256] In a single-necked flask equipped with a stirrer, methyl 2-(1-(2'-(difluoromethoxy)-[2,4'-bipyridyl]-4-yl)azetidin-3-yl)acetate (350 mg, 1.00 mmol) and anhydrous lithium hydroxide (120 mg, 5.00 mmol) were added. 10 mL of a mixture of tetrahydrofuran and water (5:1) was added at room temperature and the reaction was carried out at 70°C. After the reaction was completed as monitored by TLC, it was cooled to room temperature, concentrated, and 1 M aqueous HCl solution was added to adjust to pH 4. The mixture was extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated to give 2-(1-(2'-(difluoromethoxy)-[2,4'-bipyridyl]-4-yl)azetidin-3-yl)acetic acid (I-7-3, 180 mg, 0.54 mmol). HATU (205 mg, 0.54 mmol), DIPEA (256 μL, 1.47 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (108 mg, 0.49 mmol), and 5 mL of dichloromethane were added sequentially and reacted at room temperature. After the reaction was completed as monitored by TLC, water was added to quench the reaction, and the mixture was extracted with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was separated by silica gel column chromatography (ethyl acetate:triethylamine=100:1) to obtain 107 mg of the product. 1H NMR(300MHz,DMSO-d6)δ8.33(d,J=5.3Hz,1H),8.25(d,J=5.6Hz,1H),8.04–7.87(m,1H) ,7.78–7.47(m,2H),7.10(d,J=2.1Hz,1H),7.00(s,1H),6.43(dd,J=5.7,2.1Hz,1H),4. 80(d,J=13.3Hz,2H),4.57(d,J=12.3Hz,2H),4.19(t,J=8.2Hz,2H),3.72(dd,J=8.3,5. 6Hz,2H),3.20–3.02(m,1H),2.87(d,J=7.6Hz,2H),2.42(s,3H),2.23(d,J=4.8Hz,3H).

[0257] Example 8 Preparation of 1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-(1-(2'-(trifluoromethyl)-[2,4'-bipyridyl]-3-yl)azetidin-3-yl)ethan-1-one

[0258] Step 1: Synthesis of I-8-1

[0259] The synthetic method of reference example 6 step 1 was used, except that 2-bromo-4-fluoropyridine in step 1 was replaced by 2-bromo-3-fluoropyridine (58 μL, 0.57 mmol). Compound I-8-1 was prepared in the same manner and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 10:1) to obtain 62 mg of a light yellow oil. 1 H NMR(300MHz,Chloroform-d)δ8.77(d,J=5.1Hz,1H),8.52(dt,J=4.5,1.6Hz,1H),8.30(dt,J=1.6,0.7Hz ,1H),8.07(dd,J=5.1,1.5Hz,1H),7.52(ddd,J=11.2,8.4,1.4Hz,1H),7.37(ddd,J=8.4,4.5,3.9Hz,1H).

[0260] Step 2: Synthesis of I-8-2

[0261] The synthetic method of reference example 6 step 2 was used, except that 4-fluoro-2'-(trifluoromethyl)-2,4'-bipyridine in step 2 was replaced with 3-fluoro-2'-(trifluoromethyl)-2,4'-bipyridine (60 mg, 0.25 mmol). Compound I-8-2 was prepared in the same manner and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain 15 mg of a yellow oil. 1H NMR (300MHz, DMSO-d6) δ8.85(d,J=5.0Hz,1H),8.19(dd,J=4.5,1.3Hz,1H),8.04(d,J=1.5Hz,1H),7.87(dd,J=5.0,1.6Hz,1H),7.36(dd,J=8.3,4.4 Hz,1H),7.18(dd,J=8.4,1.4Hz,1H),3.74(t,J=7.8Hz,2H),3.56(s,3H),3.27(dd,J=7.8,5.8Hz,2H),2.87(p,J=6.8Hz,1H),2.65(d,J=7.6Hz,2H).

[0262] Step 3: Synthesis of I-8

[0263] To a single-necked flask equipped with a stirrer, methyl 2-(1-(2'-(trifluoromethyl)-[2,4'-bipyridyl]-3-yl)azetidin-3-yl)acetate (100 mg, 0.28 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (62 mg, 0.28 mmol), and 1,5,7-triazidobicyclo(4.4.0)dec-5-ene (156 mg, 1.12 mmol) were added. Anhydrous tetrahydrofuran was added at room temperature and the reaction was allowed to proceed at 70°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature and concentrated. Purified water, saturated sodium chloride solution, and saturated ammonium chloride solution were added sequentially. The mixture was extracted with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (dichloromethane:methanol = 30:1) to afford 32 mg of the product.

[0264] Example 9 Preparation of 2-(1-(2'-cyclopropyl-[2,4'-bipyridyl]-4-yl)azetidin-3-yl)-1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)ethan-1-one

[0265] Step 1: Synthesis of I-9-1

[0266] To a two-necked flask equipped with a stirrer, 2-bromo-4-fluoropyridine (118 μL, 1.14 mmol), 2-chloropyridine-4-boronic acid pinacol ester (326 mg, 1.36 mmol), tetrakistriphenylphosphine palladium (127 mg, 0.11 mmol), and cesium carbonate (1.11 g, 3.42 mmol) were added. Under nitrogen, 6 mL of a 5:1 mixture of dioxane and water was added. The mixture was purged with nitrogen three times and allowed to react at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 10:1) to afford 130 mg of a white powder. 1 H NMR(300MHz,DMSO-d6)δ8.79(dd,J=8.9,5.6Hz,1H),8.57(dd,J=5.2,0.7Hz,1H), 8.27–8.18(m,2H),8.14(dd,J=5.2,1.6Hz,1H),7.49(ddd,J=8.7,5.6,2.4Hz,1H).

[0267] Step 2: Synthesis of I-9-2

[0268] To a two-necked flask equipped with a stirrer, 2'-chloro-4-fluoro-2,4'-bipyridine (100 mg, 0.48 mmol), cyclopropylboronic acid (412 mg, 4.8 mmol), palladium acetate (11 mg, 0.05 mmol), tricyclohexylphosphine (53 mg, 0.19 mmol), and potassium phosphate (204 mg, 0.96 mmol) were added. Under nitrogen, 6 mL of a 10:1 mixture of dioxane and water was added. The mixture was purged with nitrogen three times and allowed to react at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 20:1) to afford 90 mg of a yellow oil.

[0269] Step 3: Synthesis of I-9-3

[0270] The synthetic method of reference example 6 step 2 was used, except that 4-fluoro-2'-(trifluoromethyl)-2,4'-bipyridine in step 2 was replaced by 2'-cyclopropyl-4-fluoro-2,4'-bipyridine (380 mg, 1.77 mmol). Compound I-9-3 was prepared in the same manner and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain 446 mg of a yellow oil.

[0271] Step 4: Synthesis of I-9

[0272] Refer to the synthesis method of step 3 of Example 8, except that the 2-(1-(2'-(trifluoromethyl)-[2,4'-bipyridine]-3-yl)azetidin-3-yl)acetic acid methyl ester in step 3 is replaced by 2-(1-(2'-cyclopropyl-[2,4'-bipyridine]-4-yl)azetidin-3-yl)acetic acid methyl ester (100 mg, 0.31 mmol). The same method was used to prepare compound I-9, and 80 mg of the product was separated by silica gel column chromatography (ethyl acetate: methanol: triethylamine = 50:1:0.5). 1 H NMR (300MHz, Methanol-d4) δ8.62(ddd,J=6.1,5.3,0.8Hz,1H),8.15(t,J=6.8Hz,1H),7.67(dd,J=1.9,0.8H z,1H),7.54(dd,J=5.3,1.8Hz,1H),7.11(s,1H),7.06–6.97(m,1H),6.72(ddd,J=7.1,2.5,0.8Hz,1H),4.87( d,J=1.7Hz,2H),4.74(d,J=5.5Hz,2H),4.57(t,J=9.5Hz,2H),4.14(dd,J=9.6,5.5Hz,2H),3.38(d,J=6.8Hz ,1H),3.03(dd,J=7.7,3.7Hz,2H),2.53(s,3H),2.35(d,J=2.2Hz,3H),1.43–1.27(m,2H),1.20–1.06(m,3H).

[0273] Example 10 Preparation of 1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-(1-(2'-(trifluoromethyl)-[3,4'-bipyridyl]-6-yl)azetidin-3-yl)ethan-1-one

[0274] Step 1: Synthesis of I-10-1

[0275] The synthetic method of reference example 4 step 1 was used, except that 2-bromo-5-fluoropyridine in step 1 was replaced by 2-fluoro-5-bromopyridine (300 mg, 1.70 mmol). Compound I-10-1 was prepared in the same manner and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain 230 mg of a yellow oil. 1H NMR(300MHz,Chloroform-d)δ8.80(d,J=5.1Hz,1H),8.69(dd,J=8.5,5.6Hz,1H),8.25(d,J=1.7Hz ,1H),8.01(dd,J=5.1,1.7Hz,1H),7.52(dd,J=9.6,2.3Hz,1H),7.09(ddd,J=8.0,5.6,2.3Hz,1H).

[0276] Step 2: Synthesis of I-10-2

[0277] The synthetic method of reference example 4 step 2 was used, except that 5-fluoro-2'-(trifluoromethyl)-2,4'-bipyridine in step 2 was replaced by 6-fluoro-2'-(trifluoromethyl)-3,4'-bipyridine (220 mg, 0.91 mmol). Compound I-10-2 was prepared in the same manner and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain 310 mg of a yellow oil. 1 H NMR (300MHz, Chloroform-d) δ7.52(d,J=5.1Hz,1H),7.07(d,J=5.5Hz,1H),6.95(dd,J=1.7,0.8Hz,1H),6.77(dd,J=5.1,1.6Hz,1H),5.42(d,J=2.1Hz ,1H),5.04(dd,J=5.7,2.3Hz,1H),2.97(t,J=8.1Hz,2H),2.48(dd,J=8.1,5 .4Hz,2H),2.44(s,3H),1.93(tt,J=7.9,5.4Hz,1H),1.49(d,J=7.8Hz,2H).

[0278] Step 3: Synthesis of I-10-3 and I-10

[0279] In a single-necked flask equipped with a stirrer, methyl 2-(1-(2'-(trifluoromethyl)-[3,4'-bipyridyl]-6-yl)azetidin-3-yl)acetate (350 mg, 1.00 mmol) and anhydrous lithium hydroxide (120 mg, 5.00 mmol) were added. 10 mL of a mixture of tetrahydrofuran and water (5:1) was added at room temperature and the reaction was carried out at 70°C. After the reaction was completed as monitored by TLC, it was cooled to room temperature, concentrated, and 1 M aqueous HCl solution was added to adjust to pH 4. The mixture was extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated to give 2-(1-(2'-(trifluoromethyl)-[3,4'-bipyridyl]-6-yl)azetidin-3-yl)acetic acid (I-10-3, 140 mg, 0.42 mmol). HATU (160 mg, 0.42 mmol), DIPEA (219 μL, 1.26 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (93 mg, 0.42 mmol), and 5 mL of dichloromethane were added sequentially and reacted at room temperature. After the reaction was completed as monitored by TLC, water was added to quench the reaction, and the mixture was extracted with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was separated by silica gel column chromatography (ethyl acetate:triethylamine=100:1) to obtain 175 mg of the product. 1 H NMR (300MHz, DMSO-d6) δ8.85(d,J=5.1Hz,1H),8.55–8.49(m,1H),8.38(dd,J=5.2,1.6Hz,1H),8.28(d,J=5.6Hz,1H),7.21(d,J=2. 1Hz,1H),7.01(d,J=1.9Hz,1H),6.46(dd,J=5.7,2.1Hz,1H),4.81(d,J=13.6Hz,2H),4.57(d,J=12.4Hz,2H),4.21(t,J=8.2Hz,2H), 3.74(dd,J=8.4,5.6Hz,2H),3.14(s,1H),2.88(d,J=7.7Hz,2H),2.42(d,J=1.7Hz,3H),2.23(d,J=4.9Hz,3H).

[0280] Example 11 Preparation of 4-(4-(3-(2-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-oxoethyl)azetidin-1-yl)pyridin-2-yl)-2-fluorobenzonitrile

[0281] Step 1: Synthesis of I-11-1

[0282] The synthesis method of reference example 1 step 1 was used, except that 2-methyl-6-(trifluoromethyl)pyridine-4-boronic acid pinacol ester in step 1 was replaced with 4-cyano-3-fluorophenylboronic acid pinacol ester (420 mg, 1.70 mmol). Compound I-11-1 was prepared by the same method and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 50: 1) to obtain 224 mg of white powder. 1 H NMR(300MHz, DMSO-d6)δ8.78(dd,J=9.0,5.6Hz,1H),8.26(dd,J=11.1,1.5Hz,1H),8.23–8.1 9(m,1H),8.19–8.14(m,1H),8.09(dd,J=8.2,6.8Hz,1H),7.45(ddd,J=8.6,5.6,2.4Hz,1H).

[0283] Step 2: Synthesis of I-11-2

[0284] The synthetic method of reference example 1 step 2 was used, except that 4-fluoro-2'-methyl-6'-(trifluoromethyl)-2,4'-bipyridine in step 2 was replaced by 2-fluoro-4-(4-fluoropyridin-2-yl)benzonitrile (190 mg, 0.88 mmol). Compound I-11-2 was prepared by the same method and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 1:2) to obtain 100 mg of yellow powder. 1 H NMR (300MHz, DMSO-d6) δ8.24(d,J=5.6Hz,1H),8.19(dd,J=11.4,1.5Hz,1H),8.14(dd,J=8.2,1.5Hz,1H),8.00(dd,J=8.2,6.9Hz,1H),7.07(d,J=2 .1Hz,1H),6.40(dd,J=5.7,2.2Hz,1H),4.14(t,J=8.2Hz,2H),3.69(dd,J=8.3,5.6Hz,2H),3.62(s,3H),3.16–2.95(m,1H),2.78(d,J=7.8Hz,2H).

[0285] Step 3: Synthesis of I-11-3 and I-11

[0286] In a single-necked flask equipped with a stirrer, methyl 2-(1-(2-(4-cyano-3-fluorophenyl)pyridin-4-yl)azetidin-3-yl)acetate (120 mg, 0.37 mmol) and anhydrous lithium hydroxide (89 mg, 3.69 mmol) were added. 10 mL of a mixture of tetrahydrofuran and water (5:1) was added at room temperature and the reaction was carried out at 70°C. After the reaction was completed as monitored by TLC, it was cooled to room temperature, concentrated, and 1 M aqueous HCl solution was added to adjust to pH 4. The mixture was extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated to give 2-(1-(2-(4-cyano-3-fluorophenyl)pyridin-4-yl)azetidin-3-yl)acetic acid (I-11-3, 100 mg, 0.32 mmol). HATU (147 mg, 0.39 mmol), DIPEA (223 μL, 1.28 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (71 mg, 0.32 mmol), and 5 mL of dichloromethane were added sequentially and reacted at room temperature. After the reaction was completed as monitored by TLC, water was added to quench the reaction, and the mixture was extracted with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was separated by silica gel column chromatography (ethyl acetate:triethylamine=100:1) to obtain 33 mg of the product. 1 H NMR (300MHz, DMSO-d6)δ8.31–8.08(m,3H),8.00(dd,J=8.1,6.9Hz,1H),7.08(d,J=2.1 Hz,1H),7.00(d,J=2.0Hz,1H),6.41(dd,J=5.6,2.1Hz,1H),4.80(d,J=13.4Hz,2H), 4.57(d,J=12.2Hz,2H),4.19(t,J=8.2Hz,2H),3.72(dd,J=8.3,5.6Hz,2H),3.12(d ,J=7.6Hz,1H),2.87(d,J=7.7Hz,2H),2.42(d,J=1.6Hz,3H),2.23(d,J=4.8Hz,3H).

[0287] Example 12 Preparation of 2-(1-(2'-(difluoromethyl)-[2,4'-bipyridyl]-4-yl)azetidin-3-yl)-1-(2,4-dimethyl-5,7-dihydro-6-pyrrolo[3,4-b]pyridin-6-yl)ethan-1-one

[0288] Step 1: Synthesis of I-12-1

[0289] The synthetic method of reference example 1 step 1 was used, except that 2-methyl-6-(trifluoromethyl)pyridine-4-boronic acid pinacol ester in step 1 was replaced with 2-difluoromethyl-4-pyridineboronic acid pinacol ester (480 mg, 1.88 mmol). Compound I-12-1 was prepared by the same method and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 30: 1) to obtain 224 mg of yellow powder. 1 H NMR (300MHz, DMSO-d6) δ8.84(d,J=5.4Hz,1H),8.82–8.75(m,1H),8.42(s,1H),8.34–8.18(m,2H),7.56–7.41(m,1H),7.07(t,J=54.8Hz,1H).

[0290] Step 2: Synthesis of I-12-2

[0291] The synthetic method of reference example 1 step 2 was used, except that 4-fluoro-2'-methyl-6'-(trifluoromethyl)-2,4'-bipyridine in step 2 was replaced with 2'-(difluoromethyl)-4-fluoro-2,4'-bipyridine (150 mg, 0.67 mmol). Compound I-12-2 was prepared by the same method and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 2:1) to obtain 160 mg of a yellow oil. 1 H NMR (300MHz, DMSO-d6) δ8.80(d,J=5.1Hz,1H),8.39(d,J=1.6Hz,1H),8.32(d,J=5.6Hz,1H),8.30–8.20(m,1H),7.32–6.78(m,2H),6.4 8(dd,J=5.6,2.2Hz,1H),4.21(t,J=8.1Hz,2H),3.75(dd,J=8.2,5.7Hz,2H),3.67(s,3H),3.11(h,J=6.8Hz,1H),2.83(d,J=7.7Hz,2H).

[0292] Step 3: Synthesis of I-12-3 and I-12

[0293] In a single-necked flask equipped with a stirrer, methyl 2-(1-(2'-(difluoromethyl)-[2,4'-bipyridyl]-4-yl)azetidin-3-yl)acetate (160 mg, 0.48 mmol) and anhydrous lithium hydroxide (115 mg, 4.80 mmol) were added. 10 mL of a mixture of tetrahydrofuran and water (5:1) was added at room temperature and the reaction was carried out at 70°C. After the reaction was completed as monitored by TLC, it was cooled to room temperature, concentrated, and 1 M aqueous HCl solution was added to adjust to pH 4. The mixture was extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated to give 2-(1-(2'-(difluoromethyl)-[2,4'-bipyridyl]-4-yl)azetidin-3-yl)acetic acid (I-12-3, 131 mg, 0.41 mmol). HATU (186 mg, 0.49 mmol), DIPEA (286 μL, 1.64 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (91 mg, 0.41 mmol), and 5 mL of dichloromethane were added sequentially and reacted at room temperature. After the reaction was completed as monitored by TLC, water was added to quench the reaction, and the mixture was extracted with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was separated by silica gel column chromatography (ethyl acetate:triethylamine=100:1) to obtain 102 mg of the product. 1 H NMR(300MHz,DMSO-d6)δ8.76(d,J=5.1Hz,1H),8.40–8.32(m,1H),8.27(d,J=5.6Hz,1H) ,8.22(dt,J=5.2,1.3Hz,1H),7.26–6.81(m,3H),6.44(dd,J=5.6,2.1Hz,1H),4.81(d,J= 13.2Hz,2H),4.57(d,J=12.0Hz,2H),4.21(t,J=8.1Hz,2H),3.74(dd,J=8.3,5.6Hz,2H) ,3.23–3.06(m,1H),2.87(d,J=7.7Hz,2H),2.42(d,J=1.6Hz,3H),2.23(d,J=4.8Hz,3H).

[0294] Example 13 Preparation of 1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-(1-(2'-methoxy-[2,4'-bipyridinyl]-4-yl)azetidin-3-yl)ethan-1-one

[0295] Step 1: Synthesis of I-13-1

[0296] The synthesis method of reference example 1 step 1 was used, except that 2-methyl-6-(trifluoromethyl)pyridine-4-boronic acid pinacol ester in step 1 was replaced with 2-methoxypyridine-4-boronic acid pinacol ester (400 mg, 1.70 mmol). Compound I-13-1 was prepared by the same method and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 30: 1) to obtain 180 mg of a white solid. 1 H NMR (300MHz, DMSO-d6) δ8.76(dd,J=9.0,5.6Hz,1H),8.31(d,J=5.4Hz,1H),8.11(dd,J=10.8,2.4Hz,1 H),7.70(dd,J=5.4,1.5Hz,1H),7.52(d,J=1.4Hz,1H),7.43(ddd,J=8.4,5.6,2.4Hz,1H),3.91(s,3H).

[0297] Step 2: Synthesis of I-13-2

[0298] The synthetic method of reference example 1 step 2 was used, except that 4-fluoro-2'-methyl-6'-(trifluoromethyl)-2,4'-bipyridine in step 2 was replaced with 4-fluoro-2'-methoxy-2,4'-bipyridine (180 mg, 0.88 mmol). Compound I-13-2 was prepared in the same manner and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 2:1) to obtain 194 mg of a white solid. 1 H NMR (300MHz, DMSO-d6) δ8.22(dd,J=5.5,1.9Hz,2H),7.61(dd,J=5.4,1.5Hz,1H),7.42(d,J=1.4Hz,1H),6.97(d,J=2.2Hz,1H),6.38(dd,J=5.7 ,2.1Hz,1H),4.13(t,J=8.1Hz,2H),3.86(s,3H),3.67(dd,J=8.2,5.7Hz,2H),3.61(s,3H),3.04(dq,J=13.7,6.3Hz,1H),2.77(d,J=7.7Hz,2H).

[0299] Step 3: Synthesis of I-13-3 and I-13

[0300] In a single-necked flask equipped with a stirrer, methyl 2-(1-(2'-methoxy-[2,4'-bipyridyl]-4-yl)azetidin-3-yl)acetate (194 mg, 0.62 mmol) and anhydrous lithium hydroxide (149 mg, 6.2 mmol) were added. 5 mL of a mixture of tetrahydrofuran and water (5:1) was added at room temperature and the reaction was carried out at 70°C. After the reaction was completed as monitored by TLC, it was cooled to room temperature, concentrated, and 1M aqueous HCl was added to adjust to pH 4. The mixture was extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated to give 2-(1-(2'-methoxy-[2,4'-bipyridyl]-4-yl)azetidin-3-yl)acetic acid (I-13-3, 154 mg, 0.51 mmol). HATU (236 mg, 0.62 mmol), DIPEA (359 μL, 2.06 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (113 mg, 0.51 mmol), and 5 mL of dichloromethane were added in sequence and reacted at room temperature. After the reaction was completed as monitored by TLC, water was added to quench the reaction, and the mixture was extracted with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was separated by silica gel column chromatography (ethyl acetate:triethylamine=100:1) to obtain 98 mg of the product. 1 H NMR (300MHz, DMSO-d6) δ8.40(d,J=5.4Hz,1H),8.21(d,J=6.9Hz,1H),7.58(d,J=5.5H z,1H),7.47(s,1H),7.12(s,1H),7.02(d,J=3.1Hz,1H),6.69(d,J=7.0Hz,1H),4.81( d,J=12.4Hz,2H),4.58(d,J=11.9Hz,2H),4.44(t,J=9.4Hz,2H),4.00(dd,J=10.6,5. 7Hz,2H),3.94(s,3H),3.21(s,1H),2.92(d,J=7.6Hz,2H),2.43(s,3H),2.24(s,3H).

[0301] Example 14 Preparation of 2-(1-(2'-chloro-6-(trifluoromethyl)-[2,4'-bipyridinyl]-4-yl)azetidin-3-yl)-1-(2,4-dimethyl-5,7-dihydro-6-pyrrolo[3,4-b]pyridin-6-yl)ethan-1-one

[0302] Step 1: Synthesis of I-14-1

[0303] The synthetic method of reference example 1 step 1 was used, except that the 2-methyl-6-(trifluoromethyl)pyridine-4-boronic acid pinacol ester in step 1 was replaced with 2-chloro-6-(trifluoromethyl)pyridine-4-boronic acid pinacol ester (1.00 g, 3.25 mmol). Compound I-14-1 was prepared by the same method and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 75:1) to obtain 407 mg of a white solid. 1 H NMR(300MHz,Chloroform-d)δ8.69(dd,J=8.4,5.6Hz,1H),8.17(d,J=1.4Hz,1H), 8.11–8.03(m,1H),7.51(dd,J=9.5,2.3Hz,1H),7.12(ddd,J=7.9,5.5,2.3Hz,1H).

[0304] Step 2: Synthesis of I-14-2

[0305] The synthetic method of reference example 1 step 2 was used, except that 4-fluoro-2'-methyl-6'-(trifluoromethyl)-2,4'-bipyridine in step 2 was replaced by 2'-chloro-4-fluoro-6'-(trifluoromethyl)-2,4'-bipyridine (180 mg, 0.65 mmol). Compound I-14-2 was prepared by the same method and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 2:1) to obtain 108 mg of a yellow oil. 1 H NMR (300MHz, DMSO-d6) δ8.53(dd,J=10.0,1.3Hz,2H),8.27(dd,J=5.6,1.9Hz,1H),7.28(dd,J=5.7,2.1Hz,1H),6.45(dd,J=5 .6, 2.3Hz, 1H), 4.16 (t, J = 8.2Hz, 2H), 3.71 (dd, J = 8.4, 5.7Hz, 2H), 3.62 (s, 3H), 3.07 (p, J = 6.5Hz, 1H), 2.78 (d, J = 7.7Hz, 2H).

[0306] Step 3: Synthesis of I-14-3 and I-14

[0307] In a single-necked flask equipped with a stirrer, methyl 2-(1-(2'-chloro-6-(trifluoromethyl)-[2,4'-bipyridyl]-4-yl)azetidin-3-yl)acetate (240 mg, 0.62 mmol) and anhydrous lithium hydroxide (149 mg, 6.22 mmol) were added. 5 mL of a mixture of tetrahydrofuran and water (5:1) was added at room temperature and the reaction was carried out at 70°C. After the reaction was completed as monitored by TLC, it was cooled to room temperature, concentrated, and 1 M aqueous HCl solution was added to adjust to pH 4. The mixture was extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated to give 2-(1-(2'-chloro-6-(trifluoromethyl)-[2,4'-bipyridyl]-4-yl)azetidin-3-yl)acetic acid (I-14-3, 162 mg, 0.44 mmol). HATU (198 mg, 0.52 mmol), DIPEA (303 μL, 1.74 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (97 mg, 0.44 mmol), and 5 mL of dichloromethane were added sequentially and reacted at room temperature. After the reaction was completed as monitored by TLC, water was added to quench the reaction, and the mixture was extracted with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was separated by silica gel column chromatography (ethyl acetate:triethylamine=100:1) to obtain 95 mg of the product. 1 H NMR(400MHz,DMSO-d6)δ8.25(d,J=5.6Hz,1H),8.13(s,1H),7.79(s,1H),7.17(d, J=2.2Hz,1H),7.00(d,J=2.6Hz,1H),6.44(dd,J=5.7,2.1Hz,1H),4.81(d,J=18.0H z,2H),4.57(d,J=16.4Hz,2H),4.20(t,J=8.2Hz,2H),3.73(dd,J=8.3,5.7Hz,2H) ,3.13(s,1H),2.87(d,J=7.8Hz,2H),2.42(d,J=2.2Hz,3H),2.23(d,J=6.4Hz,3H).

[0308] Example 15 Preparation of 1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-(1-(2-(3-(trifluoromethyl)phenyl)pyridin-4-yl)azetidin-3-yl)ethan-1-one

[0309] Step 1: Synthesis of I-15-1

[0310] The synthesis method of reference example 1 step 1 was used, except that 2-methyl-6-(trifluoromethyl)pyridine-4-boronic acid pinacol ester in step 1 was replaced with 3-(trifluoromethyl)phenylboronic acid pinacol ester (510 mg, 1.87 mmol). Compound I-15-1 was prepared by the same method and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 30:1) to obtain 249 mg of a yellow oil. 1 H NMR (300MHz, DMSO-d6) δ8.74 (ddd, J=7.5, 5.6, 1.8Hz, 1H), 8.53–8.39 (m, 2H), 8.13 (dt, J=12. 6,3.3Hz,1H),7.85(d,J=7.9Hz,1H),7.76(t,J=7.8Hz,1H),7.39(ddd,J=8.3,5.6,2.5Hz,1H).

[0311] Step 2: Synthesis of I-15-2

[0312] The synthetic method of reference example 1 step 2 was used, except that 4-fluoro-2'-methyl-6'-(trifluoromethyl)-2,4'-bipyridine in step 2 was replaced with 4-fluoro-2-(3-(trifluoromethyl)phenyl)pyridine (200 mg, 0.83 mmol). Compound I-15-2 was prepared in the same manner and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 1:2) to obtain 130 mg of a white solid. 1 H NMR(300MHz,DMSO-d6)δ8.40(dt,J=2.0,1.0Hz,1H),8.38–8.31(m,1H),8.24 (d,J=5.6Hz,1H),7.80–7.73(m,1H),7.73–7.62(m,1H),7.00(d,J=2.1Hz,1H ),6.36(dd,J=5.6,2.2Hz,1H),4.15(t,J=8.1Hz,2H),3.69(dd,J=8.2,5.6Hz ,2H),3.62(s,3H),3.06(ddt,J=11.2,9.0,4.5Hz,1H),2.78(d,J=7.8Hz,2H).

[0313] Step 3: Synthesis of I-15-3 and I-15

[0314] In a single-necked flask equipped with a stirrer, methyl 2-(1-(2-(3-(trifluoromethyl)phenyl)pyridin-4-yl)azetidin-3-yl)acetate (130 mg, 0.37 mmol) and anhydrous lithium hydroxide (89 mg, 3.71 mmol) were added. 10 mL of a mixture of tetrahydrofuran and water (5:1) was added at room temperature and the reaction was carried out at 70°C. After the reaction was completed as monitored by TLC, it was cooled to room temperature, concentrated, and 1 M aqueous HCl solution was added to adjust to pH 4. The mixture was extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated to give 2-(1-(2-(3-(trifluoromethyl)phenyl)pyridin-4-yl)azetidin-3-yl)acetic acid (I-15-3, 89 mg, 0.26 mmol). HATU (122 mg, 0.32 mmol), DIPEA (185 μL, 1.06 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (57 mg, 0.26 mmol), and 5 mL of dichloromethane were added sequentially and reacted at room temperature. After the reaction was completed as monitored by TLC, water was added to quench the reaction, and the mixture was extracted with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was separated by silica gel column chromatography (ethyl acetate:triethylamine=100:1) to obtain 57 mg of the product. 1 H NMR (300MHz, DMSO-d6) δ8.47–8.32(m,2H),8.23(d,J=5.6Hz,1H),7.76(d,J=7.8Hz,1H) ,7.68(t,J=7.7Hz,1H),7.00(d,J=2.2Hz,2H),6.37(dd,J=5.7,2.1Hz,1H),4.80(d,J=1 2.8Hz,2H),4.57(d,J=11.7Hz,2H),4.19(t,J=8.1Hz,2H),3.72(dd,J=8.2,5.6Hz,2H), 3.15–3.04(m,1H),2.87(d,J=7.7Hz,2H),2.42(d,J=1.6Hz,3H),2.23(d,J=4.8Hz,3H).

[0315] Example 16 Preparation of 1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-(1-(2-(4-methylpiperazin-1-yl)pyridin-4-yl)azetidin-3-yl)ethan-1-one

[0316] Step 1: Synthesis of I-16-1

[0317] To a single-necked flask equipped with a stirrer, add 4-bromo-2-fluoropyridine (900 mg, 5.11 mmol), N-methylpiperazine (615 mg, 6.14 mmol), and cesium carbonate (5 g, 15.34 mmol). DMSO was added at room temperature and the mixture was allowed to react at 120°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 5:1) to afford 1.01 g of a white oil. 1 H NMR (300MHz, Chloroform-d) δ8.00(d,J=5.3Hz,1H),6.81(d,J=1.5Hz,1H),6.77(dd,J=5.3,1.5Hz,1H),3.65–3.50(m,4H),2.57–2.50(m,4H),2.37(s,3H).

[0318] Step 2: Synthesis of I-16-2

[0319] In a two-necked flask equipped with a stirrer, 1-(4-bromopyridin-2-yl)-4-methylpiperazine (150 mg, 0.59 mmol), methyl 2-(azetidin-3-yl)acetate 2,2,2-trifluoroacetate (214 mg, 0.88 mmol), chloro(2-dicyclohexylphosphino-2',6'-di-isopropoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium(II) (47 mg, 0.06 mmol) and cesium carbonate (573 mg, 1.76 mmol) were added. Under nitrogen protection, 6 mL of anhydrous dioxane was added, nitrogen was evacuated three times, and the reaction was carried out at 110°C. After the reaction was completed as monitored by TLC, the mixture was cooled to room temperature, quenched with water, extracted with ethyl acetate, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was separated by silica gel column chromatography (ethyl acetate:triethylamine=100:1) to obtain 157 mg of a yellow oil. 1 H NMR(300MHz,Chloroform-d)δ7.94(d,J=5.8Hz,1H),5.83(dd,J=5.8,1.9Hz,1H),5.54(d,J=1.9Hz,1H),4.15(t,J=7.9Hz,2H),3.74(s,3H) ,3.65(dd,J=7.8,5.4Hz,2H),3.56(t,J=5.1Hz,4H),3.15(tt,J=8.0,5.5Hz,1H),2.75(d,J=7.8Hz,3H),2.57(t,J=5.1Hz,4H),2.39(s,3H).

[0320] Step 3: Synthesis of I-16-3 and I-16

[0321] In a single-necked flask equipped with a stirrer, methyl 2-(1-(2-(4-methylpiperazin-1-yl)pyridin-4-yl)azetidin-3-yl)acetate (350 mg, 1.15 mmol) and anhydrous lithium hydroxide (276 mg, 11.50 mmol) were added. 10 mL of a mixture of tetrahydrofuran and water (5:1) was added at room temperature and the reaction was carried out at 70°C. After the reaction was completed as monitored by TLC, it was cooled to room temperature, concentrated, and 1 M aqueous HCl was added to adjust to pH 4. The mixture was extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated to give 2-(1-(2-(4-methylpiperazin-1-yl)pyridin-4-yl)azetidin-3-yl)acetic acid (I-16-3, 233 mg, 0.80 mmol). HATU (365 mg, 0.96 mmol), DIPEA (559 μL, 3.21 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (177 mg, 0.80 mmol), and 5 mL of dichloromethane were added sequentially and reacted at room temperature. After the reaction was completed as monitored by TLC, water was added to quench the reaction, and the mixture was extracted with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was separated by silica gel column chromatography (ethyl acetate:triethylamine=100:1) to obtain 250 mg of a yellow oil. 1 H NMR (300MHz, DMSO-d6) δ7.73(d,J=5.6Hz,1H),7.01(d,J=2.2Hz,1H),5.80(dd,J=5.7,1 .7Hz,1H),5.63(d,J=1.8Hz,1H),4.79(d,J=13.8Hz,2H),4.56(d,J=12.4Hz,2H),4.03( t,J=7.9Hz,2H),3.55(dd,J=7.9,5.6Hz,2H),3.40(d,J=5.0Hz,4H),3.08(s,1H),2.82( d,J=7.6Hz,2H),2.43(s,3H),2.38(t,J=5.0Hz,4H),2.23(d,J=3.5Hz,3H),2.21(s,3H).

[0322] Example 17 Preparation of (2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)(1-(2'-(trifluoromethyl)-[2,4'-bipyridyl]-4-yl)azetidin-3-yl)methanone

[0323] Step 1: Synthesis of I-17-1

[0324] To a two-necked flask equipped with a stirrer, 2-bromo-4-fluoropyridine (177 μL, 1.70 mmol), 2-trifluoromethylpyridine-4-boronic acid pinacol ester (465 mg, 1.70 mmol), tetrakistriphenylphosphine palladium (197 mg, 0.17 mmol), and cesium carbonate (1.67 g, 5.11 mmol) were added. Under nitrogen, 12 mL of a 5:1 mixture of dioxane and water was added. The mixture was purged with nitrogen three times and allowed to react at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 20:1) to afford 130 mg of yellow crystals. 1 H NMR (300MHz, Chloroform-d) δ8.89 (dt, J=5.1, 0.7Hz, 1H), 8.78 (dd, J= 8.4, 5.6Hz, 1H), 8.35 (dd, J=1.7, 0.8Hz, 1H), 8.11 (dd, J=5.1, 1.7Hz, 1H), 7.62 (dd, J=9.6, 2.3Hz, 1H), 7.19 (ddd, J=8.0, 5.6, 2.3Hz, 1H).

[0325] Step 2: Synthesis of I-17-2

[0326] To a single-necked flask equipped with a stirrer, add 4-fluoro-2'-(trifluoromethyl)-2,4'-bipyridine (280 mg, 1.16 mmol), methyl azetidine-3-carboxylate hydrochloride (262 mg, 1.73 mmol), and cesium carbonate (1.13 g, 3.47 mmol). DMSO was added at room temperature and the reaction was allowed to proceed at 120°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 1:1) to afford 230 mg of a white solid. 1 H NMR(300MHz,Chloroform-d)δ8.74(d,J=5.1Hz,1H),8.31(d,J=5.6Hz,1H),8.17(dd,J=1.7,0.8Hz,1H),7.98(dd,J=5.1,1 .6Hz,1H),6.67(d,J=2.2Hz,1H),6.30(dd,J=5.7,2.3Hz,1H),4.27–4.10(m,4H),3.73(s,3H),3.61(tt,J=8.6,6.1Hz,1H).

[0327] Step 3: Synthesis of I-17-3 and I-17

[0328] In a single-necked flask equipped with a stirrer, 1-(2'-(trifluoromethyl)-[2,4'-bipyridyl]-4-yl)azetidine-3-carboxylic acid methyl ester (220 mg, 0.65 mmol) and anhydrous lithium hydroxide (156 mg, 6.52 mmol) were added. 5 mL of a mixture of tetrahydrofuran and water (5:1) was added at room temperature and the reaction was carried out at 70°C. After the reaction was completed as monitored by TLC, it was cooled to room temperature, concentrated, and 1M aqueous HCl solution was added to adjust to pH 4. The mixture was extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated to give 1-(2'-(trifluoromethyl)-[2,4'-bipyridyl]-4-yl)azetidine-3-carboxylic acid (I-17-3, 170 mg, 0.53 mmol). HATU (243 mg, 0.64 mmol), DIPEA (369 μL, 2.12 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (117 mg, 0.53 mmol), and 5 mL of dichloromethane were added in sequence and reacted at room temperature. After the reaction was completed as monitored by TLC, water was added to quench the reaction, and the mixture was extracted with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was separated by silica gel column chromatography (ethyl acetate: methanol = 50:1) to obtain 147 mg of the product. 1 H NMR (300MHz, DMSO-d6) δ8.87(d,J=5.1Hz,1H),8.51(d,J=1.5Hz,1H),8.38(dd,J=5 .1,1.6Hz,1H),8.33(d,J=5.7Hz,1H),7.26(d,J=2.2Hz,1H),7.03(d,J=2.9Hz,1H), 6.53(dd,J=5.7,2.2Hz,1H),4.76(d,J=11.5Hz,2H),4.64(d,J=14.6Hz,2H),4.41–4 .27(m,2H),4.22(q,J=6.1Hz,2H),4.00(q,J=6.4Hz,1H),2.44(s,3H),2.25(s,3H).

[0329] Example 18 Preparation of methyl 4-(4-(3-(2-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-oxoethyl)azetidin-1-yl)pyridin-2-yl)-2-(trifluoromethyl)benzoate

[0330] Step 1: Synthesis of I-18-1

[0331] To a two-necked flask equipped with a stirrer, 2-bromo-4-fluoropyridine (177 μL, 1.70 mmol), methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)benzoate (561 mg, 1.70 mmol), tetrakistriphenylphosphine palladium (197 mg, 0.17 mmol), and cesium carbonate (1.67 g, 5.11 mmol) were added. Under nitrogen, 6 mL of a 5:1 mixture of dioxane and water was added. The mixture was purged with nitrogen three times and allowed to react at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 20:1) to afford 350 mg of a white solid. 1 H NMR (300MHz, DMSO-d6) δ8.81–8.71(m,1H),8.59(d,J=1.9Hz,1H),8.53(dd,J=8.2,1.9Hz,1H),8 .21(ddd,J=10.9,4.2,2.4Hz,1H),7.99(dd,J=8.2,2.5Hz,1H),7.49–7.36(m,1H),3.91(s,3H).

[0332] Step 2: Synthesis of I-18-2

[0333] To a single-necked flask equipped with a stirrer, add 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (117 mg, 0.53 mmol), 2-(1-(tert-butoxycarbonyl)azetidin-3-yl)acetic acid (138 mg, 0.64 mmol), HATU (243 mg, 0.64 mmol), DIPEA (369 μL, 2.12 mmol), and 5 mL of dichloromethane. The mixture was allowed to react at room temperature. After completion of the reaction as monitored by TLC, the mixture was quenched with water and extracted with dichloromethane. The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (ethyl acetate:methanol = 50:1) to afford 165 mg of a pink oil. 1 H NMR(300MHz,Chloroform-d)δ6.85(d,J=2.5Hz,1H),4.67(d,J=15.1Hz,4H),4.10(qd,J=9.0,5.0Hz,2H),3.59(ddd,J=9.1, 5.4,1.9Hz,2H),2.97(qdd,J=6.8,4.7,1.9Hz,1H),2.66(t,J=7.4Hz,2H),2.47(s,3H),2.21(d,J=3.4Hz,3H),1.38(s,9H).

[0334] Step 3: Synthesis of I-18-3 and I-18

[0335] In a single-necked flask equipped with a stirrer, tert-butyl 3-(2-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-oxoethyl)azetidine-1-carboxylate (130 mg, 0.38 mmol) and 2 mL of dichloromethane were added. 0.5 mL of trifluoroacetic acid was added dropwise at room temperature, and the mixture was reacted at room temperature. After the reaction was complete as monitored by TLC, the mixture was concentrated under reduced pressure to give 2-(azetidin-3-yl)-1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)ethan-1-one 2,2,2-trifluoroacetate (I-18-3, 119 mg, 0.35 mmol). I-18-1 (105 mg, 0.35 mmol) and cesium carbonate (342 mg, 1.05 mmol) were then added, and DMSO was added at room temperature. The reaction was allowed to react at 120°C. After the reaction was complete as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. 85 mg of a yellow oil was isolated by silica gel column chromatography (ethyl acetate:triethylamine = 100:1). 1 H NMR (300MHz, DMSO-d6) δ8.55(d,J=1.6Hz,1H),8.46(dd,J=8.2,1.7Hz,1H),8.26(d,J=5.6Hz,1H) ,7.93(d,J=8.1Hz,1H),7.08(d,J=2.1Hz,1H),7.00(s,1H),6.41(dd,J=5.7,2.1Hz,1H),4.81(d, J=13.4Hz,2H),4.57(d,J=12.2Hz,2H),4.20(t,J=8.1Hz,2H),3.90(s,3H),3.73(dd,J=8.2,5.6H z, 2H), 3.15 (d, J = 9.2Hz, 1H), 2.87 (d, J = 7.7Hz, 2H), 2.42 (d, J = 1.6Hz, 3H), 2.23 (d, J = 4.9Hz, 3H).

[0336] Example 19 Preparation of ethyl 4-(4-(3-(2-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-oxoethyl)azetidin-1-yl)pyridin-2-yl)-2-(trifluoromethyl)benzoate

[0337] Step 1: Synthesis of I-19-1

[0338] To a single-necked flask equipped with a stirrer, add 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)benzoic acid (150 mg, 0.47 mmol), thionyl chloride (300 μL, 4.13 mmol), and 5 mL of anhydrous ethanol. The mixture was reacted at 80°C. After completion of the reaction as monitored by TLC, the mixture was concentrated under reduced pressure, quenched with water, and extracted with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 20:1) to afford 60 mg of a transparent oil. 1 H NMR (300MHz, Chloroform-d) δ8.08(s,1H),7.94(d,J=7.6Hz,1H),7.66(d,J=7.6Hz,1H),4.33(q,J=7.2Hz,2H),1.31(s,3H),1.29(s,12H).

[0339] Step 2: Synthesis of I-19-2

[0340] To a two-necked flask equipped with a stirrer, 2-bromo-4-fluoropyridine (60 μL, 0.58 mmol), ethyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)benzoate (200 mg, 0.58 mmol), tetrakistriphenylphosphine palladium (69 mg, 0.06 mmol), and cesium carbonate (567 mg, 1.74 mmol) were added. Under nitrogen, 6 mL of a 5:1 mixture of dioxane and water was added. The mixture was purged with nitrogen three times and allowed to react at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 30:1) to afford 82 mg of a white solid. 1 H NMR(300MHz,Chloroform-d)δ8.66(dd,J=8.5,5.6Hz,1H),8.34(d,J=1.8Hz,1H),8.16(dd,J=8.1,1.8Hz,1H),7.85(d,J= 8.1Hz,1H),7.47(dd,J=9.9,2.3Hz,1H),7.04(ddd,J=8.0,5.6,2.3Hz,1H),4.36(q,J=7.2Hz,2H),1.34(d,J=14.3Hz,3H).

[0341] Step 3 and Step 4

[0342] Refer to steps 2 and 3 in Example 18 to synthesize compound 1-18-3.

[0343] Step 5: Synthesis of I-19

[0344] To a single-necked flask equipped with a stirrer, add 2-(azetidin-3-yl)-1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)ethan-1-one 2,2,2-trifluoroacetate (I-18-3, 94 mg, 0.26 mmol), ethyl 4-(4-fluoropyridin-2-yl)-2-(trifluoromethyl)benzoate (I-19-2, 82 mg, 0.26 mmol), and cesium carbonate (254 mg, 0.79 mmol). DMSO was added and the mixture was allowed to react at room temperature at 120°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (ethyl acetate:triethylamine = 100:1) to afford 80 mg of a yellow oil. 1 H NMR (300MHz, DMSO-d6) δ8.54(s,1H),8.46(d,J=8.2Hz,1H),8.26(d,J=5.7Hz,1H),7.91(d,J =8.1Hz,1H),7.05(d,J=21.5Hz,2H),6.41(d,J=5.7Hz,1H),4.81(d,J=14.0Hz,2H),4.58(d, J=12.8Hz,2H),4.36(q,J=7.3Hz,2H),4.20(t,J=8.2Hz,2H),3.73(t,J=7.1Hz,2H),3.24–3. 06(m,1H),2.87(d,J=7.4Hz,2H),2.43(s,3H),2.23(d,J=5.0Hz,3H),1.34(d,J=7.2Hz,3H).

[0345] Example 20 Preparation of 1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-(1-(2-(quinolin-4-yl)pyridin-4-yl)azetidin-3-yl)ethan-1-one

[0346] Step 1: Synthesis of I-20-1

[0347] The synthetic method of reference example 1 step 1 was used, except that the 2-methyl-6-(trifluoromethyl)pyridine-4-boronic acid pinacol ester in step 1 was replaced with 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline (290 mg, 1.14 mmol). Compound I-20-1 was prepared by the same method and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 2:1) to obtain 130 mg of yellow powder. 1H NMR (300MHz, DMSO-d6) δ9.01 (d, J=4.4Hz, 1H), 8.84 (dd, J=8.9, 5.7Hz, 1H), 8.24–8. 07(m,2H),7.88–7.73(m,2H),7.73–7.57(m,2H),7.51(ddd,J=8.5,5.7,2.5Hz,1H).

[0348] Step 2: Synthesis of I-20-2

[0349] The synthetic method of reference example 1 step 2 was used, except that 4-fluoro-2'-methyl-6'-(trifluoromethyl)-2,4'-bipyridine in step 2 was replaced with 4-(4-fluoropyridin-2-yl)quinoline (220 mg, 0.98 mmol). Compound I-20-2 was prepared in the same manner and separated by silica gel column chromatography (dichloromethane: methanol = 100: 1) to obtain 100 mg of a white solid. 1 H NMR (300MHz, DMSO-d6) δ9.07(d,J=4.4Hz,1H),8.41(d,J=6.0Hz,1H),8.29(d,J=8.5 Hz,1H),8.19(d,J=8.5Hz,1H),7.88(ddd,J=8.3,6.9,1.5Hz,1H),7.74–7.62(m,2H) ,6.75(d,J=2.2Hz,1H),6.58(dd,J=5.9,2.2Hz,1H),4.24(t,J=8.1Hz,2H),3.79(dd ,J=8.3,5.7Hz,2H),3.71(d,J=1.7Hz,3H),3.28–3.08(m,1H),2.88(d,J=7.6Hz,2H).

[0350] Step 3: Synthesis of I-20-3 and I-20

[0351] In a single-necked flask equipped with a stirrer, methyl 2-(1-(2-(quinolin-4-yl)pyridin-4-yl)azetidin-3-yl)acetate (100 mg, 0.30 mmol) and anhydrous lithium hydroxide (72 mg, 3.00 mmol) were added. 5 mL of a mixture of tetrahydrofuran and water (5:1) was added at room temperature and the reaction was carried out at 70°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, concentrated, and adjusted to pH 4 with 1M aqueous HCl. The mixture was extracted with ethyl acetate, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to afford 2-(1-(2-(quinolin-4-yl)pyridin-4-yl)azetidin-3-yl)acetic acid (I-20-3, 85 mg, 0.30 mmol). HATU (114 mg, 0.30 mmol), DIPEA (157 μL, 0.90 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (66 mg, 0.30 mmol), and 5 mL of dichloromethane were subsequently added and allowed to react at room temperature. After completion of the reaction as monitored by TLC, the mixture was quenched with water and extracted with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The product (82 mg) was isolated by silica gel column chromatography (ethyl acetate:triethylamine = 100:1). 1 H NMR (300MHz, DMSO-d6) δ8.97(d,J=4.4Hz,1H),8.31(d,J=5.7Hz,1H),8.19(d,J=8.5Hz,1H),8 .09(d,J=8.4Hz,1H),7.85–7.72(m,1H),7.59(dd,J=8.9,6.2Hz,2H),7.00(d,J=2.4Hz,1H),6 .67(d,J=2.2Hz,1H),6.50(dd,J=5.8,2.3Hz,1H),4.80(d,J=13.4Hz,2H),4.57(d,J=12.7Hz, 2H),4.18(t,J=8.1Hz,2H),3.72(dd,J=8.3,5.6Hz,2H),3.24–3.06(m,1H),2.87(d,J=7.6Hz, 2H),2.42(s,3H),2.23(d,J=2.7Hz,3H).

[0352] Example 21 Preparation of 1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-(1-(2'-methyl-[2,4'-bipyridinyl]-4-yl)azetidin-3-yl)ethan-1-one

[0353] Step 1: Synthesis of I-21-1

[0354] Refer to the synthesis of step 1 in Example 9.

[0355] Step 2: Synthesis of I-21-2

[0356] To a two-necked flask equipped with a stirrer was added 2'-chloro-4-fluoro-2,4'-bipyridine (250 mg, 1.20 mmol), trimethylcyclotriboroxine (1.01 mL, 3.59 mmol), palladium acetate (27 mg, 0.12 mmol), tricyclohexylphosphine (67 mg, 0.24 mmol), and potassium phosphate (764 mg, 3.60 mmol). Under nitrogen, 6 mL of a 5:1 mixture of dioxane and water was added. The mixture was purged with nitrogen three times and allowed to react at 100°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (ethyl acetate:methanol = 300:1) to afford 180 mg of a white solid. 1 H NMR (300MHz, DMSO-d6) δ8.76(dd,J=9.0,5.6Hz,1H),8.59(dd,J=5.2,0.8Hz,1H),8.10(dd,J=10.8,2.4Hz ,1H),7.99(d,J=1.7Hz,1H),7.89(dd,J=5.2,1.7Hz,1H),7.44(ddd,J=8.7,5.6,2.4Hz,1H),2.57(s,3H).

[0357] Step 3: Synthesis of I-21-3

[0358] The synthetic method of reference example 1 step 2 was used, except that 4-fluoro-2'-methyl-6'-(trifluoromethyl)-2,4'-bipyridine in step 2 was replaced with 4-fluoro-2'-methyl-2,4'-bipyridine (180 mg, 0.96 mmol). Compound I-21-3 was prepared in the same manner and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 5:1) to obtain 240 mg of a white solid. 1 H NMR (300MHz, DMSO-d6) δ8.50(dd,J=5.3,0.8Hz,1H),8.24(d,J=5.6Hz,1H),7.93–7.87(m,1H),7.85–7.67(m,1H),6.99(d,J=2.1Hz,1H),6.39( dd,J=5.6,2.2Hz,1H),4.14(t,J=8.1Hz,2H),3.69(dd,J=8.2,5.6Hz,2H),3.62(s,3H),3.13–2.96(m,1H),2.78(d,J=7.8Hz,2H),2.54(s,3H).

[0359] Step 4: Synthesis of I-21-4 and I-21

[0360] In a single-necked flask equipped with a stirrer, methyl 2-(1-(2'-methyl-[2,4'-bipyridyl]-4-yl)azetidin-3-yl)acetate (330 mg, 1.11 mmol) and anhydrous lithium hydroxide (133 mg, 5.55 mmol) were added. 10 mL of a mixture of tetrahydrofuran and water (5:1) was added at room temperature and the reaction was carried out at 70°C. After the reaction was completed as monitored by TLC, it was cooled to room temperature, concentrated, and 1 M aqueous HCl was added to adjust to pH 4. The mixture was extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated to give 2-(1-(2'-methyl-[2,4'-bipyridyl]-4-yl)azetidin-3-yl)acetic acid (I-21-4, 250 mg, 0.88 mmol). HATU (335 mg, 0.88 mmol), DIPEA (420 μL, 2.41 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (177 mg, 0.80 mmol), and 5 mL of dichloromethane were added in sequence and reacted at room temperature. After the reaction was completed as monitored by TLC, water was added to quench the reaction, and the mixture was extracted with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was separated by silica gel column chromatography (ethyl acetate:methanol=6:1) to obtain 78 mg of the product.

[0361] Example 22 Preparation of 1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-(1-(2'-(trifluoromethyl)-[4,4'-bipyridyl]-2-yl)azetidin-3-yl)ethan-1-one

[0362] Step 1: Synthesis of I-22-1

[0363] The synthetic method of reference example 6 step 1 is used, except that 4-fluoro-2-bromopyridine in step 1 is replaced by 4-bromo-2-fluoropyridine (176 mg, 1.00 mmol). Compound I-22-1 is prepared in the same manner and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 10:1) to obtain 225 mg of white powder. 1 H NMR (300MHz, DMSO-d6) δ8.95(d,J=5.1Hz,1H),8.53–8.35(m,2H),8.23(dd,J=5.2,1.7Hz,1H),7.95(dt,J=5.3,1.8Hz,1H),7.91–7.77(m,1H).

[0364] Step 2: Synthesis of I-22-2

[0365] The synthetic method of reference example 6 step 2 was used, except that 4-fluoro-2'-(trifluoromethyl)-2,4'-bipyridine in step 2 was replaced with 2-fluoro-2'-(trifluoromethyl)-4'-bipyridine (220 mg, 0.91 mmol). Compound I-22-2 was prepared in the same manner and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 10:1) to obtain 300 mg of a yellow oil.

[0366] Step 3: Synthesis of I-22-3 and I-22

[0367] In a single-necked flask equipped with a stirrer, methyl 2-(1-(2'-(trifluoromethyl)-[4,4'-bipyridyl]-2-yl)azetidin-3-yl)acetate (300 mg, 0.85 mmol) and anhydrous lithium hydroxide (102 mg, 4.25 mmol) were added. 10 mL of a mixture of tetrahydrofuran and water (5:1) was added at room temperature and the reaction was carried out at 70°C. After the reaction was completed as monitored by TLC, it was cooled to room temperature, concentrated, and 1 M aqueous HCl was added to adjust the pH to 4. The mixture was extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated to give 2-(1-(2'-(trifluoromethyl)-[4,4'-bipyridyl]-2-yl)azetidin-3-yl)acetic acid (I-22-3, 125 mg, 0.37 mmol), followed by the addition of HATU (141 mg, 0.37 mmol), DIPEA (193 μL, 1.11 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (75 mg, 0.34 mmol), and 5 mL of dichloromethane, and the reaction was allowed to proceed at room temperature. After the reaction was completed as monitored by TLC, water was added to quench the reaction, and the mixture was extracted with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was separated by silica gel column chromatography (ethyl acetate: methanol = 100:1) to obtain 70 mg of the product. 1 H NMR (300MHz, DMSO-d6) δ8.87(d,J=5.1Hz,1H),8.26(s,1H),8.21(d,J=5.3Hz,1H),8. 11(dd,J=5.1,1.7Hz,1H),7.10(dd,J=5.4,1.5Hz,1H),7.00(s,1H),6.87(s,1H),4.81 (d,J=14.1Hz,2H),4.57(d,J=12.2Hz,2H),4.21(t,J=8.1Hz,2H),3.75(dd,J=8.4,5.6 Hz,2H),3.21–2.99(m,1H),2.86(d,J=7.6Hz,2H),2.42(s,3H),2.23(d,J=4.1Hz,3H).

[0368] Example 23 Preparation of 1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-(1-(5-(2-(trifluoromethyl)pyridin-4-yl)pyridazin-3-yl)azetidin-3-yl)ethan-1-one

[0369] Step 1: Synthesis of I-23-1

[0370] The synthetic method of reference example 6 step 1 was used, except that 4-fluoro-2-bromopyridine in step 1 was replaced by 5-bromo-3-chloropyridazine (200 mg, 1.03 mmol). Compound I-23-1 was prepared in the same manner and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain 267 mg of white powder.

[0371] Step 2: Synthesis of I-23-2

[0372] Reference is made to the synthetic method of step 2 of Example 6, except that 4-fluoro-2'-(trifluoromethyl)-2,4'-bipyridine in step 2 is replaced by 3-chloro-5-(2-(trifluoromethyl)pyridin-4-yl)pyridazine (250 mg, 0.96 mmol). Compound I-23-2 is prepared in the same manner and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 2:3) to obtain 180 mg of a yellow oil. 1 H NMR (300MHz, DMSO-d6) δ9.08(d,J=2.0Hz,1H),8.92(d,J=5.1Hz,1H),8.49–8.34(m,1H),8.23(dd,J=5.2,1.7Hz,1H),7.32( d,J=2.0Hz,1H),4.28(t,J=8.3Hz,2H),3.85(dd,J=8.6,5.7Hz,2H),3.59(s,3H),3.19–3.00(m,1H),2.80(d,J=7.7Hz,2H).

[0373] Step 3: Synthesis of I-23-3 and I-23

[0374] In a single-necked flask equipped with a stirrer, methyl 2-(1-(5-(2-(trifluoromethyl)pyridin-4-yl)pyridazin-3-yl)azetidin-3-yl)acetate (180 mg, 0.51 mmol) and anhydrous lithium hydroxide (123 mg, 5.11 mmol) were added. 5 mL of a mixture of tetrahydrofuran and water (5:1) was added at room temperature and the reaction was carried out at 70°C. After the reaction was complete as monitored by TLC, the mixture was cooled to room temperature, concentrated, and adjusted to pH 4 with the addition of 1M aqueous HCl. The mixture was extracted with ethyl acetate, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to afford 2-(1-(5-(2-(trifluoromethyl)pyridin-4-yl)pyridazin-3-yl)azetidin-3-yl)acetic acid (I-23-3, quantitative). HATU (164 mg, 0.43 mmol), DIPEA (225 μL, 1.29 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (95 mg, 0.43 mmol), and 5 mL of dichloromethane were subsequently added and allowed to react at room temperature. After the reaction was complete as monitored by TLC, the mixture was quenched with water and extracted with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The product (23 mg) was isolated by reverse-phase column chromatography (methanol:water = 82:18). 1 H NMR (400MHz, DMSO-d6) δ9.06 (dd, J=4.2, 1.9Hz, 1H), 8.93 (d, J=5.1Hz, 1H), 8.42 (s, 1H), 8.23 ​​(d d,J=5.1,1.7Hz,1H),7.32(dd,J=5.9,1.9Hz,1H),7.01(d,J=2.7Hz,1H),4.82(d,J=18.9Hz,2H), 4.58(d,J=17.3Hz,2H),4.30(dt,J=22.7,8.3Hz,2H),3.84(ddd,J=31.8,8.6,5.8Hz,2H),3.17(t dd,J=7.9,6.1,5.5,2.8Hz,1H),2.92–2.76(m,2H),2.43(d,J=1.9Hz,3H),2.23(d,J=5.1Hz,3H).

[0375] Example 24 Preparation of 4-(4-(3-(2-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-oxoethyl)azetidin-1-yl)pyridin-2-yl)-N,N-dimethylbenzamide

[0376] Step 1: Synthesis of I-24-1

[0377] To a single-necked flask equipped with a stirrer, add 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (117 mg, 0.53 mmol), 2-(1-(tert-butoxycarbonyl)azetidin-3-yl)acetic acid (138 mg, 0.64 mmol), HATU (243 mg, 0.64 mmol), DIPEA (369 μL, 2.12 mmol), and 5 mL of dichloromethane. The mixture was allowed to react at room temperature. After completion of the reaction as monitored by TLC, the mixture was quenched with water and extracted with dichloromethane. The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (ethyl acetate:methanol = 50:1) to afford 165 mg of a pink oil. 1 H NMR(300MHz,Chloroform-d)δ6.85(d,J=2.5Hz,1H),4.67(d,J=15.1Hz,4H),4.10(qd,J=9.0,5.0Hz,2H),3.59(ddd,J=9.1, 5.4,1.9Hz,2H),2.97(qdd,J=6.8,4.7,1.9Hz,1H),2.66(t,J=7.4Hz,2H),2.47(s,3H),2.21(d,J=3.4Hz,3H),1.38(s,9H).

[0378] Step 2: Synthesis of I-24-2

[0379] To a single-necked flask was added tert-butyl 3-(2-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-oxoethyl)azetidine-1-carboxylate (122 mg, 0.35 mmol), and a mixed solution of dichloromethane and trifluoroacetic acid (4:1) was added. The mixture was reacted at room temperature and concentrated under reduced pressure to obtain 2-(azetidine-3-yl)-1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)ethane-1-one trifluoroacetate, which was directly carried out into the next step without purification.

[0380] Step 3: Synthesis of I-24-3

[0381] To a one-necked flask containing 2-(azetidin-3-yl)-1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)ethan-1-one trifluoroacetate (122 mg, 0.34 mmol) was added 2-bromo-4-fluoropyridine (35 μL, 0.34 mmol) and cesium carbonate (332 mg, 1.02 mmol). DMF was added at room temperature and the reaction was allowed to proceed at 120°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature and concentrated under reduced pressure. The residue was diluted with water and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was then purified by silica gel column chromatography (dichloromethane:methanol = 40:1) to afford 83 mg of a pale yellow oil.

[0382] Step 4: Synthesis of I-24

[0383] In a two-necked flask equipped with a stirrer, 2-(1-(2-bromopyridin-4-yl)azetidin-3-yl)-1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)ethan-1-one (83 mg, 0.21 mmol), 4-(dimethylcarbonyl)phenylboronic acid dihydroxyhexanediol ester (57 mg, 0.21 mmol), tetrakis(triphenylphosphine)palladium (23 mg, 0.02 mmol) and cesium carbonate (205 mg, 0.63 mmol) were added. Under nitrogen protection, 6 mL of a mixture of dioxane and water (5:1) was added, and nitrogen was evacuated three times. The reaction was carried out at 110°C. After the reaction was completed as monitored by TLC, the mixture was cooled to room temperature and concentrated under reduced pressure. The residue was diluted with water and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was separated by silica gel column chromatography (dichloromethane: methanol = 20:1) to obtain 22 mg of the product. 1 H NMR(300MHz, DMSO-d6)δ8.22(d,J=5.6Hz,1H),8.13–8.05(m,2H),7.50–7.44(m,2H),7.00(d,J=1.9Hz,1H),6.9 0(d,J=2.1Hz,1H),6.35(dd,J=5.7,2.1Hz,1H),4.80(d,J=12.2Hz,2H),4.57(d,J=11.7Hz,2H),4.16(q,J=12.1, 10.1Hz,2H),3.71(dd,J=8.2,5.6Hz,2H),3.21–3.08(m,1H),2.97(d,J=16.1Hz,6H),2.87(d,J=7.7Hz,2H),2.42(s,3H),2.22(d,J=4.5Hz,3H).

[0384] Example 25 Preparation of 4-(4-(3-(2-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-oxoethyl)azetidin-1-yl)pyridin-2-yl)benzamide

[0385] Referring to the method of Example 24, except that the 4-(dimethylcarbonyl)phenylboronic acid dihydroxyhexanediol ester in step 4 was replaced with benzamide boronic acid pinacol ester (52 mg, 0.21 mmol), the same method was used to prepare compound I-25, and 20 mg of the product was separated by silica gel column chromatography (dichloromethane: methanol = 10:1). 1 H NMR(300MHz,DMSO-d6)δ8.14(d,J=5.6Hz,1H),8.08–7.95(m,3H),7.86(d,J=8.2H z,2H),7.34(s,1H),6.93(s,1H),6.86(d,J=2.1Hz,1H),6.28(dd,J=5.7,2.1Hz,1H ),4.73(d,J=13.6Hz,2H),4.50(d,J=12.4Hz,2H),4.10(t,J=8.1Hz,2H),3.68–3. 57(m,2H),3.05(s,1H),2.79(d,J=7.7Hz,2H),2.35(s,3H),2.15(d,J=4.9Hz,3H).

[0386] Example 26 Preparation of 1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-(1-(4-(2-(trifluoromethyl)pyridin-4-yl)phenyl)azetidin-3-yl)ethan-1-one

[0387] Step 1: Synthesis of I-26-1

[0388] The synthetic method of reference example 4 step 1 is different in that 2-bromo-5-fluoropyridine in step 1 is replaced by 4-bromochlorobenzene (400 mg, 2.09 mmol). Compound I-26-1 is prepared in the same manner and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 30:1) to obtain 462 mg of white crystals. 1 H NMR (300MHz, Chloroform-d) δ8.86(d,J=5.1Hz,1H),7.94(d,J=1.7Hz,1H),7.74(dd,J=5.1,1.7Hz,1H),7.72–7.63(m,2H),7.63–7.53(m,2H).

[0389] Step 2: Synthesis of I-26-2

[0390] To a two-necked flask equipped with a stirrer, 4-(4-chlorophenyl)-2-(trifluoromethyl)pyridine (250 mg, 0.97 mmol), methyl 2-(azetidin-3-yl)acetate 2,2,2-trifluoroacetate (282 mg, 1.16 mmol), tris(dibenzylideneacetone)dipalladium (89 mg, 0.10 mmol), 2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl (91 mg, 0.19 mmol), and potassium tert-butoxide (280 mg, 2.49 mmol) were added. Under nitrogen, 6 mL of anhydrous dioxane was added, and the mixture was purged with nitrogen three times. The reaction was allowed to proceed at 100°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 1:1) to afford 92 mg of a white solid. 1 H NMR(300MHz,Chloroform-d)δ8.64(d,J=5.2Hz,1H),7.84–7.75(m,1H),7.59(dd,J=5.3,1.7Hz,1H),7.57–7.46(m,2H),6. 58–6.42(m,2H),4.14(t,J=7.7Hz,2H),3.68(s,3H),3.65(dd,J=7.6,5.5Hz,2H),3.19–3.03(m,1H),2.72(d,J=7.8Hz,2H).

[0391] Step 3: Synthesis of I-26

[0392] Refer to the synthesis method of step 3 of Example 8, except that the 2-(1-(2'-(trifluoromethyl)-[2,4'-bipyridine]-3-yl)azetidin-3-yl)acetic acid methyl ester in step 3 is replaced by 2-(1-(4-(2-(trifluoromethyl)pyridin-4-yl)phenyl)azetidin-3-yl)acetic acid methyl ester (90 mg, 0.26 mmol). The same method was used to prepare compound I-26, and 103 mg of the product was separated by silica gel column chromatography (ethyl acetate: methanol: triethylamine = 50:1:0.5). 1H NMR (400MHz, DMSO-d6) δ8.67(d,J=5.2Hz,1H),8.05(d,J=1.7Hz,1H),7.93(dd,J=5.3 ,1.7Hz,1H),7.84–7.70(m,2H),7.00(d,J=2.2Hz,1H),6.63–6.44(m,2H),4.81(d,J=1 9.2Hz,2H),4.58(d,J=17.0Hz,2H),4.11(t,J=7.8Hz,2H),3.63(dd,J=7.6,5.6Hz,2H ),3.19–3.06(m,1H),2.94–2.79(m,2H),2.43(d,J=2.0Hz,3H),2.23(d,J=5.6Hz,3H).

[0393] Example 27 Preparation of 1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-(1-(5-(2-(trifluoromethyl)pyridin-4-yl)thiazol-2-yl)azetidin-3-yl)ethan-1-one

[0394] Step 1: Synthesis of I-27-1

[0395] To a single-necked flask, 2,5-dibromothiazole (300 mg, 1.23 mmol), DIPEA (645 μL, 3.70 mmol), and methyl 2-(azetidin-3-yl)acetate 2,2,2-trifluoroacetate (211 mg, 1.48 mmol) were added sequentially. 8 mL of dioxane was added at room temperature and the mixture was allowed to react at 80°C. After completion of the reaction as monitored by TLC, the mixture was quenched with water and extracted with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was then purified by silica gel column chromatography (petroleum ether:ethyl acetate = 20:1) to afford 154 mg of a yellow oil. 1 H NMR (300MHz, DMSO-d6) δ7.18(s,1H),4.09(t,J=8.1Hz,2H),3.70(dd,J=8.0,5.9Hz,2H),3.60(s,3H),3.15–3.01(m,1H),2.76(d,J=7.7Hz,2H).

[0396] Step 2: Synthesis of I-27-2

[0397] To a two-necked flask equipped with a stirrer was added methyl 2-(1-(5-bromothiazol-2-yl)azetidin-3-yl)acetate (150 mg, 0.52 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)pyridine (141 mg, 0.52 mmol), tetrakistriphenylphosphine palladium (60 mg, 0.05 mmol), and cesium carbonate (508 mg, 1.56 mmol). Under nitrogen, 6 mL of a 5:1 mixture of dioxane and water was added. The mixture was purged with nitrogen three times and allowed to react at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 2:1) to afford 160 mg of a yellow solid.

[0398] Step 3: Synthesis of I-27

[0399] Refer to the synthesis method of step 3 of Example 8, except that the 2-(1-(2'-(trifluoromethyl)-[2,4'-bipyridine]-3-yl)azetidin-3-yl)acetic acid methyl ester in step 3 is replaced with 2-(1-(5-(2-(trifluoromethyl)pyridin-4-yl)thiazol-2-yl)azetidin-3-yl)acetic acid methyl ester (200 mg, 0.56 mmol). The same method was used to prepare compound I-27, and 213 mg of the product was separated by silica gel column chromatography (ethyl acetate: methanol: triethylamine = 50:1:0.5). 1 H NMR(300MHz,DMSO-d6)δ8.61(d,J=5.2Hz,1H),8.18(s,1H),7.96(d,J=1.7Hz, 1H),7.64(dd,J=5.2,1.7Hz,1H),7.00(d,J=2.5Hz,1H),4.79(d,J=14.0Hz,2H) ,4.57(d,J=12.7Hz,2H),4.27(t,J=8.3Hz,2H),3.85(dd,J=8.4,5.7Hz,2H),3. 22(d,J=7.2Hz,1H),2.90(d,J=7.7Hz,2H),2.42(s,3H),2.23(d,J=2.5Hz,3H).

[0400] Example 28 Preparation of 1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-(1-(5-(2-(trifluoromethyl)pyridin-4-yl)thiophen-2-yl)azetidin-3-yl)ethan-1-one

[0401] Step 1: Synthesis of I-28-1

[0402] To a two-necked flask equipped with a stirrer, 4-bromo-2-(trifluoromethyl)pyridine (750 mg, 3.32 mmol), 2-(5-bromothiophen-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (800 mg, 2.77 mmol), tetrakistriphenylphosphine palladium (319 mg, 0.28 mmol), and cesium carbonate (2.71 g, 8.30 mmol) were added. Under nitrogen, 15 mL of a 5:1 mixture of dioxane and water was added. The mixture was purged with nitrogen three times and allowed to react at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 100:1) to afford 156 mg of a yellow solid. 1 H NMR (300MHz, Chloroform-d) δ8.72(dt,J=5.2,0.7Hz,1H),7.78(dd,J=1.8,0.8Hz,1H),7.59–7.54(m,1H),7.37(d,J=4.0Hz,1H),7.17(d,J=3.9Hz,1H).

[0403] Step 2: Synthesis of I-28-2

[0404] To a single-necked flask equipped with a stirrer were added 4-(5-bromothiophen-2-yl)-2-(trifluoromethyl)pyridine (205 mg, 0.67 mmol), methyl 2-(azetidin-3-yl)acetate 2,2,2-trifluoroacetate (194 mg, 0.80 mmol), chloro(2-dicyclohexylphosphino-2',6'-di-isopropoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium(II) (51 mg, 0.07 mmol), and cesium carbonate (650 mg, 2.00 mmol). Anhydrous dioxane was added and the reaction was allowed to proceed at room temperature at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 5:1) to afford 112 mg of a yellow solid. 1 H NMR(300MHz,Chloroform-d)δ8.53(d,J=5.3Hz,1H),7.62(d,J=1.8Hz,1H),7.39(dd,J=5.3,1.8Hz,1H),7.34(d,J=4 .1Hz,1H),5.86(d,J=4.0Hz,1H),4.18(t,J=7.7Hz,2H),3.77–3.66(m,5H),3.24–3.07(m,1H),2.77(d,J=7.8Hz,2H).

[0405] Step 3: Synthesis of I-28

[0406] To a single-necked flask equipped with a stirrer, methyl 2-(1-(5-(2-(trifluoromethyl)pyridin-4-yl)thiophen-2-yl)azetidin-3-yl)acetate (110 mg, 0.31 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (75 mg, 0.34 mmol), and 1,5,7-triazidobicyclo(4.4.0)dec-5-ene (128 mg, 0.93 mmol) were added. Anhydrous tetrahydrofuran was added at room temperature and the reaction was allowed to proceed at 70°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature and concentrated. Purified water, saturated sodium chloride solution, and saturated ammonium chloride solution were added sequentially, and the mixture was extracted with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was then separated by silica gel column chromatography (ethyl acetate) to obtain 60 mg of the product. 1 H NMR(300MHz,Chloroform-d)δ8.53(d,J=5.3Hz,1H),7.62(d,J=1.8Hz,1H),7.44–7.38(m,1H),7.34(d,J=4.0Hz,1H),6.95(d,J=10.2Hz,1H),5.86( dd,J=4.1,0.9Hz,1H),4.88–4.71(m,4H),4.27(td,J=7.8,2.5Hz,2H),3.7 6(ddd,J=7.7,5.5,4.0Hz,2H),3.32(qdd,J=7.8,4.7,2.0Hz,1H),2.85(t, J=7.5Hz,2H),2.56(d,J=2.5Hz,3H),2.29(d,J=5.9Hz,3H).

[0407] Example 29 Preparation of 4'-(3-(2-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-oxoethyl)azetidin-1-yl)-3-fluoro-[1,1'-biphenyl]-4-carbonitrile

[0408] Step 1: Synthesis of I-29-1

[0409] To a two-necked flask equipped with a stirrer, 1,4-dibromobenzene (764 mg, 3.24 mmol), 2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (400 mg, 1.62 mmol), tetrakistriphenylphosphine palladium (187 mg, 0.16 mmol), and cesium carbonate (1.58 g, 4.85 mmol) were added. Under nitrogen, 12 mL of a 5:1 mixture of dioxane and water was added. The mixture was purged with nitrogen three times and allowed to react at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether) to afford 200 mg of a white solid.

[0410] Step 2: Synthesis of I-29-2

[0411] To a single-necked flask equipped with a stirrer were added 4'-bromo-3-fluoro-[1,1'-biphenyl]-4-carbonitrile (200 mg, 0.72 mmol), methyl 2-(azetidin-3-yl)acetate 2,2,2-trifluoroacetate (176 mg, 0.72 mmol), chloro(2-dicyclohexylphosphino-2',6'-di-isopropoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium(II) (56 mg, 0.07 mmol), and cesium carbonate (708 g, 2.17+ mmol). Anhydrous dioxane was added and the mixture was allowed to react at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 20:1) to afford 452 mg of a yellow solid.

[0412] Step 3: Synthesis of I-29

[0413] To a single-necked flask equipped with a stirrer, methyl 2-(1-(4'-cyano-3'-fluoro-[1,1'-biphenyl]-4-yl)azetidin-3-yl)acetate (200 mg, 0.62 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (136 mg, 0.62 mmol), and 1,5,7-triazidobicyclo(4.4.0)dec-5-ene (343 mg, 2.47 mmol) were added. Anhydrous tetrahydrofuran was added at room temperature and the mixture was allowed to react at 70°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature and concentrated. Purified water, saturated sodium chloride solution, and saturated ammonium chloride solution were added sequentially. The mixture was extracted with dichloromethane, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was then separated by silica gel column chromatography (ethyl acetate) to afford 80 mg of the product. 1H NMR(400MHz,Chloroform-d)δ7.52(dd,J=8.2,6.8Hz,1H),7.42–7.38(m,2H),7.34(dd,J=8 .1,1.7Hz,1H),7.28(dd,J=10.8,1.6Hz,1H),6.84(d,J=5.8Hz,1H),6.47–6.33(m,2H),4.6 9(dd,J=14.7,7.7Hz,4H),4.14(td,J=7.8,2.0Hz,2H),3.62(ddd,J=8.2,5.3,3.0Hz,2H),3 .25–3.12(m,1H),2.76(dd,J=9.7,7.7Hz,2H),2.46(d,J=4.2Hz,3H),2.20(d,J=4.7Hz,3H).

[0414] Example 30 Preparation of 1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-(1-(4-(2-methylpyridin-4-yl)phenyl)azetidin-3-yl)ethan-1-one

[0415] Step 1: Synthesis of I-30-1

[0416] To a two-necked flask equipped with a stirrer, 4-bromo-2-methylpyridine (168 μL, 1.41 mmol), 4-bromophenylboronic acid pinacol ester (400 mg, 1.41 mmol), tetrakistriphenylphosphine palladium (164 mg, 0.14 mmol), and cesium carbonate (1.38 g, 4.24 mmol) were added. Under nitrogen, 12 mL of a 5:1 mixture of dioxane and water was added. The mixture was purged with nitrogen three times and allowed to react at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 10:1) to afford 322 mg of a white solid. 1 HNMR(300MHz,Chloroform-d)δ8.48(dd,J=5.3,0.8Hz,1H),7.55(d,J=2.0Hz,1H),7.53(d,J=2.1Hz,1H),7. 43(d,J=2.1Hz,1H),7.41(d,J=1.9Hz,1H),7.28(d,J=1.7Hz,1H),7.22(dd,J=5.3,1.8Hz,1H),2.57(s,3H).

[0417] Step 2: Synthesis of I-30-2

[0418] To a single-necked flask equipped with a stirrer were added 4-(4-bromophenyl)-2-methylpyridine (322 mg, 1.30 mmol), methyl 2-(azetidin-3-yl)acetate 2,2,2-trifluoroacetate (316 mg, 1.30 mmol), chloro(2-dicyclohexylphosphino-2',6'-di-isopropoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium(II) (101 mg, 0.13 mmol), and cesium carbonate (1.27 g, 3.89 mmol). Anhydrous dioxane was added and the reaction was allowed to proceed at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 1:1) to afford 370 mg of a yellow solid.

[0419] Step 3: Synthesis of I-30

[0420] To a single-necked flask equipped with a stirrer, methyl 2-(1-(4-(2-methylpyridin-4-yl)phenyl)azetidin-3-yl)acetate (300 mg, 1.01 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (224 mg, 1.01 mmol), and 1,5,7-triazidobicyclo(4.4.0)dec-5-ene (507 mg, 4.04 mmol) were added. Anhydrous tetrahydrofuran was added at room temperature and the mixture was allowed to react at 70°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature and concentrated. Purified water, saturated sodium chloride solution, and saturated ammonium chloride solution were added sequentially. The mixture was extracted with dichloromethane, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was separated by silica gel column chromatography (ethyl acetate) to obtain 80 mg of the product. 1 H NMR(400MHz,Chloroform-d)δ8.37(d,J=5.4Hz,1H),7.51–7.42(m,2H),7.29– 7.17(m,2H),6.84(d,J=5.3Hz,1H),6.49–6.40(m,2H),4.69(dd,J=15.0,8.0Hz ,4H),4.14(td,J=7.7,1.8Hz,2H),3.61(ddd,J=7.6,5.3,3.8Hz,2H),3.19(ddd t,J=15.5,7.8,5.0,3.1Hz,1H),2.75(dd,J=9.5,7.7Hz,2H),2.52(s,3H),2.46 (d,J=4.4Hz,3H),2.19(d,J=4.5Hz,3H).

[0421] Example 31 Preparation of 1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-(1-(4-morpholinophenyl)azetidin-3-yl)ethan-1-one

[0422] Step 1: Synthesis of I-31-1

[0423] To a single-necked flask equipped with a stirrer, 4-(4-bromophenyl)morpholine (250 mg, 1.03 mmol), methyl 2-(azetidin-3-yl)acetate 2,2,2-trifluoroacetate (301 mg, 1.24 mmol), chloro(2-dicyclohexylphosphino-2',6'-di-isopropoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium(II) (80 mg, 0.11 mmol), and cesium carbonate (1.01 g, 3.01 mmol) were added. Anhydrous dioxane was added and the mixture was allowed to react at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 10:1) to afford 199 mg of a yellow powder.

[0424] Step 2: Synthesis of I-31

[0425] To a single-necked flask equipped with a stirrer, methyl 2-(1-(4-morpholinophenyl)azetidin-3-yl)acetate (185 mg, 0.64 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (169 mg, 0.76 mmol), and 1,5,7-triazidobicyclo(4.4.0)dec-5-ene (266 mg, 1.91 mmol) were added. Anhydrous tetrahydrofuran was added at room temperature and the reaction was allowed to proceed at 70°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature and concentrated. Purified water, saturated sodium chloride solution, and saturated ammonium chloride solution were added sequentially. The mixture was extracted with dichloromethane, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was then separated by silica gel column chromatography (ethyl acetate) to afford 167 mg of the product. 1H NMR(300MHz,Chloroform-d)δ6.92(d,J=4.9Hz,3H),6.49(d,J=8.4Hz,2H),4.77(dd,J=10.6,6.6Hz,4H),4.12(t,J=7.3Hz,2H),3.89(t,J=4 .8Hz,4H),3.60(s,2H),3.30–3.13(m,1H),3.05(d,J=4.9Hz,4H),2.83(dd,J=10.8,7.6Hz,2H),2.55(d,J=2.8Hz,3H),2.28(d,J=2.9Hz,3H).

[0426] Example 32 Preparation of 1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-(1-(4-(4-methylpiperazin-1-yl)phenyl)azetidin-3-yl)ethan-1-one

[0427] Step 1: Synthesis of I-32-1

[0428] To a single-necked flask equipped with a stirrer were added 1-(4-bromophenyl)-4-methylpiperazine (300 mg, 1.18 mmol), methyl 2-(azetidin-3-yl)acetate 2,2,2-trifluoroacetate (243 mg, 1.41 mmol), chloro(2-dicyclohexylphosphino-2',6'-di-isopropoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium(II) (91 mg, 0.12 mmol), and cesium carbonate (1.15 g, 3.53 mmol). Anhydrous dioxane was added and the mixture was allowed to react at room temperature at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 10:1) to afford 335 mg of a yellow solid. 1 H NMR(300MHz,Chloroform-d)δ7.02–6.75(m,2H),6.55–6.20(m,2H),4.03(t,J=7.4Hz,2H),3.71(s,3H),3.51(dd,J= 7.1,5.5Hz,2H),3.15–3.07(m,4H),3.07–2.96(m,1H),2.71(d,J=7.8Hz,2H),2.62(dd,J=6.2,3.7Hz,4H),2.38(s,3H).

[0429] Step 2: Synthesis of I-32

[0430] To a single-necked flask equipped with a stirrer, methyl 2-(1-(4-(4-methylpiperazin-1-yl)phenyl)azetidin-3-yl)acetate (200 mg, 0.66 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (160 mg, 0.73 mmol), and 1,5,7-triazidobicyclo(4.4.0)dec-5-ene (367 mg, 2.64 mmol) were added. Anhydrous tetrahydrofuran was added at room temperature and the reaction was allowed to proceed at 70°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature and concentrated. Purified water, saturated sodium chloride solution, and saturated ammonium chloride solution were added sequentially. The mixture was extracted with dichloromethane, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was separated by silica gel column chromatography (ethyl acetate) to obtain 123 mg of the product. 1 H NMR(300MHz,Chloroform-d)δ6.98–6.85(m,3H),6.52–6.37(m,2H),4.77(dd,J= 10.9, 6.3Hz, 4H), 4.10 (t, J=7.4Hz, 2H), 3.57 (ddd, J=7.2, 5.3, 1.8Hz, 2H), 3.20 (tdt,J=10.4,7.6,3.8Hz,1H),3.11(dd,J=6.2,3.7Hz,4H),2.81(t,J=7.5Hz,2H ),2.72–2.60(m,4H),2.54(d,J=3.1Hz,3H),2.39(s,3H),2.27(d,J=3.0Hz,3H).

[0431] Example 33 Preparation of 1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-(1-(4-(2-(dimethylamino)pyridin-4-yl)phenyl)azetidin-3-yl)ethan-1-one

[0432] Step 1: Synthesis of I-33-1

[0433] To a two-necked flask equipped with a stirrer, 4-bromo-N,N-dimethylpyridin-2-amine (400 mg, 1.99 mmol), 4-bromophenylboronic acid pinacol ester (563 mg, 1.99 mmol), tetrakistriphenylphosphine palladium (230 mg, 0.20 mmol), and cesium carbonate (1.94 g, 5.95 mmol) were added. Under nitrogen, 12 mL of a 5:1 mixture of dioxane and water was added. The mixture was purged with nitrogen three times and allowed to react at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 250:1) to afford 315 mg of a white solid.1 H NMR (300MHz, Chloroform-d) δ8.14(d,J=5.3Hz,1H),7.55–7.47(m,2H),7.47–7.35(m,2H),6.65(dd,J=5.3,1.5Hz,1H),6.55(d,J=1.4Hz,1H),3.08(s,6H).

[0434] Step 2: Synthesis of I-33-2

[0435] To a single-necked flask equipped with a stirrer was added 4-(4-bromophenyl)-N,N-dimethylpyridin-2-amine (315 mg, 1.14 mmol), methyl 2-(azetidin-3-yl)acetate 2,2,2-trifluoroacetate (277 mg, 1.14 mmol), chloro(2-dicyclohexylphosphino-2',6'-di-isopropoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium(II) (88 mg, 0.11 mmol), and cesium carbonate (1.11 g, 3.41 mmol). Anhydrous dioxane was added and the reaction was allowed to proceed at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (pure ethyl acetate) to afford 291 mg of a white solid. 1 H NMR(300MHz,Chloroform-d)δ8.09(dd,J=5.4,0.7Hz,1H),7.52–7.37(m,2H),6.67(dd,J=5.4,1.5Hz,1H),6.57(dd,J=1.5,0.8 Hz,1H),6.49–6.22(m,2H),4.04(t,J=7.6Hz,2H),3.63(s,3H),3.54(dd,J=7.4,5.4Hz,2H),3.07(s,7H),2.66(d,J=7.8Hz,2H).

[0436] Step 3: Synthesis of I-33

[0437] To a single-necked flask equipped with a stirrer, methyl 2-(1-(4-(2-(dimethylamino)pyridin-4-yl)phenyl)azetidin-3-yl)acetate (200 mg, 0.61 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (136 mg, 0.61 mmol), and 1,5,7-triazidobicyclo(4.4.0)dec-5-ene (343 mg, 2.46 mmol) were added. Anhydrous tetrahydrofuran was added at room temperature and the reaction was allowed to proceed at 70°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature and concentrated. Purified water, saturated sodium chloride solution, and saturated ammonium chloride solution were added sequentially. The mixture was extracted with dichloromethane, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was then separated by silica gel column chromatography (ethyl acetate) to obtain 80 mg of the product. 1 H NMR (400MHz, Chloroform-d) δ8.09 (d, J = 5.4 Hz, 1H), 7.46 (d, J = 8.2 Hz, 2H), 6.85 (d, J = 5. 3Hz,1H),6.70(dd,J=5.4,1.4Hz,1H),6.59(d,J=1.5Hz,1H),6.53–6.38(m,2H),4.70(dd, J=15.1,8.2Hz,4H),4.14(td,J=7.6,1.5Hz,2H),3.61(dt,J=7.5,4.7Hz,2H),3.26–3.13 (m,1H),3.09(s,6H),2.76(t,J=8.4Hz,2H),2.47(d,J=4.3Hz,3H),2.20(d,J=4.4Hz,3H).

[0438] Example 34 Preparation of 2-(1-(4-(2-(difluoromethyl)pyridin-4-yl)phenyl)azetidin-3-yl)-1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)ethan-1-one

[0439] Step 1: Synthesis of I-34-1

[0440] To a two-necked flask equipped with a stirrer, 4-bromo-2-(difluoromethyl)pyridine (180 μL, 1.41 mmol), 4-bromophenylboronic acid pinacol ester (400 mg, 1.41 mmol), tetrakistriphenylphosphine palladium (164 mg, 0.14 mmol), and cesium carbonate (1.38 g, 4.24 mmol) were added. Under nitrogen, 12 mL of a 5:1 mixture of dioxane and water was added. The mixture was purged with nitrogen three times and allowed to react at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 100:1) to afford 306 mg of a white solid. 1 H NMR(300MHz,Chloroform-d)δ8.63(d,J=5.1Hz,1H),7.75(d,J=1.8Hz,1H),7. 63–7.54(m,2H),7.54–7.50(m,1H),7.50–7.40(m,2H),6.63(t,J=55.4Hz,1H).

[0441] Step 2: Synthesis of I-34-2

[0442] To a single-necked flask equipped with a stirrer were added 4-(4-bromophenyl)-2-(difluoromethyl)pyridine (300 mg, 1.06 mmol), methyl 2-(azetidin-3-yl)acetate 2,2,2-trifluoroacetate (257 mg, 1.06 mmol), chloro(2-dicyclohexylphosphino-2',6'-di-isopropoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium(II) (82 mg, 0.11 mmol), and cesium carbonate (1.03 g, 3.18 mmol). Anhydrous dioxane was added and the mixture was allowed to react at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 10:1) to afford 230 mg of a yellow solid. 1 H NMR(300MHz,Chloroform-d)δ8.51(d,J=5.2Hz,1H),7.71(d,J=1.7Hz,1H),7.56–7.42(m,3H),6.68(d,J=55.6Hz,1H),6.42(dd,J=8 .9,2.2Hz,2H),4.06(t,J=7.7Hz,2H),3.63(s,3H),3.56(dd,J=7.5,5.4Hz,2H),3.05(pt,J=7.8,5.4Hz,1H),2.66(d,J=7.8Hz,2H).

[0443] Step 3: Synthesis of I-34

[0444] To a single-necked flask equipped with a stirrer, methyl 2-(1-(4-(2-(difluoromethyl)pyridin-4-yl)phenyl)azetidin-3-yl)acetate (230 mg, 0.69 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (153 mg, 0.69 mmol), and 1,5,7-triazidobicyclo(4.4.0)dec-5-ene (386 mg, 2.77 mmol) were added. Anhydrous tetrahydrofuran was added at room temperature and the reaction was allowed to proceed at 70°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature and concentrated. Purified water, saturated sodium chloride solution, and saturated ammonium chloride solution were added sequentially, and the mixture was extracted with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was then separated by silica gel column chromatography (ethyl acetate) to obtain 80 mg of the product. 1 H NMR(300MHz,Chloroform-d)δ8.48(d,J=5.2Hz,1H),7.68(d,J=1.8Hz,1H),7.4 7(dd,J=9.0,2.3Hz,3H),7.15(s,1H),6.86–6.70(m,1H),6.50–6.29(m,2H),4. 79–4.52(m,4H),4.12(td,J=7.7,1.8Hz,2H),3.59(ddd,J=8.0,5.3,2.8Hz,2H) ,3.26–3.05(m,1H),2.72(t,J=7.2Hz,2H),2.43(s,3H),2.16(d,J=6.4Hz,3H).

[0445] Example 35 Preparation of 6-(4-(3-(2-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-oxoethyl)azetidin-1-yl)phenyl)isobenzofuran-1(3H)-one

[0446] Step 1: Synthesis of I-35-1

[0447] To a two-necked flask equipped with a stirrer was added 6-bromobenzofuran-1(3H)-one (301 mg, 1.41 mmol), 4-bromophenylboronic acid pinacol ester (400 mg, 1.41 mmol), 1,1'-bis(diphenylphosphino)ferrocenepalladium(II) dichloride (103 mg, 0.14 mmol), and potassium phosphate (600 mg, 2.82 mmol). Under nitrogen, 12 mL of a 6:1 mixture of dioxane and water was added. The mixture was purged with nitrogen three times and allowed to react at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 10:1) to afford 202 mg of a white solid.

[0448] Step 2: Synthesis of I-35-2

[0449] To a single-necked flask equipped with a stirrer, 6-(4-bromophenyl)isobenzofuran-1(3H)-one (200 mg, 0.69 mmol), methyl 2-(azetidin-3-yl)acetate 2,2,2-trifluoroacetate (168 mg, 0.69 mmol), chloro(2-dicyclohexylphosphino-2',6'-di-isopropoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium(II) (54 mg, 0.07 mmol), and cesium carbonate (676 mg, 2.08 mmol) were added. Anhydrous dioxane was added and the mixture was allowed to react at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 3:1) to afford 188 mg of a white solid. 1 H NMR(300MHz,Chloroform-d)δ7.99(d,J=1.6Hz,1H),7.78(dd,J=8.0,1.7Hz,1H),7 .48–7.35(m,2H),6.79(d,J=2.2Hz,1H),6.65(dd,J=8.2,2.2Hz,1H),6.55–6.40(m, 1H),5.21(d,J=35.9Hz,2H),4.05(td,J=7.5,6.1Hz,2H),3.64(d,J=1.1Hz,3H),3. 55(dt,J=7.4,5.2Hz,2H), 3.05(tt,J=7.9,5.5Hz,1H), 2.67(dd,J=7.8,1.5Hz,2H).

[0450] Step 3: Synthesis of I-35

[0451] To a single-necked flask equipped with a stirrer, methyl 2-(1-(4-(3-oxo-1,3-dihydroisobenzofuran-5-yl)phenyl)azetidin-3-yl)acetate (181 mg, 0.54 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (119 mg, 0.54 mmol), and 1,5,7-triazidobicyclo(4.4.0)dec-5-ene (299 mg, 2.15 mmol) were added. Anhydrous tetrahydrofuran was added at room temperature and the reaction was allowed to proceed at 70°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature and concentrated. Purified water, saturated sodium chloride solution, and saturated ammonium chloride solution were added sequentially, and the mixture was extracted with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were separated by silica gel column chromatography (ethyl acetate) to afford 50 mg of a red oil. 1 H NMR(300MHz,Chloroform-d)δ7.99(d,J=1.6Hz,1H),7.79(dd,J=8.0,1.7Hz,1H),7.49–7 .38(m,1H),7.23(s,1H),6.90–6.78(m,2H),6.67(dd,J=8.3,2.2Hz,1H),6.51–6.42(m,1 H),5.22(d,J=34.8Hz,2H),4.79–4.60(m,4H),4.20–4.00(m,2H),3.60(ddt,J=7.5,5.4, 2.7Hz,2H),3.34–3.04(m,1H),2.76(t,J=7.5Hz,2H),2.47(s,3H),2.21(d,J=6.7Hz,3H).

[0452] Example 36 Preparation of 1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-(1-(4'-nitro-3'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)azetidin-3-yl)ethan-1-one

[0453] Step 1: Synthesis of I-36-1

[0454] To a two-necked flask equipped with a stirrer, 4-bromo-1-nitro-2-(trifluoromethyl)benzene (300 mg, 1.11 mmol), 4-bromophenylboronic acid pinacol ester (314 mg, 1.11 mmol), tetrakistriphenylphosphine palladium (128 mg, 0.11 mmol), and cesium carbonate (1.09 g, 3.33 mmol) were added. Under nitrogen, 10 mL of a 5:1 mixture of dioxane and water was added, and the mixture was purged with nitrogen three times. The reaction was allowed to proceed at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 50:1) to afford 348 mg of a yellow solid.

[0455] Step 2: Synthesis of I-36-2

[0456] To a single-necked flask equipped with a stirrer, 4'-bromo-4-nitro-3-(trifluoromethyl)-1,1'-biphenyl (284 mg, 0.82 mmol), methyl 2-(azetidin-3-yl)acetate 2,2,2-trifluoroacetate (239 mg, 0.98 mmol), chloro(2-dicyclohexylphosphino-2',6'-di-isopropoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium(II) (63 mg, 0.08 mmol), and cesium carbonate (802 mg, 2.46 mmol) were added. Anhydrous dioxane was added and the reaction was allowed to proceed at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 10:1) to afford 270 mg of a dark yellow solid.

[0457] Step 3: Synthesis of I-36

[0458] To a single-necked flask equipped with a stirrer, methyl 2-(1-(4'-nitro-3'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)azetidin-3-yl)acetate (260 mg, 0.66 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (160 mg, 0.73 mmol), and 1,5,7-triazidobicyclo(4.4.0)dec-5-ene (275 mg, 1.98 mmol) were added. Anhydrous tetrahydrofuran was added at room temperature and the reaction was allowed to proceed at 70°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature and concentrated. Purified water, saturated sodium chloride solution, and saturated ammonium chloride solution were added sequentially. The mixture was extracted with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was separated by silica gel column chromatography (ethyl acetate) to obtain 167 mg of the product. 1H NMR (400MHz, Chloroform-d) δ8.02–7.94 (m, 2H), 7.82 (dd, J=8.5, 2.0Hz, 1H), 7.53 (dd, J= 9.1, 2.4Hz, 2H), 6.93 (d, J = 7.3Hz, 1H), 6.56 (dd, J = 10.1, 8.7Hz, 2H), 4.79 (dd, J = 15.6, 7. 2Hz, 4H), 4.25 (td, J=7.7, 1.9Hz, 2H), 3.72 (ddd, J=8.5, 5.4, 3.4Hz, 2H), 3.29 (dddt, J=10 .6,8.0,5.6,2.9Hz,1H),2.90–2.76(m,2H),2.55(d,J=2.5Hz,3H),2.29(d,J=5.2Hz,3H).

[0459] Example 37 Preparation of 2-(1-(2'-(difluoromethoxy)-[3,4'-bipyridyl]-6-yl)azetidin-3-yl)-1-(2,4-dimethyl-5,7-dihydro-6-pyrrolo[3,4-b]pyridin-6-yl)ethan-1-one

[0460] Step 1: Synthesis of I-37-1

[0461] To a single-necked flask equipped with a stirrer, add 5-bromo-2-fluoropyridine (295 μL, 2.84 mmol), methyl 2-(azetidin-3-yl)acetate 2,2,2-trifluoroacetate (759 mg, 3.13 mmol), and cesium carbonate (2.78 g, 8.52 mmol). Add 7 mL of DMF at room temperature and react at 120°C. After completion of the reaction as monitored by TLC, cool to room temperature, quench with water, and extract with ethyl acetate. The combined organic phases are dried over anhydrous sodium sulfate, filtered, and concentrated. 414 mg of a white solid is isolated by silica gel column chromatography (petroleum ether:ethyl acetate = 50:1). 1 H NMR(300MHz,Chloroform-d)δ8.07(s,1H),7.53–7.32(m,1H),6.10(d,J=8.8Hz,1H),4.12( t,J=8.1Hz,2H),3.65(s,2H),3.64–3.57(m,3H),3.16–2.90(m,1H),2.65(d,J=7.8Hz,2H).

[0462] Step 2: Synthesis of I-37-2

[0463] To a two-necked flask equipped with a stirrer was added methyl 2-(1-(5-bromopyridin-2-yl)azetidin-3-yl)acetate (203 mg, 0.71 mmol), 2-(difluoromethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (231 mg, 0.85 mmol), tetrakistriphenylphosphine palladium (82 mg, 0.07 mmol), and cesium carbonate (695 mg, 2.14 mmol). Under nitrogen, 6 mL of a 5:1 mixture of dioxane and water was added. The mixture was purged with nitrogen three times and allowed to react at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 3:1) to afford 157 mg of a light yellow powder. 1 H NMR(300MHz,Chloroform-d)δ8.38(dd,J=2.5,0.8Hz,1H),8.11(dd,J=5.4,0.6H z,1H),7.69–7.62(m,1H),7.43(s,1H),7.16(dd,J=5.4,1.6Hz,1H),6.93(dd,J= 1.6, 0.7Hz, 1H), 6.29 (dd, J=8.7, 0.8Hz, 1H), 4.25 (t, J=8.3Hz, 2H), 3.76 (dd, J= 8.5,5.4Hz,2H),3.64(s,3H),3.09(tt,J=7.9,5.4Hz,1H),2.68(d,J=7.8Hz,2H).

[0464] Step 3: Synthesis of I-37

[0465] To a single-necked flask equipped with a stirrer, methyl 2-(1-(2'-(difluoromethoxy)-[3,4'-bipyridyl]-6-yl)azetidin-3-yl)acetate (170 mg, 0.49 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (118 mg, 0.54 mmol), and 1,5,7-triazidobicyclo(4.4.0)dec-5-ene (203 mg, 1.46 mmol) were added. Anhydrous tetrahydrofuran was added at room temperature and the reaction was allowed to proceed at 70°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature and concentrated. Purified water, saturated sodium chloride solution, and saturated ammonium chloride solution were added sequentially. The mixture was extracted with dichloromethane, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was then separated by silica gel column chromatography (ethyl acetate) to afford 154 mg of the product. 1H NMR(300MHz,Chloroform-d)δ8.38(d,J=2.4Hz,1H),8.10(d,J=5.4Hz,1H),7.74–7.64(m,1H),7 .43(s,1H),7.17(dd,J=5.4,1.6Hz,1H),6.93(d,J=1.5Hz,1H),6.84(d,J=4.0Hz,1H),6.29(d,J= 8.7Hz,1H),4.77–4.62(m,4H),4.31(td,J=8.3,2.7Hz,2H),3.80(dd,J=8.6,5.4Hz,2H),3.23(d dd,J=13.2,7.9,5.5Hz,1H),2.77(t,J=7.7Hz,2H),2.46(d,J=2.8Hz,3H),2.20(d,J=2.1Hz,3H).

[0466] Example 38 Preparation of 2-(1-(4-(2-(difluoromethoxy)pyridin-4-yl)phenyl)azetidin-3-yl)-1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)ethan-1-one

[0467] Step 1: Synthesis of I-38-1

[0468] To a two-necked flask equipped with a stirrer, p-dibromobenzene (609 mg, 2.58 mmol), 2-(difluoromethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (350 mg, 1.29 mmol), tetrakistriphenylphosphine palladium (149 mg, 0.13 mmol), and cesium carbonate (1.26 g, 3.87 mmol) were added. Under nitrogen, 12 mL of a 5:1 mixture of dioxane and water was added, and the mixture was purged with nitrogen three times. The reaction was allowed to proceed at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether) to afford 206 mg of an oil.

[0469] Step 2: Synthesis of I-38-2

[0470] To a single-necked flask equipped with a stirrer were added 4-(4-bromophenyl)-2-(difluoromethoxy)pyridine (206 mg, 0.69 mmol), methyl 2-(azetidin-3-yl)acetate 2,2,2-trifluoroacetate (167 mg, 0.69 mmol), chloro(2-dicyclohexylphosphino-2',6'-di-isopropoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium(II) (54 mg, 0.07 mmol), and cesium carbonate (671 mg, 2.06 mmol). Anhydrous dioxane was added and the reaction was allowed to proceed at room temperature at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 10:1) to afford 216 mg of a yellow solid.

[0471] Step 3: Synthesis of I-38

[0472] To a single-necked flask equipped with a stirrer, methyl 2-(1-(4-(2-(difluoromethoxy)pyridin-4-yl)phenyl)azetidin-3-yl)acetate (216 mg, 0.62 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (137 mg, 0.62 mmol), and 1,5,7-triazidobicyclo(4.4.0)dec-5-ene (156 mg, 1.12 mmol) were added. Anhydrous tetrahydrofuran was added at room temperature and the reaction was allowed to proceed at 70°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature and concentrated. Purified water, saturated sodium chloride solution, and saturated ammonium chloride solution were added sequentially, and the mixture was extracted with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was separated by silica gel column chromatography (ethyl acetate) to obtain 110 mg of the product. 1 H NMR (400 MHz, Chloroform-d) δ8.06 (d, J = 5.4 Hz, 1H), 7.54–7.34 (m, 2H), 7.20–7.16 (m, 1H), 6.96 (d, J = 1.5 Hz, 1H), 6.85 (d, J = 11.3 Hz, 1H), 6.49–6.37 (m, 2H), 4.77–4.62 (m, 4H), 4.14 (td, J = 7.7, 2.2 Hz, 2H), 3.61 (ddd, J = 7.8, 5.3, 3.7 Hz, 2H), 3.28–3.10 (m, 1H), 2.75 (t, J = 8.4 Hz, 2H), 2.47 (s, 3H), 2.20 (d, J = 8.1 Hz, 3H). (One peak overlaps with the deuterated reagent)

[0473] Example 39 Preparation of 1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-(1-(4-(2-methoxypyridin-4-yl)phenyl)azetidin-3-yl)ethan-1-one

[0474] Step 1: Synthesis of I-39-1

[0475] To a two-necked flask equipped with a stirrer, add p-dibromobenzene (555 mg, 2.35 mmol), 2-methoxypyridine-4-boronic acid (180 mg, 1.18 mmol), tetrakistriphenylphosphine palladium (136 mg, 0.12 mmol), and cesium carbonate (1.15 g, 3.53 mmol). Under nitrogen, add 10 mL of a 5:1 mixture of dioxane and water. The mixture was purged with nitrogen three times and allowed to react at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (petroleum ether) to afford 200 mg of an oily substance.

[0476] Step 2: Synthesis of I-39-2

[0477] In a single-necked flask equipped with a stirrer, 4-(4-bromophenyl)-2-methoxypyridine (200 mg, 0.76 mmol), methyl 2-(azetidin-3-yl)acetate 2,2,2-trifluoroacetate (184 mg, 0.76 mmol), (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl) (2-amino-1,1'-biphenyl-2-yl) palladium (II) methanesulfonate (64 mg, 0.08 mmol), 2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl (71 mg, 0.15 mmol) and potassium tert-butoxide (255 mg, 2.27 mmol) were added. Anhydrous dioxane was added at room temperature and the reaction was carried out at 110°C. After the reaction was completed as monitored by TLC, the mixture was cooled to room temperature, quenched with water, extracted with ethyl acetate, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was separated by silica gel column chromatography (petroleum ether: ethyl acetate = 10:1) to obtain 150 mg of a yellow solid.

[0478] Step 3: Synthesis of I-39

[0479] To a single-necked flask equipped with a stirrer, methyl 2-(1-(4-(2-methoxypyridin-4-yl)phenyl)azetidin-3-yl)acetate (150 mg, 0.48 mmol), 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (106 mg, 0.48 mmol), and 1,5,7-triazidobicyclo(4.4.0)dec-5-ene (264 mg, 1.92 mmol) were added. Anhydrous tetrahydrofuran was added at room temperature and the reaction was allowed to proceed at 70°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature and concentrated. Purified water, saturated sodium chloride solution, and saturated ammonium chloride solution were added sequentially. The mixture was extracted with dichloromethane, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was then separated by silica gel column chromatography (ethyl acetate) to afford 80 mg of the product. 1 H NMR(300MHz,Chloroform-d)δ8.06(d,J=5.4Hz,1H),7.51–7.39(m,2H),7.00(dd, J=5.5,1.6Hz,1H),6.87–6.80(m,2H),6.50–6.32(m,2H),4.80–4.61(m,4H),4.13 (td,J=7.7,1.6Hz,2H),3.90(s,3H),3.60(ddd,J=7.9,5.3,2.8Hz,2H),3.17(qd, J=8.1,7.6,3.8Hz,1H),2.75(t,J=7.1Hz,2H),2.47(s,3H),2.20(d,J=6.4Hz,3H).

[0480] Example 40 Preparation of 1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-(1-(2-(4-nitro-3-(trifluoromethyl)phenyl)pyridin-4-yl)azetidin-3-yl)ethan-1-one

[0481] Step 1: Synthesis of I-40-1

[0482] To a two-necked flask equipped with a stirrer, add 4-bromo-1-nitro-2-(trifluoromethyl)benzene (300 mg, 1.11 mmol), pinacol diboron (339 mg, 1.33 mmol), 1,1'-bis(diphenylphosphino)ferrocenepalladium(II) dichloride (81 mg, 0.11 mmol), and potassium acetate (218 mg, 2.22 mmol). Under nitrogen, add 10 mL of anhydrous dioxane, evacuate the mixture three times, and react at 110°C. After completion of the reaction as monitored by TLC, cool to room temperature, filter through celite, and obtain 300 mg of crude product without purification.

[0483] Step 2: Synthesis of I-40-2

[0484] The synthetic method of reference example 1 step 1 was used, except that the 2-methyl-6-(trifluoromethyl)pyridine-4-boronic acid pinacol ester in step 1 was replaced with 4,4,5,5-tetramethyl-2-(4-nitro-3-(trifluoromethyl)phenyl)-1,3,2-dioxaborolane (300 mg, 0.95 mmol). Compound I-40-2 was prepared by the same method and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 20:1) to obtain 163 mg of yellow crystals. 1 H NMR(300MHz,Chloroform-d)δ8.68(dd,J=8.5,5.6Hz,1H),8.45(d,J=1.9Hz,1H),8.26(dd,J=8.4, 2.0Hz, 1H), 7.95 (d, J=8.4Hz, 1H), 7.49 (dd, J=9.7, 2.3Hz, 1H), 7.08 (ddd, J=8.0, 5.6, 2.3Hz, 1H).

[0485] Step 2: Synthesis of I-40-3

[0486] Refer to the synthesis method of step 2 of Example 1, except that the 4-fluoro-2'-methyl-6'-(trifluoromethyl)-2,4'-bipyridine in step 2 is replaced by 4-fluoro-2-(4-nitro-3-(trifluoromethyl)phenyl)pyridine (155 mg, 0.54 mmol). Compound I-40-3 was prepared in the same manner and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 10:1) to obtain 76 mg of a yellow solid. 1 H NMR (300MHz, DMSO-d6) δ8.66(s,1H),8.62(d,J=8.9Hz,1H),8.30–8.22(m,2H),7.16(d,J=2.1Hz,1H),6.42(dd,J=5.7,2. 2Hz, 1H), 4.16 (t, J = 8.1Hz, 2H), 3.71 (dd, J = 8.3, 5.7Hz, 2H), 3.62 (s, 3H), 3.03 (d, J = 22.0Hz, 1H), 2.78 (d, J = 7.7Hz, 2H).

[0487] Step 4: Synthesis of I-40

[0488] Refer to the synthesis method of step 3 of Example 8, except that the 2-(1-(2'-(trifluoromethyl)-[2,4'-bipyridyl]-3-yl)azetidin-3-yl)acetic acid methyl ester in step 3 is replaced with 2-(1-(2-(4-nitro-3-(trifluoromethyl)phenyl)pyridin-4-yl)azetidin-3-yl)acetic acid methyl ester (70 mg, 0.18 mmol). The same method was used to prepare compound I-40, and 49 mg of the product was separated by silica gel column chromatography (ethyl acetate: methanol = 50:1). 1 H NMR(300MHz,Chloroform-d)δ8.44(d,J=1.8Hz,1H),8.40–8.26(m,2H),7.99(d,J=8.4H z,1H),6.94(d,J=4.5Hz,1H),6.69(d,J=2.0Hz,1H),6.34(ddd,J=5.7,2.2,1.2Hz,1H), 4.78(dd,J=10.3,6.1Hz,4H), 4.34(td,J=8.2,1.9Hz,2H), 3.82(dt,J=8.1,5.0Hz,2H), 3.44–3.24(m,1H),2.86(t,J=7.4Hz,2H),2.55(d,J=3.2Hz,3H),2.29(d,J=3.6Hz,3H).

[0489] Example 41 Preparation of 1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-(1-(5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)azetidin-3-yl)ethan-1-one

[0490] Step 1: Synthesis of I-41-1

[0491] To a two-necked flask equipped with a stirrer, add p-2-fluoro-5-bromopyridine (117 μL, 1.14 mmol), 3-(trifluoromethyl)phenylboronic acid pinacol ester (309 mg, 1.14 mmol), tetrakistriphenylphosphine palladium (131 mg, 0.11 mmol), and cesium carbonate (1.11 g, 3.41 mmol). Under nitrogen, add 10 mL of a 5:1 mixture of dioxane and water. The mixture is purged with nitrogen three times and allowed to react at 110°C. After completion of the reaction as monitored by TLC, the mixture is cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases are combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases are then separated by silica gel column chromatography (petroleum ether) to afford 270 mg of an oily substance. 1H NMR (300MHz, DMSO-d6) δ8.71(d,J=2.9Hz,1H),8.37(dt,J=9.4,1.8Hz,2H),8.22(dd,J=8.9,4.3Hz,1H),7.89(td,J=8.7,3.0Hz,1H),7.83–7.70(m,2H).

[0492] Step 2: Synthesis of I-41-2

[0493] The synthetic method of reference example 1 step 2 was used, except that 4-fluoro-2'-methyl-6'-(trifluoromethyl)-2,4'-bipyridine in step 2 was replaced with 2-fluoro-5-(3-(trifluoromethyl)phenyl)pyridine (270 mg, 1.12 mmol). Compound I-41-2 was prepared by the same method and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain 21 mg of a yellow solid. 1 H NMR (300MHz, DMSO-d6) δ8.47(d,J=2.5Hz,1H),7.99–7.91(m,2H),7.90(s,1H),7.84–7.46(m,2H),6.47(d,J=8.7H z,1H),4.13(t,J=8.1Hz,2H),3.69(dd,J=8.3,5.7Hz,2H),3.61(s,3H),3.12–2.92(m,1H),2.76(d,J=7.7Hz,2H).

[0494] Step 3: Synthesis of I-41

[0495] Refer to the synthesis method of step 3 of Example 8, except that the 2-(1-(2'-(trifluoromethyl)-[2,4'-bipyridyl]-3-yl)azetidin-3-yl)acetic acid methyl ester in step 3 is replaced with 2-(1-(5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)azetidin-3-yl)acetic acid methyl ester (120 mg, 0.34 mmol). The same method was used to prepare compound I-41, and the product was separated by silica gel column chromatography (ethyl acetate: methanol = 50:1) to obtain 70 mg. 1H NMR(300MHz,DMSO-d6)δ8.48(d,J=2.4Hz,1H),7.94(t,J=2.6Hz,1H),7.91(t,J=2.2Hz,2H), 7.65(dd,J=4.8,1.9Hz,2H),7.01(d,J=2.0Hz,1H),6.48(d,J=8.7Hz,1H),4.81(d,J=14.4Hz ,2H),4.58(d,J=12.7Hz,2H),4.17(t,J=8.1Hz,2H),3.72(dd,J=8.3,5.6Hz,2H),3.11(dq,J =14.3,7.3,6.8Hz,1H),2.86(d,J=7.6Hz,2H),2.43(d,J=1.4Hz,3H),2.23(d,J=3.7Hz,3H).

[0496] Example 42 Preparation of 2-(1-(2'-chloro-[4,4'-bipyridinyl]-2-yl)azetidin-3-yl)-1-(2,4-dimethyl-5,7-dihydro-6-pyrrolo[3,4-b]pyridin-6-yl)ethan-1-one

[0497] Step 1: Synthesis of I-42-1

[0498] Referring to the synthesis method of step 1 of Example 2, except that 2-bromo-4-fluoropyridine was replaced with 4-bromo-2-fluoropyridine (175 μL, 1.70 mmol), compound I-42-1 was prepared in the same manner and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 10:1) to obtain 280 mg of a white solid.

[0499] Step 2: Synthesis of I-42-2

[0500] Referring to the synthesis method of step 2 of Example 2, except that 2'-chloro-4-fluoro-2,4'-bipyridine was replaced with 2-chloro-2'-fluoro-4,4'-bipyridine (280 mg, 1.34 mmol), compound I-42-2 was prepared in the same manner, and 88 mg of a yellow oil was separated by silica gel column chromatography (petroleum ether: ethyl acetate = 3:1).

[0501] Step 3: Synthesis of I-42

[0502] Reference was made to the synthesis method of step 3 of Example 8, except that 2-(1-(2'-(trifluoromethyl)-[2,4'-bipyridyl]-3-yl)azetidin-3-yl)acetic acid methyl ester in step 3 was replaced with 2-(1-(2'-chloro-[4,4'-bipyridyl]-2-yl)azetidin-3-yl)acetic acid methyl ester (80 mg, 0.25 mmol). Compound I-42 was prepared by the same method and separated by silica gel column chromatography (ethyl acetate: methanol = 50: 1) to obtain 70 mg of the product. 1 H NMR (400MHz, DMSO-d6) δ8.51(d,J=5.2Hz,1H),8.19(d,J=5.3Hz,1H),7.94(d,J=1.4Hz, 1H),7.81(dd,J=5.2,1.6Hz,1H),7.07–6.95(m,2H),6.79(d,J=1.5Hz,1H),4.81(d,J=1 9.2Hz,2H),4.57(d,J=17.1Hz,2H),4.19(t,J=8.1Hz,2H),3.74(dd,J=8.3,5.7Hz,2H), 3.16–3.00(m,1H),2.85(d,J=7.6Hz,2H),2.43(d,J=2.0Hz,3H),2.23(d,J=5.5Hz,3H).

[0503] Example 43 Preparation of 1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-(1-(2'-ethoxy-6'-(trifluoromethyl)-[4,4'-bipyridyl]-2-yl)azetidin-3-yl)ethan-1-one

[0504] Step 1: Synthesis of I-43-1

[0505] Referring to the synthesis method of step 1 of Example 42, except that 2-chloropyridine-4-boronic acid pinacol ester was replaced with 2-ethoxy-6-trifluoromethylpyridine-4-boronic acid pinacol ester (541 mg, 1.71 mmol), compound I-43-1 was prepared in the same manner, and 446 mg of a white solid was separated by silica gel column chromatography (petroleum ether: ethyl acetate = 80:1). 1 H NMR(300MHz,DMSO-d6)δ8.39(dt,J=5.3,0.7Hz,1H),7.94–7.88(m,2H),7.82–7.76 (m,1H),7.63(dd,J=1.4,0.7Hz,1H),4.40(q,J=7.1Hz,2H),1.37(t,J=7.0Hz,3H).

[0506] Step 2: Synthesis of I-43-2

[0507] Referring to the synthesis method of step 2 of Example 2, except that 2'-chloro-4-fluoro-2,4'-bipyridine was replaced with 2-ethoxy-2'-fluoro-6-(trifluoromethyl)-4'-bipyridine (300 mg, 1.05 mmol), compound I-43-2 was prepared in the same manner and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 5:1) to obtain 222 mg of a yellow oil. 1 H NMR (300MHz, DMSO-d6) δ8.17 (dd, J=5.3, 0.7Hz, 1H), 7.81 (d, J=1.3Hz, 1H), 7. 56–7.47(m,1H),7.08(dd,J=5.3,1.6Hz,1H),6.83(dd,J=1.6,0.8Hz,1H),4.39 (q,J=7.0Hz,2H),4.15(t,J=8.2Hz,2H),3.70(dd,J=8.4,5.7Hz,2H),3.62(s, 3H), 3.01(tt,J=7.6,5.7Hz,1H), 2.75(d,J=7.7Hz,2H), 1.37(t,J=7.0Hz,3H).

[0508] Step 3: Synthesis of I-43

[0509] Refer to the synthesis method of step 3 of Example 8, except that the 2-(1-(2'-(trifluoromethyl)-[2,4'-bipyridine]-3-yl)azetidin-3-yl)acetic acid methyl ester in step 3 is replaced by 2-(1-(2'-ethoxy-6'-(trifluoromethyl)-[4,4'-bipyridine]-2-yl)azetidin-3-yl)acetic acid methyl ester (210 mg, 0.53 mmol). The same method was used to prepare compound I-43, and 245 mg of the product was separated by silica gel column chromatography (ethyl acetate: methanol = 50:1). 1H NMR (300MHz, DMSO-d6) δ8.17(d,J=5.3Hz,1H),7.81(s,1H),7.51(s,1H),7.06(dd,J=5.3,1.6Hz,1H),6.99( s,1H),6.83(d,J=1.5Hz,1H),4.80(d,J=14.2Hz,2H),4.57(d,J=12.2Hz,2H),4.39(q,J=7.0Hz,2H),4.19(t, J=8.2Hz,2H),3.74(dd,J=8.4,5.6Hz,2H),3.08(d,J=9.6Hz,1H),2.85(d,J= 7.6Hz, 2H), 2.45–2.38 (m, 3H), 2.22 (d, J = 4.1Hz, 3H), 1.37 (t, J = 7.0Hz, 3H).

[0510] Example 44 Preparation of methyl 4-(2-(3-(2-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-oxoethyl)azetidin-1-yl)pyridin-4-yl)-2-(trifluoromethyl)benzoate

[0511] The synthetic method of reference example 18 was used, except that 2-bromo-4-fluoropyridine was replaced with 4-bromo-2-fluoropyridine (175 μL, 1.70 mmol). Compound I-44 was prepared in the same manner and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 80:1) to obtain 446 mg of the product. 1 H NMR(300MHz,Chloroform-d)δ8.26(d,J=5.3Hz,1H),7.99–7.87(m,2H),7.82(dd,J=8.1 ,1.7Hz,1H),6.93(d,J=3.6Hz,1H),6.82(dt,J=5.4,1.4Hz,1H),6.44(t,J=1.0Hz,1H),4 .86–4.68(m,4H),4.38(td,J=8.1,2.0Hz,2H),3.98(s,3H),3.86(dd,J=8.2,5.4Hz,2H) ,3.39–3.25(m,1H),2.86(t,J=7.6Hz,2H),2.55(d,J=3.5Hz,3H),2.28(d,J=1.9Hz,3H).

[0512] Example 45 Preparation of 1-[2-[2-(trifluoromethyl)pyridin-4-yl]pyridin-4-yl]azetidin-3-yl 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[4,3-b]pyridine-6-carboxylate

[0513] Step 1: Synthesis of I-45-1

[0514] Referring to the synthesis method of step 1 of Example 2, except that 2-bromo-4-fluoropyridine was replaced with 2-bromo-4-chloropyridine (115 μL, 1.04 mmol), compound I-45-1 was prepared in the same manner and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 30:1) to obtain 245 mg of a white solid. 1 H NMR (300MHz, DMSO-d6) δ8.93 (dt, J=5.1, 0.7Hz, 1H), 8.76 (dd, J=5.3, 0.6Hz, 1H), 8.59 (dd, J= 1.7,0.8Hz,1H),8.53(dd,J=1.9,0.6Hz,1H),8.49–8.39(m,1H),7.72(dd,J=5.3,1.9Hz,1H).

[0515] Step 2: Synthesis of I-45-2

[0516] To a two-necked flask equipped with a stirrer was added p-4-chloro-2'-(trifluoromethyl)-2,4'-bipyridine (120 mg, 0.46 mmol), 3-hydroxyazetidine hydrochloride (51 mg, 0.46 mmol), tris(dibenzylideneacetone)palladium (43 mg, 0.05 mmol), 4,5-bis(diphenylphosphino-9,9-dimethylxanthene) (54 mg, 0.09 mmol), and cesium carbonate (454 mg, 1.40 mmol). Under nitrogen, 6 mL of anhydrous dioxane was added, and the mixture was purged with nitrogen three times. The reaction was allowed to proceed at 110°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phases were then separated by silica gel column chromatography (dichloromethane:methanol = 50:1) to afford 108 mg of a yellow solid. 1 H NMR (300MHz, DMSO-d6) δ8.85(d,J=5.1Hz,1H),8.50(dd,J=1.7,0.8Hz,1H),8.37(dd,J=5.1,1.6Hz,1H),8.29(d,J=5.6Hz,1H),7.20(d,J =2.1Hz,1H),6.46(dd,J=5.6,2.2Hz,1H),5.91–5.69(m,1H),4.65(qt,J=6.5,4.5Hz,1H),4.33–4.14(m,2H),3.75(dd,J=9.0,4.5Hz,2H).

[0517] Step 2: Synthesis of I-45-3

[0518] To a single-necked flask equipped with a stirrer, add 2,4-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (120 mg, 0.54 mmol), triethylamine (377 μL, 2.71 mmol), and 6 mL of dichloromethane. Add triphosgene (81 mg, 0.27 mmol) under ice-cooling and allow the reaction to proceed. After completion of the reaction, as monitored by TLC, the crude product was directly dried and purified without further purification.

[0519] Step 4: Synthesis of I-45

[0520] To a single-necked flask equipped with a stirrer, 1-(2'-(trifluoromethyl)-[2,4'-bipyridyl]-4-yl)azetidin-3-ol (108 mg, 0.36 mmol) and 6 mL of anhydrous tetrahydrofuran were added. Sodium cyanide (26 mg, 1.08 mmol) was added under ice-cooling and the mixture was allowed to react at room temperature for 1 h. 2,4-Dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carbonyl chloride (quantitative) was then added and the reaction continued at room temperature. After TLC monitoring, the reaction was quenched with water and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. Purification by reverse-phase chromatography (water:methanol = 2:98) afforded 84 mg of the product. 1 H NMR(300MHz, DMSO-d6)δ8.86(d,J=5.1Hz,1H),8.58–8.48(m,1H),8.38(dd,J=5.2, 1.6Hz,1H),8.32(d,J=5.6Hz,1H),7.29(d,J=2.1Hz,1H),6.99(s,1H),6.54(dd,J=5 .6,2.1Hz,1H),5.35(tq,J=7.8,4.2Hz,1H),4.73–4.53(m,4H),4.42(dd,J=9.6,6. 6Hz, 2H), 4.05 (dd, J=9.8, 3.9Hz, 2H), 2.41 (d, J=2.1Hz, 3H), 2.21 (d, J=7.8Hz, 3H).

[0521] Example 46 Preparation of 1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-(1-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)azetidin-3-yl)ethan-1-one

[0522] Step 1: Synthesis of I-46-1

[0523] To a single-necked flask equipped with a stirrer, add p-5-bromo-2-fluoropyridine (234 μL, 1.71 mmol), N-methylpiperazine (303 μL, 2.73 mmol), cesium carbonate (2.22 g, 6.82 mmol), and 6 mL of DMSO. The mixture was allowed to react at 120°C. After completion of the reaction as monitored by TLC, the mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The organic phase was then separated by silica gel column chromatography (petroleum ether:ethyl acetate = 10:1) to afford 320 mg of a white solid. 1 H NMR (400MHz, Chloroform-d) δ8.21(d,J=2.5Hz,1H),7.63–7.44(m,1H),6.57(d,J=9.1Hz,1H),3.57(t,J=5.1Hz,4H),2.56(t,J=5.1Hz,4H),2.39(s,3H).

[0524] Step 2: Synthesis of I-46-2

[0525] Refer to the synthesis method of step 2 of Example 29, except that 4'-bromo-3-fluoro-[1,1'-biphenyl]-4-carbonitrile in step 2 is replaced by 1-(5-bromopyridin-2-yl)-4-methylpiperazine (313 mg, 1.22 mmol). Compound I-46-2 was prepared in the same manner and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 2:1) to obtain 264 mg of a yellow solid. 1 H NMR(400MHz,Chloroform-d)δ7.56(d,J=2.9Hz,1H),6.78(dd,J=8.9,3.0Hz,1H),6.64(d,J=8.8Hz,1H),4.03(t,J=7.3Hz,2H),3.71(s,3H),3.52(d d,J=7.0,5.6Hz,2H),3.45(t,J=4.7Hz,4H),3.09(pt,J=7.7,5.6Hz,1H),2.73(d,J=7.8Hz,2H),2.62(dd,J=6.6,3.4Hz,4H),2.40(d,J=2.0Hz,3H).

[0526] Step 3: Synthesis of I-46

[0527] Refer to the synthesis method of step 3 of Example 29, except that the 2-(1-(4'-cyano-3'-fluoro-[1,1'-biphenyl]-4-yl)azetidin-3-yl)acetic acid methyl ester in step 3 is replaced by 2-(1-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)azetidin-3-yl)acetic acid methyl ester (150 mg, 0.49 mmol). Compound I-46 was prepared by the same method, and 171 mg of the product was separated by silica gel column chromatography (ethyl acetate). 1 H NMR (400MHz, DMSO-d6) δ7.44(d,J=2.9Hz,1H),7.00(d,J=2.3Hz,1H),6.82(dd,J=8.9,2.9Hz ,1H),6.73(d,J=9.0Hz,1H),4.79(d,J=19.1Hz,2H),4.56(d,J=17.2Hz,2H),3.93(t,J=7.3Hz ,2H),3.43(t,J=6.4Hz,2H),3.30–3.20(m,4H),3.02(tt,J=8.0,3.7Hz,1H),2.80(dd,J=7.8, 1.7Hz,2H),2.42(d,J=1.3Hz,3H),2.39(t,J=5.0Hz,4H),2.23(d,J=4.5Hz,3H),2.20(s,3H).

[0528] Example 48 Preparation of 1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-(1-(2'-ethoxy-[2,4'-bipyridinyl]-4-yl)azetidin-3-yl)ethan-1-one

[0529] The synthesis method of Reference Example 47 was used, except that 4-cyano-3-fluorophenylboronic acid pinacol ester in step 1 was replaced with 2-ethoxypyridine-4-boronic acid pinacol ester (400 mg, 1.61 mmol). Compound I-48 was prepared by the same method and separated by silica gel column chromatography (ethyl acetate: methanol = 50:1) to obtain 64 mg of the product. 1H NMR(300MHz,DMSO-d6)δ8.26(dd,J=7.9,5.5Hz,2H),7.66(dd,J=5.4,1.5Hz,1H),7.45(s, 1H),7.10–6.96(m,2H),6.45(dd,J=5.6,2.2Hz,1H),4.86(d,J=13.3Hz,2H),4.62(d,J=12 .5Hz,2H),4.39(q,J=7.0Hz,2H),4.23(t,J=8.2Hz,2H),3.76(dd,J=8.2,5.6Hz,2H),3.18 (s,1H),2.92(d,J=7.6Hz,2H),2.48(s,3H),2.28(d,J=4.8Hz,3H),1.39(t,J=7.0Hz,3H).

[0530] Example 49 Preparation of 1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-(1-(2'-(trifluoromethyl)-[3,4'-bipyridyl]-5-yl)azetidin-3-yl)ethan-1-one

[0531] Step 1: Synthesis of I-49-1

[0532] Refer to the synthesis method of step 1 of Example 4, except that the 2-bromo-5-fluoropyridine in step 1 is replaced with 3,5-dibromopyridine (300 mg, 1.27 mmol). Compound I-49-1 was prepared in the same manner and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 20:1) to obtain 176 mg of a white solid.

[0533] Step 2: Synthesis of I-49-2

[0534] Refer to the synthetic method of step 2 of Example 28, except that 4-(5-bromothiophen-2-yl)-2-(trifluoromethyl)pyridine is replaced with 5-bromo-2'-(trifluoromethyl)-3,4'-bipyridine (170 mg, 0.56 mmol). Compound I-49-2 is prepared in the same manner and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 2:1) to obtain 157 mg of a yellow solid.

[0535] Step 3: Synthesis of I-49-3

[0536] Refer to the synthesis method of step 3 of Example 28, except that 2-(1-(5-(2-(trifluoromethyl)pyridin-4-yl)thiophen-2-yl)azetidin-3-yl)acetic acid methyl ester is replaced with 2-(1-(2'-(trifluoromethyl)-[3,4'-bipyridine]-5-yl)azetidin-3-yl)acetic acid methyl ester (150 mg, 0.43 mmol). Compound I-49-3 was prepared in the same manner, and 138 mg of the product was separated by silica gel column chromatography (ethyl acetate). 1 H NMR (400MHz, DMSO-d6) δ8.84(d,J=5.1Hz,1H),8.40(d,J=1.8Hz,1H),8.26(s,1H),8.11(dd ,J=5.2,1.6Hz,1H),7.94(d,J=2.6Hz,1H),7.31(t,J=2.3Hz,1H),7.00(d,J=2.6Hz,1H),4.8 1(d,J=18.3Hz,2H),4.57(d,J=16.4Hz,2H),4.17(t,J=7.8Hz,2H),3.70(dd,J=7.7,5.7Hz, 2H),3.21–3.04(m,1H),2.87(d,J=7.6Hz,2H),2.42(d,J=2.1Hz,3H),2.23(d,J=5.4Hz,3H).

[0537] Example 50 Preparation of 1-(2,4-dimethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-2-(1-(2'-ethoxy-6'-(trifluoromethyl)-[2,4'-bipyridyl]-4-yl)azetidin-3-yl)ethan-1-one

[0538] Step 1: Synthesis of I-50-1

[0539] The synthetic method of reference example 1 step 2 was used, except that 4-fluoro-2'-methyl-6'-(trifluoromethyl)-2,4'-bipyridine in step 1 was replaced with 2-bromo-4-fluoropyridine (294 μL, 2.84 mmol). Compound I-50-1 was prepared in the same manner and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 15:1) to obtain 434 mg of a transparent oil. 1H NMR(300MHz,Chloroform-d)δ7.96(d,J=5.8Hz,1H),6.41(d,J=2.1Hz,1H),6.20(dd,J=5.8,2.1Hz,1H),4 .18(t,J=8.2Hz,2H),3.73(s,3H),3.70(dd,J=8.3,5.4Hz,2H),3.31–3.09(m,1H),2.75(d,J=7.8Hz,2H).

[0540] Step 2: Synthesis of I-50-2

[0541] The synthetic method of reference example 1 step 1 was used, except that the 2-bromo-4-fluoropyridine in step 1 was replaced with 2-(1-(2-bromopyridin-4-yl)azetidin-3-yl)acetate (244 mg, 0.86 mmol). Compound I-50-2 was prepared in the same manner and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 10:1) to obtain 200 mg of a white solid. 1 H NMR(300MHz,Chloroform-d)δ8.35(d,J=5.8Hz,1H),7.82(d,J=1.3Hz,1H),7.46(s,1H),6.66(d,J=2.2Hz,1H),6.34(dd,J=5.9,2.3Hz,1H),4.48(q,J= 7.1Hz,2H),4.28(t,J=8.2Hz,2H),3.79(dd,J=8.3,5.4Hz,2H),3.74(s,3H) ,3.23(tt,J=7.9,5.5Hz,1H),2.79(d,J=7.8Hz,2H),1.44(t,J=7.1Hz,3H).

[0542] Step 2: Synthesis of I-50-3 and I-50

[0543] Reference is made to the synthesis method of step 3 of Example 1, except that the 2-(1-(2'-methyl-6'-(trifluoromethyl)-[2,4'-bipyridine]-4-yl)azetidin-3-yl)acetic acid methyl ester in step 3 is replaced with 2-(1-(2'-ethoxy-6'-(trifluoromethyl)-[2,4'-bipyridine]-4-yl)azetidin-3-yl)acetic acid methyl ester (200 mg, 0.51 mmol). The same method is used to obtain compound 2-(1-(2'-ethoxy-6'-(trifluoromethyl)-[2,4'-bipyridine]-4-yl)azetidin-3-yl)acetic acid (I-50-3, 160 mg, 0.42 mmol), and then the same method is used to obtain compound I-50, which was separated by silica gel column chromatography (ethyl acetate) to obtain 104 mg of a yellow oil. 1H NMR (300MHz, DMSO-d6) δ8.25(d,J=5.6Hz,1H),8.11(d,J=1.2Hz,1H),7.77(s,1H),7.18(d ,J=2.1Hz,1H),7.00(s,1H),6.43(dd,J=5.7,2.1Hz,1H),4.81(d,J=13.7Hz,2H),4.57(d, J=12.5Hz,2H),4.39(q,J=7.0Hz,2H),4.13(s,2H),3.73(dd,J=8.4,5.6Hz,2H),3.13(s,1 H),2.87(d,J=7.7Hz,2H),2.45–2.39(m,3H),2.23(d,J=4.6Hz,3H),1.37(t,J=7.0Hz,3H).

[0544] Examples 51-78

[0545] The structure of CVL-231 mentioned in this disclosure is shown below, and it was prepared according to the method of Example 11 of PCT / IB2017 / 053565.

[0546] Test Example 1 Pharmacological Example

[0547] 1. In vitro positive allosteric modulation assay of M4 receptor

[0548] 1.1 In vitro isotope binding assay

[0549] 1.1.1 Preparation of cell receptor membranes

[0550] Thaw cells naturally after removal from a -80°C freezer. Centrifuge at 1000g at 4°C for 10 minutes. Collect the pellet and discard the supernatant. Add buffer to the pellet. Mix the cells for 20-30 seconds, then centrifuge at 48,000g at 4°C for 25 minutes. Carefully discard the supernatant, add buffer again, mix, centrifuge at 48,000g at 4°C for 25 minutes, and store at -80°C.

[0551] 1.1.2 Preparation of test samples

[0552] Before preparing the test sample, mark the 2mL EP tubes. Each tube corresponds to a different concentration of each supply. Calculate the theoretical sample volume according to the designed concentration and the required volume. Generally, 5.0×10 -3 M is the initial preparation dose, which is dissolved in DMSO and then diluted with DMSO to 5.0×10 -4 M~5.0×10 -9 M, dilute the diluted DMSO solution with buffer to the working concentration, with a final DMSO concentration of 1% in the working solution (the final DMSO concentration in the reaction system is 0.2%). If the test sample does not dissolve well or is unevenly suspended, add HCl (1M, 50μL) as appropriate, or perform appropriate suspension or sonication. After preparation, store the test sample at 4°C and discard after the experiment. After the experiment, return the remaining test sample to the test sample manager.

[0553] 1.1.3 Test steps

[0554] Step 1: First, use the prepared membrane buffer to make a membrane suspension of a certain concentration for later use.

[0555] Step 2: Add 50 μL of buffer to the total binding tube (TB) and 50 μL of atropine (final concentration 1.0×10 -5 M), 50 μL of the orthosteric agonist acetylcholine (8 concentration gradient) was added to the test compound tube (CB), and 50 μL of the allosteric modulator was added to all tubes.

[0556] Step 3: Add 50 μL of buffer to each reaction tube.

[0557] Step 4: Add 50 μL of the corresponding radioligand to each reaction tube.

[0558] Step 5: Add 50 μL of membrane preparation to each reaction tube.

[0559] Step 6: Incubate each reaction tube at the corresponding temperature and time. After the reaction is complete, the bound ligand is quickly filtered under reduced pressure. The filter plate is saturated with 0.5% PEI solution 1 hour in advance, washed thoroughly with ice-cold Tris-HCl buffer, dried at 60°C for 30 minutes, and 40uL of scintillation fluid is added.

[0560] Step 7: Let it stand overnight and place the filter plate into a liquid scintillation counter for counting.

[0561] 1.2 In vitro inositol 1-phosphate (IP-1) assay method

[0562] (1) Prepare the reaction buffer (1 x Stimulation buffer) required for the experiment: dilute the 5 x Stimulation buffer in the Cisbio IP-one kit with double distilled water (ddH2O) at a ratio of 1:4 and set aside.

[0563] (2) Compound preparation: Dilute the compound to a 5 mM stock solution with DMSO, then dilute it 3.16-fold to form 10 gradients, and then dilute the prepared compound to the corresponding concentration (4 x) with 1 x Stimulation buffer for later use.

[0564] (3) Cell preparation: Trypsinize the CHO-M4 cells on the culture dish, wash the cells with culture medium and collect them into a 5 mL centrifuge tube. Centrifuge at 1000 rpm for 5 minutes and discard the supernatant. Add 3 mL of PBS and mix thoroughly by gently pipetting. Centrifuge again at 1000 rpm for 5 minutes and discard the supernatant. Resuspend the cells in 1 x Stimulation buffer and count them using a Countstar cell counter. Adjust the cell density to 2.14 x 10 6 / mL, for future use.

[0565] (4) Cell addition: Add the cell suspension to the experimental plate, 7 μL / well (i.e., approximately 15,000 cells / well).

[0566] (5) Add 1 x Stimulation buffer and compound:

[0567] Allosteric regulation mode: Add the compound diluted in 1 x Stimulation buffer to the above assay plate at 3.5 μL / well.

[0568] (6) Reaction incubation: After slow shaking, incubate the experimental plate at 37°C for 20 minutes.

[0569] (7) Compound addition and EC 20 The agonist is added:

[0570] Stimulation mode: Add the compound diluted in 1x Stimulation buffer to the above assay plate, 3.5 μL / well.

[0571] Allosteric regulation mode: EC 20 Add 4 x Acetylcholine chloride solution to the above experimental plate, 3.5 μL / well.

[0572] (8) Reaction incubation: After slow shaking, incubate the experimental plate at 37°C for 60 minutes.

[0573] (9) Add detection reagents: Dilute IP1-d2 and Anti-IP1 cryptate at a 1:20 ratio using the Lysis & Detection Buffer in the Cisbio IP-one Detection Kit. Add 3 μL of each diluted IP1-d2 and Anti-IP1 cryptate to the assay plate at each well. After shaking, incubate the plate at room temperature for 60 minutes.

[0574] (10) Experimental reading: Read the plate on Envision, detect the readings of the 665nm and 615nm channels, and calculate the ratio of 665nm / 615nm readings.

[0575] 1.3 Test results

[0576] The results of in vitro isotope binding assay and in vitro IP-1 assay both indicate that the compound of the present invention is an effective positive allosteric modulator of M4 receptor.

[0577] For example, in vitro isotope binding experiments show that the compounds of exemplary Examples 1, 10, 12, 13, 14, 18, 19, 20, 21, 22, 23, 24, 28, 29, 30, 33, 34, 36, 40, 43, 44, 48, 49, 50, 51, 60, 66, 55, 58, 70, 73, 74, 76, 77, 78, 79, 83, 84, 88, 90, 91, 95, 96, 98, 101, 104, and 105 have better in vitro activity than CVL-231.

[0578] The results of the in vitro IP-1 test showed that the compounds of exemplary Examples 6, 7, 10, 14, 18, 19, 30, 33, 40, 48, 49, 50, 54, 60, 63, 64, 66, 67, 55, 58, 70, 73, 74, 77, 79, 83, 84, 87, 88, 95, 97, 98, 101, 104, and 105 had better in vitro activity than CVL-231.

[0579] In summary, this series of compounds has the potential to treat schizophrenia.

[0580] Note: " / " indicates not tested. *The Ki value of acetylcholine at a compound concentration of 1 μM. The rest are the Ki values ​​of acetylcholine at a compound concentration of 10 μM.

[0581] 2. Effects of Compounds on MK-801-Induced Hyperactivity in Mice

[0582] 2.1 Test method

[0583] 30 minutes after oral administration of the test article (or control article), 0.3 mg / kg (dosage volume 10 mL / kg body weight) of MK-801 was injected intraperitoneally, and the mice were placed in an autonomous activity box for video recording for 60 minutes. At the end of the recording, video analysis was performed to evaluate the mouse activity.

[0584] 2.2 Test data

[0585] Through experiments, it can be seen that the compounds of exemplary Examples 6, 11, 30, 33, 40, 43, 46, 48, 64, 70, 80, 105, and CVL-231 inhibit the ED of mice induced by MK-801 with high activity behavior. 50 The concentrations of the compounds were 28.49, 20.04, 24.17, 25.32, 19.23, 21.08, 45.66, 17.85, 37.56, 25.33, 17.04, 25.89 and 26.70 mg / kg, respectively, indicating that the compounds of the present invention have good ability to inhibit the hyperactivity behavior induced by MK-801 in mice and have the potential to treat schizophrenia.

[0586] 3. Pharmacokinetic Test in Rat

[0587] Using CVL-231 as a control, oral administration / tail vein injection in rats was used to compare the pharmacokinetic parameters such as half-life and brain penetration of the compound with those of the control drug, and to evaluate the in vivo pharmacokinetic properties.

[0588] 3.1 Test method

[0589] Intravenous solution preparation: Prepare the compound into a 0.2 mg / mL solution using 20% ​​hydroxypropyl-β-cyclodextrin solution. The administration volume is 0.5 mL / 100 g body weight, which translates to a dose of 1 mg / kg body weight.

[0590] Preparation of oral administration solution: Use 0.5% methylcellulose aqueous solution to suspend and disperse to prepare a 1 mg / mL suspension. The administration volume is 1 mL / 100 g body weight, which is equivalent to a dose of 10 mg / kg body weight.

[0591] Three rats per group received the above-mentioned doses orally by gavage and intravenously. Blood was collected from the orbital cavity 5, 15, 30, 1, 2, 4, 7, and 10 hours after administration. Plasma samples were prepared and analyzed using LC / MS / MS.

[0592] 3.2 Test results

[0593] The rat pharmacokinetic test showed that the compounds of Examples 13, 18, 19, 26, 28, 30, 33, 41, 45, 46, 50, 54, 64, 65, 70, 73, 74, 89, 90, 105, etc. 1 / 2 Compared to CVL-231, these compounds all showed significant improvements, suggesting the potential to reduce medication frequency and increase patient compliance. Furthermore, the compounds of Examples 18, 26, 28, 33, 41, 45, 54, 55, 64, 65, 70, and 105 demonstrated improved brain penetration compared to CVL-231, reducing peripheral drug exposure at effective doses and, presumably, reducing the occurrence of peripheral adverse reactions.

[0594] It will be clear to those skilled in the art that many modifications and variations of the present invention may be made without departing from its spirit and scope. The specific embodiments described herein are provided by way of example only and are not intended to be limiting in any way. The true scope and spirit of the present invention are shown by the appended claims, and the description and examples are merely exemplary.

Claims

1. A compound as shown in formula I, its stereoisomer, deuterated substance or pharmaceutically acceptable salt thereof, in, R1, R2, R3 are each independently selected from H, deuterium, halogen, hydroxyl, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl and C2-C6 alkynyl; Each R4, when present, is independently selected from deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, and hydroxyl; E is selected from -(CH2)q-, -O- and -NH-; L is selected from C optionally substituted by one or more substituents 6-14 Aryl, 5-10 membered heteroaryl optionally substituted by one or more substituents, and 5-8 membered nitrogen-containing heterocyclic group optionally substituted by one or more substituents; the one or more substituents are independently selected from deuterium, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 deuterated alkyl, C1-C6 deuterated alkoxy, nitro, C1-C6 alkylthio, hydroxyl and cyano; A is selected from 5-14 membered heteroaryl, C 6-14 Aryl, 5-8 membered heterocyclic group and C 6-10 Aryl and 5-8 membered heterocyclic group; Each Ra group, when present, is independently selected from deuterium, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkylthio, halogen, cyano, hydroxy, nitro, amino, oxo, optionally substituted C3-C6 cycloalkyl, -N(R5)(R6), -N(R5)(C(=O)R6), -C(=O)-N(R5)(R6), -C( =O)-OR7, -C(=O)-R7 and -S(=O)2-R7, the optional substituents being independently selected from deuterium, halogen, C1-C6 alkyl, hydroxy, C1-C6 alkoxy, -N(R5)(R6), -N(R5)(C(=O)R6), -C(=O)-N(R5)(R6), -C(=O)-OR7, -C(=O)-R7 and -S(=O)2-R7; R5 and R6 are each independently selected from H, deuterium, C1-C6 alkyl optionally substituted with one or more Rb, C3-C8 cycloalkyl optionally substituted with one or more Rb, C1-C6 alkoxy optionally substituted with one or more Rb, and C1-C6 alkylthio optionally substituted with one or more Rb, wherein Rb is independently selected from hydrogen, deuterium, C1-C6 alkoxy, halogen, -N(CH3)2, -NHCH3, and hydroxyl; or R5 and R6 are linked to the nitrogen atom to which they are connected to form a 3-8 membered nitrogen-containing heterocyclic group optionally substituted by one or more substituents; the one or more substituents are independently selected from deuterium, hydrogen, halogen, hydroxyl, nitro, amino, C1-C6 alkylthio, C1-C6 deuterated alkylthio, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 deuterated alkyl, C1-C6 deuterated alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy; R7 is a C1-C6 alkyl group; m is 0, 1, 2, 3 or 4; p is 0, 1, 2 or 3; q is 0, 1, 2, or 3; n is any integer from 0 to 5.

2. The compound according to claim 1, its stereoisomer, deuterated substance or pharmaceutically acceptable salt thereof, characterized in that: R1, R2, R3 are each independently selected from H, deuterium, halogen, hydroxyl, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl and C2-C6 alkynyl; Each R4, when present, is independently selected from deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, and hydroxyl; E is selected from -(CH2)q-, -O- and -NH-; L is selected from C optionally substituted by one or more substituents 6-14 Aryl, 5-10 membered heteroaryl optionally substituted by one or more substituents, and 5-8 membered nitrogen-containing heterocyclic group optionally substituted by one or more substituents; the one or more substituents are independently selected from deuterium, halogen, C1-C6 alkyl, C1-C6 alkoxy and cyano; A is selected from 5-14 membered heteroaryl, C 6-14 Aryl, 5-8 membered heterocyclic group and C 6-10 Aryl and 5-8 membered heterocyclic group; Each Ra group, when present, is independently selected from deuterium, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkylthio, halogen, cyano, hydroxyl, nitro, amino, oxo, optionally substituted C3-C6 cycloalkyl, -N(R5)(R6), -N(R5)(C(=O)R6), -C(=O)-N(R5)(R6), -C(=O)-OR7, -C(=O)-R7 and -S(=O)2-R7, and the optional substituents are independently selected from deuterium, halogen and hydroxyl; R5 and R6 are each independently selected from H, deuterium and C1-C6 alkyl, or R5 and R6 are linked to the nitrogen atom to form a 3-8 membered nitrogen-containing heterocyclic group; R7 is a C1-C6 alkyl group; m is 0, 1, 2, 3 or 4; p is 0, 1, 2 or 3; q is 0, 1, 2, or 3; n is any integer from 0 to 5.

3. A compound of formula IA, its stereoisomer, deuterated product or pharmaceutically acceptable salt thereof, in, R1, R2, R3 are independently selected from H, deuterium, halogen, hydroxyl, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl and C2-C6 alkynyl; Each R4, when present, is independently selected from deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, and hydroxyl, and when m is 2 or more, R4 may be different; L is selected from C optionally substituted by one or more substituents 6-14 Aryl, 5-10 membered heteroaryl optionally substituted by one or more substituents and 5-8 membered nitrogen-containing heterocyclic group optionally substituted by one or more substituents; further preferably selected from phenyl optionally substituted by one or more substituents and phenyl optionally substituted by one or more substituents The one or more substituents are independently selected from deuterium, halogen, C1-C6 alkyl, C1-C6 alkoxy and cyano; A is selected from 5-14 membered heteroaryl, C 6-14 Aryl and 5-8 membered heterocyclic and C 6-10 Aryl and 5-8 membered heterocyclic group, preferably selected from 5-14 membered heteroaryl containing 1-5 heteroatoms selected from nitrogen, oxygen, sulfur, C 6-10 Aryl and 5-8 membered nitrogen-containing heterocyclic group, further preferably selected from 5-7 membered monocyclic heteroaryl containing 1-3 heteroatoms selected from nitrogen, oxygen and sulfur, 8-10 membered bicyclic heteroaryl containing 1-3 heteroatoms selected from nitrogen, oxygen and sulfur, phenyl and 6 membered nitrogen-containing heterocyclic group; further preferably selected from pyridyl, phenyl, piperazinyl and quinolyl; Each Ra group, when present, is independently selected from deuterium, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, halogen, cyano, optionally substituted C3-C6 cycloalkyl, -C(=O)-N(R5)(R6) and -C(=O)-OR7, the optional substituents being independently selected from deuterium, halogen and hydroxyl, and when n is 2 or 3 or 4 or 5, Ra may be different; R5 and R6 are each independently selected from H, deuterium and C1-C6 alkyl; R7 is selected from C1-C6 alkyl; m is 0, 1, 2, 3 or 4; p is 0, 1, 2 or 3; q is 0, 1, 2, or 3; n is any integer of 0-5, preferably any integer of 0-4, and more preferably any integer of 0-2.

4. The compound according to any one of claims 1 to 3, its stereoisomer, deuterated substance or pharmaceutically acceptable salt thereof, characterized in that: One or more of the following conditions are met: (1) R1, R2, and R3 are each independently selected from hydrogen, halogen, C1-C6 alkyl, and C1-C6 alkoxy, preferably hydrogen, halogen, or C1-C6 alkyl; (2) each R4, when present, is independently a C1-C6 alkyl group, preferably a C1-C3 alkyl group; (3) L is selected from C optionally substituted by one or more substituents 6-14 aryl, 5-10 membered heteroaryl containing 1-3 heteroatoms selected from nitrogen, oxygen and sulfur, which are optionally substituted by one or more substituents, and 5-8 membered nitrogen-containing heterocyclic group which are optionally substituted by one or more substituents; preferably selected from C 6-14 Aryl, 5-10 membered heteroaryl containing 1-3 heteroatoms selected from nitrogen, oxygen and sulfur, which are optionally substituted by one or more substituents; preferably selected from C 6-10 Aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms selected from nitrogen, oxygen and sulfur, which is optionally substituted by one or more substituents; preferably selected from phenyl optionally substituted by one or more substituents, pyridyl optionally substituted by one or more substituents, pyrazinyl optionally substituted by one or more substituents, pyrimidinyl optionally substituted by one or more substituents, pyridazinyl optionally substituted by one or more substituents, thiazolyl optionally substituted by one or more substituents and thienyl optionally substituted by one or more substituents; preferably selected from phenyl optionally substituted by one or more substituents, pyridyl optionally substituted by one or more substituents, pyridazinyl optionally substituted by one or more substituents, pyrazinyl optionally substituted by one or more substituents, thiazolyl optionally substituted by one or more substituents and thienyl optionally substituted by one or more substituents; preferably selected from Optionally substituted with one or more substituents The one or more substituents are independently selected from deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 deuterated alkyl, C1-C6 deuterated alkoxy, C1-C6 alkylthio, hydroxyl and cyano, preferably selected from deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 deuterated alkyl and C1-C6 deuterated alkoxy, further preferably selected from halogen, C1-C6 alkyl and C1-C6 haloalkyl; (4) A is selected from a 5-14 membered heteroaryl group containing 1-5 heteroatoms selected from nitrogen, oxygen, and sulfur, 6-14 Aryl, 5-8 membered heterocyclic group containing 1-3 heteroatoms selected from nitrogen, oxygen, sulfur and C 6-10 The 5-8 membered heterocyclic group containing 1-3 heteroatoms selected from nitrogen, oxygen and sulfur is preferably selected from a 5-10 membered heteroaryl group containing 1-3 heteroatoms selected from nitrogen, oxygen and sulfur, a C 6-10 Aryl, 5-6 membered nitrogen-containing heterocyclic group, 5-6 membered oxygen-containing heterocyclic group, benzo 5-6 membered oxygen-containing heterocyclic group, benzo 5-6 membered sulfur-containing heterocyclic group and benzo 5-6 membered nitrogen-containing heterocyclic group, preferably selected from phenyl, piperazinyl, piperidinyl, pyridinyl, pyrazolyl, quinolyl, isoquinolyl, morpholinyl, thienyl, indolyl, isoindolyl, dihydrobenzofuranyl, dihydroisobenzofuranyl, benzodioxolyl, imidazopyridine phenyl, oxazolyl, benzothiadiazolyl, benzothiazolyl, imidazolyl, oxazolidinyl and pyrrolyl, preferably selected from phenyl, piperazinyl, piperidinyl, pyridinyl, pyrazolyl, quinolyl, isoquinolyl, morpholinyl, thienyl, indolyl, isoindolyl, dihydrobenzofuranyl, dihydroisobenzofuranyl, benzodioxolyl, imidazopyridinyl, benzothiadiazolyl, benzothiazolyl, imidazolyl, oxazolidinyl and pyrrolyl; (5) n is any integer from 0 to 4, preferably 0, 1, 2 or 3; (6) Each Ra group, when present, is independently selected from deuterium, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, halogen, cyano, nitro, oxo, amino, optionally substituted C3-C6 cycloalkyl, -N(R5)(R6), -C(=O)-N(R5)(R6), -C(=O)-OR7, -C(=O)-R7, -N(R5)C(=O)R6 and -S(=O)2-R7, preferably selected from deuterium, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, halogen, cyano, nitro, oxo, optionally substituted C3-C6 cycloalkyl, -N(R5)(R6) 6), -C(=O)-N(R5)(R6), -C(=O)-OR7, -N(R5)C(=O)R6 and -S(=O)2-R7, further preferably selected from deuterium, -CHF2, -CF3, -OCHF2, cyano, cyclopropyl, -C(=O)-NH2, -C(=O)-N(CH3)2, fluorine, chlorine, -C(=O)-OCH2CH3, -C(=O)-OCH3, methyl, ethyl, isopropyl, -OCH3, -OCH2CH3, -OCH2F, -OCF3, -N(CH3)2, oxo, nitro, -S(=O)2-CH3, -CH2N(CH3)2, nitrogen heterocycle Butyl, Azocyclopentyl, -NHCH(CH3)2, -N(CH3)CH(CH3)2, -NH2, -NH(CH2)3OCH3, -NHCH2CH3, -N(CH2CH3)2, -NHCH3, -NCH3CD3, -N(CH3)(C2H5) and -NHC(=O)CH3; The optional substituents are independently selected from deuterium, C1-C6 alkyl, halogen, hydroxyl, -N(R5)(R6), -C(=O)-OR7, -C(=O)-R7 and -S(=O)2-R7, preferably selected from deuterium, halogen and -N(R5)(R6), further preferably selected from deuterium, fluorine, chlorine and -N(CH3)2; (7) R5 and R6 are each independently selected from H, deuterium, C1-C3 alkyl optionally substituted by one or more Rb, C3-C6 cycloalkyl optionally substituted by one or more Rb, and C1-C3 alkoxy optionally substituted by one or more Rb, preferably selected from H, C1-C3 alkyl optionally substituted by one or more Rb, cyclopropyl, cyclobutyl, and C1-C3 alkoxy optionally substituted by one or more Rb; said Rb is independently selected from deuterium, halogen, and C1-C3 alkoxy; or R5 and R6 are linked to the nitrogen atom to which they are connected to form a 5-6 membered nitrogen-containing heterocyclic group optionally substituted by one or more substituents; the one or more substituents are independently selected from deuterium, hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 deuterated alkyl, C1-C6 deuterated alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy, preferably selected from deuterium, hydrogen, halogen and C1-C3 alkyl, further preferably selected from fluorine, chlorine and C1-C3 alkyl; (8) R7 are each independently selected from C 1-3 alkyl; (9) m is 0, 1 or 2, preferably 0; (10) p is 0, 1 or 2, preferably 1 or 2; (11) q is 0, 1 or 2, preferably 0 or 1.

5. The compound according to any one of claims 1 to 4, its stereoisomer, deuterated substance or pharmaceutically acceptable salt thereof, characterized in that: The compound of formula I is a compound of formula II, preferably a compound of formula III: wherein X1, X2, and X3 are each independently N or CH, and X1, X2, and X3 are not N at the same time, and the remaining R1, R2, R3, R4, Ra, L, A, m, and n are as defined in any one of claims 1 to 4.

6. The compound according to any one of claims 1 to 5, its stereoisomer, deuterated substance or pharmaceutically acceptable salt thereof, wherein Rc is selected from deuterium, halogen, C1-C6 alkyl, C1-C6 alkoxy and C1-C6 haloalkyl, preferably selected from halogen, C1-C6 alkyl and C1-C6 haloalkyl; z is selected from integers of 0-4, preferably 0 or 1.

7. The compound according to any one of claims 1 to 6, its stereoisomer, deuterated substance or pharmaceutically acceptable salt thereof, characterized in that: Selected from the following compounds:

8. A pharmaceutical composition, characterized in that Containing the compound according to any one of claims 1 to 7, its stereoisomer, deuterated substance or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

9. Use of the compound according to any one of claims 1 to 7, its stereoisomer, deuterated substance or pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 8 in the preparation of a medicament, preferably in the preparation of a medicament for treating an M4-mediated or M4-related disease or disorder.

10. The use as claimed in claim 9, wherein the M4-mediated or M4-related disease or disorder is selected from: Alzheimer's disease, schizophrenia, pain, addiction, sleep disorders, cognitive disorders, Parkinson's disease, Parkinson's disease-levodopa-induced dyskinesia, Huntington's disease, movement disorders, dry mouth, pulmonary hypertension, chronic obstructive pulmonary disease, asthma, urinary incontinence, glaucoma, trisomy 21 syndrome, cerebral amyloid angiopathy, dementia, Dutch hereditary amyloidosis cerebral hemorrhage, Creutzfeld-Jakob disease, prion disorder, amyotrophic lateral sclerosis, progressive supranuclear palsy, head trauma, stroke, pancreatitis, inclusion body myositis, other peripheral amyloidosis, diabetes, autism and atherosclerosis, preferably selected from one or more of Alzheimer's disease, schizophrenia, pain, addiction and sleep disorders, preferably schizophrenia.

11. A compound of formula V, Va, Vb, Vc, Vd, Ve, Vf, Vg, Vh, Vi, Vj, Vk, Vl, Vm, Vn, Vo, Vp, Vq, Vr, Vs or formula VI, VIa, VIb, VIc, VId, VIe, VIf, VIg, VIh, VIi, a stereoisomer thereof, a deuterated product thereof or a salt thereof: wherein A, Ra, and n are as defined in any one of claims 1 to 7, and R8 is a C1-C6 alkyl group.

12. A method for preparing a compound according to any one of claims 1 to 7, characterized in that: The following steps are involved: (i) a compound represented by formula IA or a salt thereof undergoes a substitution reaction with a compound represented by formula IB or formula I-B' to generate a compound represented by formula I; (ii) a compound represented by formula IC or a salt thereof undergoes a substitution reaction with a compound represented by formula ID to generate a compound represented by formula I; (iii) the compound represented by formula IE undergoes a substitution reaction with the compound represented by formula IF to generate the compound represented by formula I; or, (iv) the compound represented by formula IG undergoes a substitution reaction with the compound represented by formula IH to generate the compound represented by formula i-1; Wherein R8 is C1-C6 alkyl; Y1 is halogen, preferably fluorine, chlorine or bromine, preferably fluorine; Y2 is halogen, preferably fluorine, chlorine or bromine, preferably bromine; Y3 is halogen, preferably fluorine, chlorine or bromine, preferably chlorine; R1, R2, R3, R4, L, A, Ra, m, n, p and E are as defined in any one of claims 1 to 7.

Citation Information

Patent Citations

  • Compounds that are agonists of muscarinic receptors and tha may be effective in treating pain, alzheimer's disease and / or schizophrenia

    CN101484442A

  • 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases

    CN109641898A

  • Pyrrolidine derivatives

    CN114728964A

  • Inhibitors of histone deacetylase

    US20180099977A1

  • Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4

    WO2013126856A1

Cited By

  • Substituted azetidine derivative, preparation method therefor, and medical use thereof

    WO2026017066A1

  • Substituted pyrrolopyrimidine compound, pharmaceutical composition, and use thereof

    WO2026189340A1